0001144204-12-062136.txt : 20121114 0001144204-12-062136.hdr.sgml : 20121114 20121114121802 ACCESSION NUMBER: 0001144204-12-062136 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20120930 FILED AS OF DATE: 20121114 DATE AS OF CHANGE: 20121114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REPROS THERAPEUTICS INC. CENTRAL INDEX KEY: 0000897075 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 760233274 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-15281 FILM NUMBER: 121202419 BUSINESS ADDRESS: STREET 1: 2408 TIMBERLOCH PL STREET 2: SUITE B-7 CITY: WOODLANDS STATE: TX ZIP: 77380 BUSINESS PHONE: 2817193400 MAIL ADDRESS: STREET 1: 2408 TIMBERLOCH PLACE B-7 CITY: THE WOODLANDS STATE: TX ZIP: 77380 FORMER COMPANY: FORMER CONFORMED NAME: REPROS THERAPEUTICS INC DATE OF NAME CHANGE: 20060503 FORMER COMPANY: FORMER CONFORMED NAME: ZONAGEN INC DATE OF NAME CHANGE: 19930208 10-Q 1 v326064_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2012

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission file number: 001-15281

REPROS THERAPEUTICS INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	2408 Timberloch Place, Suite B-7	76-0233274
(State or other jurisdiction of	The Woodlands, Texas 77380	(IRS Employer
incorporation or	(Address of principal executive offices	Identification No.)
organization)	and zip code)

	(281) 719-3400

	(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or smaller reporting company. See definition of "accelerated filer", "large accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨ Accelerated filer ¨ Non-accelerated filer ¨ Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of November 6, 2012, there were outstanding 17,116,357 shares of Common Stock, par value $.001 per share, of the Registrant.

REPROS THERAPEUTICS INC.

(A development stage company)

For the Quarter Ended September 30, 2012

INDEX

		Page
FACTORS AFFECTING FORWARD-LOOKING STATEMENTS		3

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements (unaudited)	4

Unaudited Condensed Consolidated Balance Sheets as of September 30, 2012 and December 31, 2011		5
Unaudited Condensed Consolidated Statements of Operations for the three months and nine months ended September 30, 2012 and 2011 and from Inception (August 20, 1987) through September 30, 2012		6
Unaudited Condensed Consolidated Statements of Stockholders' Equity for the nine months ended September 30, 2012		7
Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2012 and 2011 and from Inception (August 20, 1987) through September 30, 2012		8
Notes to Unaudited Condensed Consolidated Financial Statements		9
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations		13
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	25
Item 4.	Controls and Procedures	26

PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	27
Item 1A.	Risk Factors	27
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	28
Item 3.	Defaults Upon Senior Securities	28
Item 4.	Mine Safety Disclosures	28
Item 5.	Other Information	28
Item 6.	Exhibits	28

SIGNATURES		31

FACTORS AFFECTING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words "may," "anticipate," "believe," "expect," "estimate," "project," "suggest," "intend" and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, expected, estimated, projected, suggested or intended. These risks and uncertainties include risks associated with the Company's ability to continue as a going concern and to continue to be able to raise additional capital on acceptable terms or at all in order to have available funding for the continued development of Androxal® and Proellex®; the success of the clinical trials for Androxal® and Proellex®; uncertainty related to the Company's ability to obtain approval of the Company's products by the Food and Drug Administration, or FDA, and regulatory bodies in other jurisdictions; uncertainty relating to the Company's patent portfolio; and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission. For additional discussion of such risks, uncertainties and assumptions, see "Part I. Financial Information - Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources" included elsewhere in this quarterly report on Form 10-Q and “Item 1A. Risk Factors” to Part I of Form 10-K for the fiscal year ended December 31, 2011.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

The following unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (which include only normal recurring adjustments) considered necessary for a fair statement of the interim periods presented have been included. The year-end balance sheet data was derived from audited financial statements, but does not include all the disclosures required by accounting principles generally accepted in the United States of America. Operating results for the three and nine month periods ended September 30, 2012 are not necessarily indicative of the results that may be expected for the year ended December 31, 2012. For further information, refer to the financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2011.

REPROS THERAPEUTICS INC. AND SUBSIDIARY

(A development stage company)

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited and in thousands except share and per share amounts)

	September 30,			December 31,
	2012			2011

ASSETS

Current Assets
Cash and cash equivalents	$	29,583		$	4,565
Prepaid expenses and other current assets		451			99
Total current assets		30,034			4,664
Fixed assets, net		59			15
Other assets, net		1,939			1,385
Total assets	$	32,032		$	6,064

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities
Accounts payable	$	1,508		$	1,145
Accrued expenses		329			253
Total current liabilities		1,837			1,398

Commitments and contingencies (note 5)

Stockholders' Equity
Undesignated Preferred Stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding		-			-
Common Stock, $.001 par value, 75,000,000 shares authorized, 17,228,707 and 12,470,694 shares issued, respectively and 17,116,357 and 12,358,344 shares outstanding, respectively		17			12
Additional paid-in capital		233,416			197,769
Cost of treasury stock, 112,350 shares		(1,380	)		(1,380	)
Deficit accumulated during the development stage		(201,858	)		(191,735	)
Total stockholders' equity		30,195			4,666
Total liabilities and stockholders' equity	$	32,032		$	6,064

The accompanying notes are an integral part of these condensed consolidated financial statements.

REPROS THERAPEUTICS INC. AND SUBSIDIARY

(A development stage company)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited and in thousands except per share amounts)

													From Inception
													(August 20, 1987)
													through
	Three Months Ended September 30,						Nine Months Ended September 30,						September 30,
	2012			2011			2012			2011			2012

Revenues
Licensing fees	$	-		$	-		$	-		$	-		$	28,755
Product royalties		-			-			-			-			627
Research and development grants		-			-			-			-			1,219
Interest income		1			-			1			1			16,300
Gain on disposal of fixed assets		-			-			-			-			102
Other Income		-			-			-			-			1,003
Total revenues and other income		1			-			1			1			48,006
Expenses
Research and development		3,131			3,234			6,776			6,980			188,692
General and administrative		1,453			726			3,348			2,780			51,441
Interest expense and amortization of intangibles		-			-			-			-			388
Total expenses		4,584			3,960			10,124			9,760			240,521

Loss from continuing operations		(4,583	)		(3,960	)		(10,123	)		(9,759	)		(192,515	)
Loss from discontinued operations		-			-			-			-			(1,828	)
Gain on disposal of discontinued operation		-			-			-			-			939
Net loss before cumulative effect of change in accounting principle		(4,583	)		(3,960	)		(10,123	)		(9,759	)		(193,404	)
Cumulative effect of change in accounting principle		-			-			-			-			(8,454	)
Net loss	$	(4,583	)	$	(3,960	)	$	(10,123	)	$	(9,759	)	$	(201,858	)

Loss per share - basic and diluted:	$	(0.30	)	$	(0.32	)	$	(0.69	)	$	(0.82	)

Weighted average shares used in loss per share calculation:
Basic		15,422			12,315			14,746			11,840
Diluted		15,422			12,315			14,746			11,840

The accompanying notes are an integral part of these condensed consolidated financial statements.

REPROS THERAPEUTICS INC. AND SUBSIDIARY

(A development stage company)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(unaudited and in thousands except share and per share amounts)

												Deficit
												Accumulated
					Additional							During the			Total
	Common Stock				Paid-in		Treasury Stock					Development			Stockholders'
	Shares		Amount		Capital		Shares		Amount			Stage			Equity
Balance at December 31, 2011		12,470,694	$	12	$	197,769		112,350	$	(1,380	)	$	(191,735	)	$	4,666
Stock based option compensation		-		-		1,902		-		-			-			1,902
Issuance of 100 shares of common stock at a share price of $5.07		100		-		-		-		-			-			-
Issuance of 2,463,537 shares of common stock at a share price of $4.50, net of offering costs of $777		2,463,537		3		10,307		-		-			-			10,310
Exercise of stock options to purchase common stock for cash ($1.33 to $10.88 per share)		16,488		-		121		-		-			-			121
Issuance of 11,173 shares of common stock for the cashless exercise of 27,915 stock options		11,173		-		-		-		-			-			-
Exercise of 121,079 Series B Warrants to purchase common stock for cash @ $2.49 per share		121,079		-		301		-		-			-			301
Issuance of 2,145,636 shares of common stock at a share price of $11.00, net of offering costs of $586		2,145,636		2		23,016		-		-			-			23,018
Net loss		-		-		-		-		-			(10,123	)		(10,123	)
Balance at September 30, 2012		17,228,707	$	17	$	233,416		112,350	$	(1,380	)	$	(201,858	)	$	30,195

The accompanying notes are an integral part of these consolidated financial statements.

REPROS THERAPEUTICS INC. AND SUBSIDIARY

(A development stage company)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited and in thousands)

							From Inception
							(August 20, 1987)
							through
	Nine Months Ended September 30,						September 30,
	2012			2011			2012

Cash Flows from Operating Activities
Net loss	$	(10,123	)	$	(9,759	)		(201,858	)
Gain on disposal of discontinued operations		-			-			(939	)
Gain on disposal of fixed assets		-			-			(102	)
Adjustments to reconcile net loss to net cash used in operating activities:
Noncash financing costs		-			-			316
Noncash inventory impairment		-			-			4,417
Noncash patent impairment		-			-			2,614
Noncash other income		-			-			(709	)
Noncash decrease in accounts payable		-			-			(1,308	)
Depreciation and amortization		106			84			4,262
Noncash stock-based compensation		1,902			1,654			11,435
Common stock issued for agreement not to compete		-			-			200
Series B Preferred Stock issued for consulting services		-			-			18
Changes in operating assets and liabilities
(net effects of purchase of businesses in 1988 and 1994):
Increase in receivables		-			-			(199	)
Increase in inventory		-			-			(4,447	)
(Increase) decrease in prepaid expenses and other current assets		(352	)		140			(148	)
Increase (decrease) in accounts payable and accrued expenses		367			744			9,937
Net cash used in operating activities		(8,100	)		(7,137	)		(176,511	)

Cash Flows from Investing Activities
Change in trading marketable securities		-			-			(191	)
Capital expenditures		(54	)		(15	)		(2,447	)
Capitalization of patents and patent applications		(578	)		(247	)		(5,534	)
Proceeds from sale of PP&E		-			-			225
Cash acquired in purchase of FTI		-			-			3
Proceeds from sale of subsidiary, less
$12,345 for operating losses during
1990 phase-out period		-			-			138
Proceeds from sale of the assets of FTI		-			-			2,250
Increase in net assets held for disposal		-			-			(213	)
Net cash used in investing activities		(632	)		(262	)		(5,769	)

Cash Flows from Financing Activities
Proceeds from issuance of common stock, net of offering costs		33,328			11,509			207,431
Exercise of stock options & warrants		422			3			797
Proceeds from a shareholder transaction		-			-			327
Proceeds from issuance of preferred stock		-			-			23,688
Purchase of treasury stock		-			-			(21,487	)
Proceeds from issuance of notes payable		-			-			2,839
Principal payments on notes payable		-			-			(1,732	)
Net cash provided by financing activities		33,750			11,512			211,863
Net increase (decrease) in cash and cash equivalents		25,018			4,113			29,583
Cash and cash equivalents at beginning of period		4,565			2,957			-
Cash and cash equivalents at end of period	$	29,583		$	7,070		$	29,583

The accompanying notes are an integral part of these condensed consolidated financial statements.

REPROS THERAPEUTICS INC. AND SUBSIDIARY

(A development stage company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2012

(Unaudited)

NOTE 1 — Organization, Operations and Liquidity

Repros Therapeutics Inc. (the “Company”, “RPRX,” “Repros,” or “we,” “us” or “our”) was organized on August 20, 1987. We are a development stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.

Our primary product candidate, Androxal®, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. We are developing Androxal® for men of reproductive age with low testosterone levels. Androxal® treats the underlying mechanism that causes secondary hypogonadism and restores normal testicular function. On July 9, 2012, we announced that we reached an agreement with the Food and Drug Administration (“FDA”) for the design of the pivotal efficacy studies for Androxal® for the treatment of secondary hypogonadism. The pivotal studies are being conducted under a Special Protocol Assessment (“SPA”).

Proellex®, our product candidate for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. On October 8, 2012, we announced that the FDA has agreed to a reclassification of the full clinical hold to a partial clinical hold on low dose oral Proellex® to allow us to conduct a Phase 2 study in the treatment of endometriosis. We initiated this study in November 2012 and expect to complete enrollment in the second quarter of 2013. Additionally, the FDA has accepted an Investigational New Drug Application (“IND”) for vaginally delivered Proellex® and, as a result, we commenced a Phase 2 vaginal administration study for uterine fibroids in the first quarter of 2012 and intend to report final study results around year end 2012.

Our product development pipeline is summarized in the table below:

Product Candidate (Indication) Androxal®	Status	Next Expected Milestone(s)

Secondary Hypogonadism	Phase 3	Complete first Phase 3 pivotal study (Q2 2013) Complete open label safety study (Q4 2013) Complete DEXA study (Q1 2014)
Proellex®
Uterine Fibroids	Phase 2	Complete Phase 2 study (vaginal delivery) (Q4 2012)
Endometriosis	Phase 2	Initiate Phase 2 study (oral delivery) (Q4 2012)

We also continue to maintain our patent portfolio of our phentolamine-based products for the treatment of sexual dysfunction and in order to create value from these assets in various ways which includes product out-licensing.

On February 1, 2012, we completed a registered direct offering to certain institutional investors, including certain existing shareholders, of 2,463,537 shares of our common stock at a price per share of $4.50. Net proceeds to us, after deducting placement agent's fees and offering expenses, were approximately $10.3 million.

On May 9, 2012, we announced that we held a meeting with the FDA to discuss the design of pivotal Phase 3 efficacy studies for Androxal® as well as the components of the overall drug development program required for a New Drug Application (“NDA”) submission. During this meeting we agreed with the FDA upon the registration requirements for Androxal® oral therapy for the treatment of secondary hypogonadism, including a safety database comprising of safety data for 100 subjects exposed to Androxal® for one year and 800 subjects exposed for six months, with a focus on overweight men under 60 years of age. The FDA further advised that a one year dual-energy X-ray absorptiometry (“DEXA”) study be conducted to ensure that there is no bone loss.

On July 9, 2012, we announced that we reached an agreement with the FDA for the design of the pivotal efficacy studies for Androxal® for the treatment of secondary hypogonadism. The pivotal studies are being conducted under a Special Protocol Assessment. The first pivotal study is fully enrolled in November 2012 and we have begun enrolling subjects into the second pivotal study. Additionally, we began enrolling men into a 500 subject open label safety study in June 2012 and began enrolling men into a one year DEXA study in the third quarter of 2012. Depending on study enrollment and the completion of other studies, we believe we may be able to submit an NDA in the first half of 2014.

At the end of July 2012, we satisfied our enrollment requirement of study subjects in the ongoing ZPV-200 Phase 2 study for the use of Proellex®-V, the proprietary vaginal delivery formulation of telapristone acetate, in the treatment of uterine fibroids and we intend to report the final study results around year end 2012. Additionally, we have begun enrolling subjects who completed the ZPV-200 study into a one year open label safety trial in order to begin collecting long term safety data which we expect the FDA to require in connection with the submission of an NDA.

On September 7, 2012, we completed a private placement of 2,145,636 shares of our common stock at a price per share of $11.00. Net proceeds to us, after deducting offering expenses, were approximately $23 million.

As of September 30, 2012, we had accumulated losses of $201.9 million, approximately $29.6 million in cash and cash equivalents, and our accounts payable and accrued expenses were approximately $1.8 million. We anticipate that our current liquidity will be sufficient to continue these planned studies into the second quarter of 2014; however, significant additional capital will be required for us to complete the development of our product candidates through NDA approval. We continue to explore potential additional financing alternatives (including corporate partnering opportunities) that would provide sufficient funds to enable us to continue to develop our two product candidates through NDA approval; however, there can be no assurance that we will be successful in raising any such additional funds on a timely basis or at all. The foregoing matters raise substantial doubt about our ability to continue as a going concern.

NOTE 2 — Patents and Patent Applications

As of September 30, 2012, we had approximately $1,939,000 in capitalized patent and patent application costs reflected on its balance sheet. Of this amount, $1,594,000 relates to patent and patent application costs for Androxal® and $345,000 relates to patent and patent application costs for Proellex®.

Should we not continue development of either drug candidate or should we not continue as a going concern, the remaining capitalized patent and patent application costs may not be recoverable, which would result in charges to operating results in future periods.

NOTE 3 — Accrued Expenses

Accrued expenses consist of the following (in thousands):

	September 30, 2012		December 31, 2011

Patent costs	$	123	$	51
Research and development costs		44		87
Personnel related costs		28		70
Other		134		45
Total	$	329	$	253

NOTE 4 — Loss Per Share

Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed using the average share price for the period and applying the treasury stock method to potentially dilutive outstanding options. In all applicable periods, all potential common stock equivalents were anti-dilutive and, accordingly, were not included in the computation of diluted loss per share.

The following table presents information necessary to calculate loss per share for the three and nine month periods ended September 30, 2012 and 2011 (in thousands, except per share amounts):

	Three Months Ended Sept. 30,						Nine Months Ended Sept. 30,
	2012			2011			2012			2011

Net Loss	$	(4,583	)	$	(3,960	)	$	(10,123	)	$	(9,759	)
Average common shares outstanding		15,422			12,315			14,746			11,840
Basic and diluted loss per share	$	(0.30	)	$	(0.32	)	$	(0.69	)	$	(0.82	)

Potential common stock of 5,264,207 and 5,260,795 common shares underlying stock options and warrants for the periods ended September 30, 2012 and 2011, respectively, were excluded from the above calculation of diluted loss per share because they were anti-dilutive. Potential common stock for the periods ended September 30, 2012 and 2011, includes Series A Warrants to purchase 1,749,270 shares of our common stock at an exercise price of $0.01. Also included in potential common stock for the periods ended September 30, 2012 and 2011, are Series B Warrants to purchase 1,569,421 and 1,690,500 shares, respectively, of our common stock at an exercise price of $2.49 issued in our February 8, 2011 public offering.

NOTE 5 — Commitments and Contingencies

Therapeutic uses of our Androxal^® product candidate are covered in the United States by five issued U.S. patents and seven pending patent applications. Foreign coverage of therapeutic uses of our Androxal^® product candidate includes 55 issued foreign patents and 53 foreign pending patent applications. The issued patents and pending applications relate to methods for treating certain conditions including the treatment of testosterone deficiency in men, the treatment of diabetes mellitus Type 2, the treatment of metabolic syndrome and conditions associated therewith, and the treatment of infertility in hypogonadal men. Androxal^® (the trans-isomer of clomiphene) is purified from clomiphene citrate. A third party individual holds two issued patents related to the use of an anti-estrogen such as clomiphene citrate and others for use in the treatment of androgen deficiency and disorders related thereto. We requested re-examination of one of these patents by the U.S. Patent and Trademark Office (“PTO”) based on prior art. The patent holder amended the claims in the re-examination proceedings, which led the PTO to determine that the amended claims were patentable in view of those publications under consideration and a re-examination certificate was issued. We subsequently filed a second request for re-examination by the PTO in light of a number of additional publications. The request was granted and all of the claims were finally rejected by the PTO in the re-examination. The patent holder appealed the rejections to the PTO Board of Patent Appeals and Interferences (the “PTO Board”) which ultimately reversed the rejections of several dependent claims in view of those publications under consideration. The patent holder filed a Notice of Appeal to the Federal Circuit on September 28, 2010 contesting the rejections maintained by the PTO Board. A decision was rendered by the Federal Circuit on December 12, 2011, affirming the rejection of the appealed claims. We expect that a re-examination certificate will be issued confirming the patentability of the remaining claims; however, if such a re-examination certificate were to issue, we believe that our development of Androxal® would not infringe any of the remaining claims and that all of the remaining claims are invalid on various grounds including additional prior art publications. We also believe that the second of these two patents is invalid in view of published prior art not considered by the PTO. If necessary, we intend to vigorously defend any and all claims against the holder of such patents in a court of competent jurisdiction in order to develop Androxal^® further. Adverse determinations in litigation proceedings could require us to seek licenses which may not be available on commercially reasonable terms, or at all, or subject us to significant liabilities, in which case we may not be able to successfully commercialize or out-license Androxal® until such patents expire or are otherwise no longer in force.

On March 1, 2010, we were served with a lawsuit where we were named as a co-defendant along with one of our clinical regulatory service providers (“CRO”) relating to the Proellex^® clinical trial study. The lawsuit was filed in the State of Tennessee, 30th Judicial District Chancery Court at Memphis by an investigator and claims that the CRO did not pay it amounts owing to it relating to the Proellex® study. We did not engage the investigator and under our agreement with the CRO, we believe the CRO is responsible for any such costs or damages regarding such lawsuit. Pursuant to a Settlement Agreement and Mutual Release entered into in October 2009, such CRO, on behalf of itself and its agents, released us from all claims which could be asserted by them against us. We believe such release covers the claims set forth in this lawsuit. The CRO failed to respond to the lawsuit, and a default judgment was entered against it in the amount of $172,901.29. We intend to vigorously defend any and all claims asserted by the investigator. An estimate of the possible costs or expenses to defend ourselves in this matter or risk of exposure under the litigation cannot be made at this time.

NOTE 6 — Subsequent Events

On October 31, 2012, Dr. Jean Fourcroy, MD, PhD, MPH, a member of Repros Therapeutics Inc.’s (the “Company”) board of directors (the “Board”) resigned her position as a member of the Board. Such resignation was not a result of any disagreements relating to the Company’s operations, policies or practices.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") that involve risk and uncertainties. Any statements contained in this quarterly report that are not statements of historical fact may be forward-looking statements. When we use the words "may," "anticipates," "believes," "plans," "expects" and similar expressions, we are identifying forward-looking statements. Forward-looking statements involve risks and uncertainties which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. The following discussion of financial condition should be read in conjunction with the accompanying consolidated financial statements and related notes.

Repros Therapeutics Inc.

Repros Therapeutics Inc. (the “Company,” “Repros,” or “we,” “us” or “our”) was organized on August 20, 1987. We are a development stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. Both of our product candidates have exhibited strong efficacy results in every study completed to date, and we believe the studies presently underway or scheduled to start in 2012 will place both programs on a clear late stage clinical development path.

We are developing Androxal®, an oral therapy that normalizes testicular function, for the treatment of low testosterone due to secondary hypogonadism. Secondary hypogonadism is associated with obesity and we believe it is among the most common causes of low testosterone in men. It is estimated that 13 million men in the U.S. experience low levels of testosterone, and the condition is becoming recognized with more frequency. As of 2011, sales of preparations for the treatment of low testosterone have exceeded $1 billion in the U.S. and first tier pharmaceutical companies have entered the low testosterone marketplace.

We believe Androxal® is highly differentiated from currently marketed testosterone treatments or those treatments in late stage development because it is an oral therapy and it treats the cause of secondary hypogonadism, which is inadequate pituitary hormones. We believe that by treating the cause of secondary hypogonadism, Androxal® also has the potential to maintain reproductive status and potentially improve overall metabolic profiles.

In December 2011, we completed a Phase 2B study of Androxal® in men with secondary hypogonadism, but naïve to testosterone treatment, at the Food and Drug Administration’s (the “FDA”) recommendation. Top line results of this study demonstrated that Androxal® was generally well tolerated compared to placebo and that there was no drug related serious adverse events that led to discontinuation. We met with the FDA in May 2012 to discuss the design of pivotal Phase 3 efficacy studies for Androxal® as well as the components of the overall drug development program required for a New Drug Application (“NDA”) submission. During this meeting, we agreed upon registration requirements for Androxal® oral therapy for the treatment of secondary hypogonadism. On July 9, 2012, we announced that we reached an agreement with the FDA for the design of the pivotal efficacy studies for Androxal® for the treatment of secondary hypogonadism. The pivotal studies are being conducted under a Special Protocol Assessment (“SPA”). The first pivotal study is fully enrolled in November 2012 and we have begun enrolling subjects into the second pivotal study. Additionally, we began enrolling men into a 500 subject open label safety study in June 2012 at 28 U.S. clinical sites and began enrolling men into a one year dual-energy X ray absorptiometry (“DEXA”) study in the third quarter of 2012 at 10 U.S. clinical sites. We anticipate these two studies to be fully enrolled in March 2013. Depending on study enrollment and the completion of other studies, we believe we may be able to submit an NDA in the first half of 2014.

We are also developing Proellex®, an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Uterine fibroids and endometriosis affect millions of women of reproductive age. Proellex® has shown statistically significant results in previous Phase 2 studies for endometriosis and uterine fibroids. We completed a low dose escalating study as permitted by the FDA in late 2011, to determine both signals of efficacy and safety for low oral doses of the drug. There was no evidence of elevations of liver enzymes over baseline, suggesting these lower doses avoid the type of adverse events seen at much higher doses in earlier studies. On October 8, 2012, we announced that the FDA has agreed to a reclassification of the full clinical hold to a partial clinical hold on low dose oral Proellex® to allow us to conduct a Phase 2 study in the treatment of endometriosis. We initiated this study in November 2012 and expect to complete enrollment in the second quarter of 2013.

The FDA has accepted an Investigational New Drug Application (“IND”) for vaginally delivered Proellex® and, as a result, we commenced a Phase 2 vaginal administration study for uterine fibroids in the first quarter of 2012. At the end of July 2012, we satisfied our enrollment requirement of subjects for the Phase 2 study and intend to report final study results around the end of 2012. We will then request an end of Phase 2 meeting with the FDA, so that we can commence a Phase 3 vaginal administration study for uterine fibroids. Additionally, we have begun enrolling subjects who completed the Phase 2 study into a one year open label safety trial in order to begin collecting long term safety data which we expect the FDA to require in connection with the submission of an NDA.

Our Research and Development Program

Our product development pipeline is summarized in the table below:

Product Candidate (Indication) Androxal®	Status	Next Expected Milestone(s)

Secondary Hypogonadism	Phase 3	Complete first Phase 3 pivotal study (Q2 2013) Complete open label safety study (Q4 2013) Complete DEXA study (Q1 2014)
Proellex®
Uterine Fibroids	Phase 2	Complete a Phase 2 study (vaginal delivery) (Q4 2012)
Endometriosis	Phase 2	Initiate Phase 2 study (oral delivery) (Q4 2012)

As of September 30, 2012, we had accumulated losses of $201.9 million, approximately $29.6 million in cash and cash equivalents, and our accounts payable and accrued expenses were approximately $1.8 million. On February 1, 2012, we completed a registered direct offering to certain institutional investors, including certain existing shareholders, of 2,463,537 shares of our common stock at a price per share of $4.50. Net proceeds to us, after deducting placement agent's fees and offering expenses, were approximately $10.3 million. On September 7, 2012, we completed a private placement of 2,145,636 shares of our common stock at a price per share of $11.00. Net proceeds to us, after deducting offering expenses, were approximately $23 million. We anticipate that our current liquidity will be sufficient to continue these planned studies into the second quarter of 2014; however, significant additional capital will be required for us to complete the development of our product candidates through NDA approval. We continue to explore potential additional financing alternatives (including corporate partnering opportunities) that would provide sufficient funds to enable us to continue to develop our two product candidates through NDA approval; however, there can be no assurance that we will be successful in raising any such additional funds on a timely basis or at all. The foregoing matters raise substantial doubt about our ability to continue as a going concern.

Androxal®

Product Overview

Our primary product candidate, Androxal®, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. We are developing Androxal® for men of reproductive age with low testosterone levels. Androxal® treats the underlying mechanism that causes secondary hypogonadism and restores normal testicular function. Unlike testosterone replacement which suppresses testicular function, Androxal® does not impair the reproductive status of men being treated for low testosterone.

Testosterone is an important male hormone. Testosterone deficiency in men is linked to several negative physical and mental conditions, including loss of muscle tone, reduced sexual desire and deterioration of memory and certain other cognitive functions. Testosterone production normally decreases as men age and this decline can be accelerated by obesity, sometimes leading to testosterone deficiency. The leading therapy for low testosterone is AndroGel®, a commercially available testosterone replacement cream marketed by Abbott Laboratories for the treatment of low testosterone, which we believe has had and continues to have significant sales in North America.

Based on our own clinical trial screening data, we believe over 70% of men that have low testosterone suffer from secondary hypogonadism, a pituitary defect which is characterized by suboptimal levels of LH (luteinizing hormone) and FSH (follicle stimulating hormone). LH and FSH are the pituitary hormones that stimulate testicular testosterone and sperm production, respectively. Men with secondary hypogonadism can be readily distinguished from those that have primary testicular failure via assessment of the levels of secretions of pituitary hormones, as men with primary testicular failure experience elevated secretions of pituitary hormones. In secondary hypogonadism, the low levels of LH and FSH fail to provide adequate hormone signaling to the testes, causing testosterone levels to drop to a level where we believe pituitary secretions fall under the influence of estrogen, which is enhanced in obese men, thus further suppressing the testicular stimulation from the pituitary.

Androxal® acts centrally to restore testicular function and, hence, normal testosterone in the body. The administration of exogenous testosterone can restore serum testosterone levels, but does not restore testicular function and thereby generally leads to the cessation of or significant reduction in sperm production. Androxal®, by contrast, restores levels of both LH and FSH, which stimulate testicular testosterone and sperm production, respectively.

We tested Androxal® in two studies designed to show that Androxal® improved testosterone levels as well as AndroGel® in men with secondary hypogonadism. These studies indicated that Androxal® had a superior ability to improve testosterone levels when compared to AndroGel® and that the improvement was statistically significant. In the meeting held on November 8, 2010, the FDA determined that improved testosterone levels would be sufficient provided that both placebo and Androxal® maintained sperm counts in a statistically significant manner as compared to an approved topical testosterone.

Androxal® will be required to undergo the full regulatory approval process, including pivotal Phase 3 trials, long-term Open Label Safety Studies and a dual-energy X ray absorptiometry (DEXA) study, as well as other requirements. Androxal® is closely related chemically to the drug, Clomid®, which is approved for use in women to treat certain infertility disorders. Clomid® contains both the trans and cis isomers of clomiphene citrate; Androxal® contains only the trans isomer. The FDA has indicated that testicular tumors, gynecomastia and adverse ophthalmologic events, which have been reported in males taking Clomid®, are potential risks that should be included in informed consent forms for our Androxal® clinical trials. We do not believe that Androxal® will present with the same adverse events given its reduced half-life and lack of cis isomer as compared to Clomid®. In our preclinical studies and our clinical trials to date, we have observed no evidence of any of these events except for certain ophthalmologic events in our preclinical dog study at doses significantly higher than those administered in the clinical trials.

All clinical trial results are subject to review by the FDA and the FDA may disagree with our conclusions about safety and efficacy. We caution that the results discussed herein are based on data from non-pivotal trials and that any necessary pivotal Phase 3 and long-term Open Label Safety Trial data may not agree with these results which will be based upon significantly larger and more diverse patient populations treated for longer periods of time.

Treatment for Secondary Hypogonadism in Men Wishing to Preserve Testicular Function (Reproductive Status)

On November 8, 2010, we held a Type B meeting with the FDA to discuss whether the FDA would review our protocols for a Phase 3 trial of Androxal® in men with secondary hypogonadism under an SPA. In the meeting, the FDA recommended that a Phase 2B study in men with secondary hypogonadism but naïve to testosterone treatment be conducted if we desired the protocols to be reviewed under an SPA. The FDA further opined that such Phase 2B study would provide for a more solid data base for design of Phase 3 studies and eventual approval of such studies under an SPA.

We have completed the Phase 2B trial which consisted of four arms; placebo, two doses of Androxal® and topical testosterone. In this study, at baseline the men exhibited morning testosterone less than 250 ng/dl and there was no statistical difference between the groups in testosterone at baseline. At the end of the three month dosing period, median morning testosterone levels were placebo (196 ng/dl), 12.5 mg Androxal® (432 ng/dl), 25 mg Androxal® (416 ng/dl) and Testim® (393 ng/dl). A comparison of final median morning testosterone in all three of the active arms to placebo showed them to be highly statistically different and there was no statistical difference observed between these active arms. This trial also showed that Androxal® was able to maintain sperm counts in men being treated for their low testosterone levels, whereas Testim® resulted in suppressed sperm levels.

On July 9, 2012, we announced that we reached an agreement with the FDA for the design of the pivotal efficacy studies for Androxal® for the treatment of secondary hypogonadism. The pivotal studies are being conducted under an SPA. The first pivotal study is fully enrolled in November 2012 and we have begun enrolling subjects into our second pivotal study. Based on the completed enrollment into our first pivotal study, we believe we will have top line results from this study in April 2013.

We began enrolling men into a 500 subject, six month open label safety study in June 2012 at 28 U.S. clinical sites. Currently, this study has enrolled 280 subjects and we anticipate full enrollment in March 2013. Incoming results from the first group of subjects in this study (n=62) to have completed six weeks of dosing have surpassed the FDA threshold of 75% above the lower limit of normal testosterone level, 300 ng/dL. 80.6% of the men would be considered responders via this criteria. The men included in the study meet the same criteria as the pivotal trial except that men currently using approved testosterone gels are allowed in the open label study following a washout period. Approximately one-third of the men in the open label study are current or previous testosterone users. The mean testosterone at the end of the first six weeks of dosing was 428 ng/dL as compared to a mean baseline level of 206 ng/dL. This highly statistically significant shift is even more impressive given the number of men who had washed out of recent testosterone use. No men achieved testosterone levels outside the normal range.

We began enrolling men into a one year, 150 subject DEXA study in the third quarter of 2012 at 10 U.S. clinical sites. Currently, this study has enrolled 53 subjects and we anticipate full enrollment in March 2013. This study is on the critical path to submission of the NDA. Depending on study enrollment and the completion of other studies, we believe we may be able to submit an NDA in the first half of 2014.

Unlike testosterone replacement therapies, Androxal® maintains the normal daily rhythm of testosterone peaks and valleys. We previously conducted three studies in which 24 hour testosterone levels were obtained and, unlike topical testosterone, morning testosterone was the maximum concentration observed, consistent with the normal circadian rhythm in men. These studies provide evidence that one assessment of testosterone between 8 a.m. and 10 a.m. correlates to the maximum value of testosterone for a given subject on a given day. Additionally, we conducted one additional 24 hour study which showed that Androxal®’s action in maintaining the normal rhythm is both predictable and dose-dependent.

We believe the advantages of oral delivery, maintenance of testicular function and additional metabolic benefits will be important differentiating factors for Androxal®, should it be approved. There can be no assurance, however, that we will be successful in implementing this strategy or that the FDA will approve our drug for commercial use.

Proellex®

Product Overview

Proellex®, our product candidate for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. There are currently no FDA-approved orally administered drug treatments for the long-term treatment of either uterine fibroids or endometriosis. The National Uterine Fibroids Foundation estimates that 80% of all women in the U.S. have uterine fibroids, and one in four of these women have symptoms severe enough to require treatment. According to the Endometriosis Association, endometriosis affects 6.3 million women in the U.S. and Canada and millions more worldwide.

The current standards of care for uterine fibroids and endometriosis consist of surgery or short-term treatment with gonadotropin-releasing hormone (“GnRH”) agonists drugs, such as Lupron®. GnRH agonists induce a low estrogen, menopausal-like state and promote bone loss and are not recommended for use for more than six months.

We have conducted numerous studies with Proellex® dosing approximately 700 women with the drug. All Proellex® studies completed to date exhibited strong efficacy signals, whether in uterine fibroids or endometriosis. In a 120 patient study of Proellex® as a treatment of uterine fibroids conducted in the United States (roughly 40 subjects per arm), both a 12.5 and 25 mg dose of Proellex® were compared to placebo. In this study each of the 12.5 and 25 mg doses achieved highly statistically significant results when compared to placebo when menstrual bleeding was assessed (p<0.0001). The two doses also achieved highly statistically significant improvement in quality of life measures using the Uterine Fibroid Symptom Quality of Life questionnaire developed and validated by Georgetown University and used in the development of device like treatments of uterine fibroids such as uterine artery embolization. There was no statistical difference in efficacy measures between the two doses. Importantly, in the Phase 2 U.S. trial a significant percentage of women stopped menstruating. Proellex® resulted in the induction of amenorrhea (cessation of menses), which we believe is a strong surrogate signal of efficacy. Over 80% of women on both the 12.5 and 25 mg doses exhibited no menses during the three month trial, whereas all women on placebo exhibited at least one menses.

Up until the summer of 2009, all side effects exhibited in the studies were considered manageable and the benefit of Proellex® far outweighed the risk. However, in Phase 3 efficacy and larger Phase 3 safety studies in diverse populations, a small number of subjects exhibited serious adverse effects associated with elevated liver enzymes. As a result of these findings, we elected to stop the trials and the FDA subsequently placed Proellex® on full clinical hold. All women that experienced elevated liver enzymes and returned for follow-up visits returned to baseline conditions with no overnight hospitalization necessary. An analysis of all the subjects that experienced such serious adverse effects showed that the effect only occurred in a small percentage of subjects that were exposed to the 50 mg dose of the drug for any period of time. Based on these findings, we petitioned the FDA to allow us to conduct a low dose study to demonstrate both safety and signals of efficacy in low oral doses of Proellex®, up to 12 mg administered per day. The FDA upgraded the full clinical hold to a partial hold to allow the low dose study to be conducted. In addition, we undertook two related initiatives: (i) the exploration of vaginal delivery as an alternative administrative route to bypass first-pass liver effects and reduce systemic exposure, which is currently in a Phase 2 study; and (ii) the screening of second generation molecules that do not possess the specific structures that may have induced the liver toxicity exhibited at higher doses of Proellex®.

Low Dose Study

Pursuant to the terms of the partial clinical hold currently in place as a result of the liver toxicity exhibited by Proellex®, the FDA allowed us to run a single study to test low doses of Proellex® for signals of safety and efficacy. The study tested 5 different doses of Proellex® (1, 3, 6, 9 and 12 mg), with 1 mg being the first dose tested. Each dose was then compared to placebo with weekly assessments of liver function during both the placebo and drug period. Subjects were dosed with the active drug for 10 weeks, which allowed for adequate time to determine the impact of a given dose on trends in liver function. Each dose was tested in up to 12 different subjects and assessment of pharmacokinetic parameters was obtained at the start of dosing and the end of the dosing period to determine overall and maximum drug exposure for a given dose. We also monitored changes in menstrual bleeding patterns and ovulation as well as changes in endometrial thickness. The FDA required that an independent Drug Safety Monitoring Board be established and that the informed consent clearly state the liver toxicity previously experienced with Proellex®. We have completed this study and have announced that there was no evidence of elevations of liver enzymes over baseline, suggesting these lower doses avoid the type of adverse events seen at much higher doses in earlier studies.

On July 16, 2012, we announced that we held a teleconference with the FDA to discuss the development of low dose oral Proellex® as a treatment for endometriosis. Subsequently, on October 8, 2012, we announced that the FDA has agreed to reclassify the full clinical hold to a partial clinical hold on low dose oral Proellex® to allow us to conduct a Phase 2 study in the treatment of endometriosis. We initiated this 90 subject, four month active dosing study in November 2012 and anticipate full enrollment in the second quarter of 2013. Depending on study enrollment, we expect to release results from this study in the fourth quarter of 2013.

Vaginal Administration

We are assessing vaginal administration of Proellex® to avoid first pass liver effects and achieve higher reproductive tract concentrations of the drug while minimizing systemic exposure. We reported results from two in vivo animal studies which confirmed reduced maximum circulating concentrations of the drug when administered vaginally, as well as efficacy signals at substantially lower doses than oral administration. The FDA has since accepted an IND for vaginally delivered Proellex® and, as a result, we commenced a Phase 2 vaginal administration study for uterine fibroids in the first quarter of 2012. At the end of July 2012, we satisfied our enrollment requirement of subjects into our Phase 2 vaginal administration study for uterine fibroids. We intend to report the final study results around year end 2012 and request an end of Phase 2 meeting with the FDA, so that we can commence a Phase 3 vaginal administration study for uterine fibroids. The Company has reviewed preliminary results from the women that have completed dosing at 3, 6 and 12 mg of the drug. The 12 mg dose achieved statistically significant improvement in menstrual bleeding, uterine fibroid symptoms and reduction in fibroid volume even with the low number of subjects enrolled into the study (n=12 @ 12 mg). Based on these findings, the Company believes the 12 mg dose is appropriate for further development. Exposure levels of the drug after vaginal administration of the 12 mg dose were extremely low, yet these low levels were able to produce significant clinical benefit. The two lower doses did not achieve the same level of improvement and the 12 mg dose was able to achieve separation from the two lower doses that approached or were significant. The 12 mg dose was well tolerated.

Additionally, we have begun enrolling subjects who completed the Phase 2 study into a one year open label safety trial in order to begin collecting long term safety data which we expect the FDA to require in connection with the submission of an NDA. The majority of the women being dosed with 12 mg in the Phase 2 study have elected to roll into the open label safety study.

Other Products

We continue limited out-licensing efforts for our phentolamine-based product candidates, including VASOMAX®, which had previously been approved for marketing in several countries in Latin America for the treatment of male erectile dysfunction under the brand name Z-Max. VASOMAX® has been on partial clinical hold in the U.S. since 1998, and no further development activities are planned.

Business Strategy

We plan to focus our clinical program on (i) conducting Phase 3 secondary hypogonadism trials for Androxal®, (ii) conducting a Phase 2 vaginal administration trial, and a subsequent Phase 3 trial, for Proellex® for uterine fibroids and (iii) conducting a Phase 2 trial for low dose oral Proellex® for endometriosis. We anticipate that our current liquidity will be sufficient to continue these planned studies into the second quarter of 2014; however, significant additional capital will be required for us to complete the development of our product candidates through NDA approval. We will continue to explore corporate partnering opportunities for assistance in the clinical development funding and commercialization of our products, as appropriate; however, there can be no assurance that an acceptable corporate partnering opportunity will be successfully completed or that we will be successful in raising the additional funds.

Risks Affecting Us

Our business is subject to numerous risks as discussed more fully in “Item 1A. Risk Factors" in our annual report on Form 10-K for the year ended December 31, 2011 and the section entitled “Risk Factors” in this quarterly report. We are investigating a variety of sources for raising capital. No assurance can be given that we will be successful in obtaining financing on acceptable terms or at all. We anticipate that if we are able to secure financing, that such financing will result in significant dilution of the ownership interests of our current stockholders and may provide certain rights to the new investors senior to the rights of our current stockholders, including but not limited to voting rights and rights to proceeds in the event of a sale or liquidation of the Company. In the event that we are unable to obtain adequate financing to meet our future needs, we will pursue other options, including but not limited to, reductions of expenses, sale of the Company, sale or license of a portion or all of our assets or the liquidation of the Company.

In addition, we have not received regulatory approval for any of our product candidates, have not successfully earned any significant commercial revenues from any of our product candidates and may never launch either of our product candidates. If we do not successfully commercialize any of our product candidates, we will be unable to achieve our business objectives. In addition, the reported results of our clinical trials completed to date may not be indicative of results that will be achieved in later-stage clinical trials involving larger and more diverse patient populations. As of September 30, 2012, we had accumulated losses of $201.9 million, approximately $29.6 million in cash and cash equivalents, and our accounts payable and accrued expenses were approximately $1.8 million. We believe we have sufficient funding to continue all of the clinical trials currently underway for Proellex® and Androxal®, and to commence planned subsequent clinical trials in 2012; however, based on the current and planned clinical trials, we will need to raise additional capital no later than the second quarter of 2014. Significant additional capital will be required for us to complete development of our product candidates through NDA approval. We continue to explore potential additional financing alternatives (including corporate partnering opportunities) that would provide sufficient funds to enable us to continue to develop our two product candidates through NDA approval; however, there can be no assurance that we will be successful in raising any such additional funds on a timely basis or at all. The foregoing matters raise substantial doubt about our ability to continue as a going concern and we expect to continue to incur significant losses over the next several years, and we may never become profitable. Our financial statements do not include any adjustments that might result from the outcome of these uncertainties.

Corporate Information

We were organized as a Delaware corporation in August 1987. Our principal executive offices are located at 2408 Timberloch Place, Suite B-7, The Woodlands, Texas, 77380, and our telephone number is (281) 719-3400. We maintain an internet website at www.reprosrx.com. The information on our website or any other website is not incorporated by reference into this quarterly report and does not constitute a part of this quarterly report. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and all amendments to such reports are made available free of charge through the Investor Relations section of our website as soon as reasonably practicable after they have been filed or furnished with the Securities and Exchange Commission.

General

We have experienced negative cash flows from operations since inception and have funded our activities to date primarily from equity financings and corporate collaborations. Based on our current and planned clinical trials, we will need to raise additional capital no later than the second quarter of 2014 in order to complete our development activities. It is possible that our current and planned clinical trial activities will be more costly and take longer than we anticipate; accordingly, there can be no assurance that additional capital will not be necessary prior to the time anticipated. We believe that we will secure sufficient capital to continue our ongoing and planned clinical programs assuming that the results of our current or planned clinical trials with Androxal® and Proellex® are favorable. If the results of these trials are unfavorable, there can be no assurance that we will be successful in obtaining additional capital in amounts sufficient to continue to fund its operations, which outcome would have a material adverse effect on the Company. The uncertainties relating to the foregoing matters raise substantial doubt about our ability to continue as a going concern. Our financial statements do not include any adjustments that might result from the outcome of these uncertainties.

We have 21 full-time employees. We utilize the services of contract research organizations, contract manufacturers and various consultants to assist us in performing clinical and regulatory services for the clinical development of our products. We are substantially dependent on our various contract groups to adequately perform the activities required to obtain regulatory approval of our products.

We have accumulated net operating losses through September 30, 2012 and the value of the tax asset associated with these accumulated net operating losses can be substantially diminished in value due to various tax regulations, including change in control provisions in the tax code. Our public offerings completed on February 5, 2007, October 2, 2008, September 11, 2009, October 13, 2009, February 8, 2011, February 1, 2012, the private placement completed on September 7, 2012, the sale and issuance of the ATM Shares and the issuance of unregistered shares as part of previously-disclosed settlements of certain claims may have created a change of ownership for Federal income tax purposes. We have not undertaken a study to determine if this has occurred. A change in ownership for Federal income tax purposes may result in a limitation on the use of net operating loss and tax credit carryforwards in future periods.

Losses have resulted principally from costs incurred in conducting clinical trials for our product candidates, in research and development activities related to efforts to develop our products and from the associated administrative costs required to support those efforts. There can be no assurance that we will be able to successfully complete the transition from a development stage company to the successful introduction of commercially viable products. Our ability to achieve profitability will depend on, among other things, successfully completing the clinical development of our products in a reasonable time frame and at a reasonable cost, obtaining regulatory approvals, establishing marketing, sales and manufacturing capabilities or collaborative arrangements with others that possess such capabilities, and, if applicable, continuing to raise sufficient funds to finance our activities. There can be no assurance that we will be able to achieve profitability.

Critical Accounting Policies and the Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Capitalized Patent and Patent Application Costs

We capitalize the cost associated with building our patent library for Androxal® and Proellex®. As of September 30, 2012, other assets consist of capitalized patent and patent application costs in the amount of $1,939,000. Patent costs, which include legal and application costs related to the patent portfolio, are being amortized over 20 years, or the lesser of the legal or the estimated economic life of the patent. Amortization of patent costs was $34,000 and $28,000 for the three month periods ended September, 30, 2012 and 2011, respectively, and was $96,000 and $80,000 for the nine month periods ended September 30, 2012 and 2011, respectively. Of the $1,939,000 in capitalized patent and patent application costs, $1,594,000 related to Androxal^® and $345,000 related to Proellex^®.

We review capitalized patent and patent application costs for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when estimated undiscounted cash flows expected to result from the patent are less than its carrying amount. The impairment loss recognized represents the excess of the patent cost as compared to its estimated fair value. We believe that our remaining capitalized patent and patent application costs are not impaired as of September 30, 2012.

Should we not continue development of either drug candidate or should we not continue as a going concern, capitalized patent and patent application costs may not be recoverable, which would result in a charge to operating results in future periods.

Accrued Expenses

We estimate accrued expenses as part of our process of preparing financial statements. Examples of areas in which subjective judgments may be required include costs associated with services provided by contract organizations for clinical trials, preclinical development and manufacturing of clinical materials. We accrue for costs incurred as the services are being provided by monitoring the status of the trials or services provided and the invoices received from our external service providers. In the case of clinical trials, a portion of the estimated cost normally relates to the projected cost to treat a patient in our trials, and we recognize this cost over the estimated term of the study based on the number of patients enrolled in the trial on an ongoing basis, beginning with patient enrollment. As actual costs become known to us, we adjust our accruals. To date, our estimates have not differed significantly from the actual costs incurred. However, subsequent changes in estimates may result in a material change in our accruals, which could also materially affect our balance sheet and results of operations.

R&D Expense

Research and development, or R&D, expenses include salaries and related employee expenses, contracted regulatory affairs activities, insurance coverage for clinical trials and prior product sales, contracted research and consulting fees, facility costs, amortization of capitalized patent costs and internal research and development supplies. We expense research and development costs in the period they are incurred. These costs consist of direct and indirect costs associated with specific projects as well as fees paid to various entities that perform research on our behalf.

Share-Based Compensation

We had one stock-based compensation plan at September 30, 2012, the 2011 Equity Incentive Plan. Accounting for stock based compensation generally requires the recognition of the cost of employee services for share-based compensation based on the grant date fair value of the equity or liability instruments issued. We use the Black-Scholes option pricing model to estimate the fair value of our stock options. Expected volatility is determined using historical volatilities based on historical stock prices for a period equal to the expected term. The expected volatility assumption is adjusted if future volatility is expected to vary from historical experience. The expected term of options represents the period of time that options granted are expected to be outstanding and falls between the options' vesting and contractual expiration dates. The risk-free interest rate is based on the yield at the date of grant of a zero-coupon U.S. Treasury bond whose maturity period equals the option's expected term.

Income Taxes

Our losses from inception to date have resulted principally from costs incurred in conducting clinical trials and in research and development activities related to efforts to develop our products and from the associated administrative costs required to support those efforts. We have recorded a deferred tax asset for our net operating losses (“NOL”); however, as we have incurred losses since inception, and since there is no certainty of future profits, a valuation allowance has been provided in full on our deferred tax assets in the accompanying consolidated financial statements. If we have an opportunity to use this NOL to off-set tax liabilities in the future, the use of this asset would be restricted based on Internal Revenue Service, state and local NOL use guidelines. Our public offerings completed on February 5, 2007, October 2, 2008, September 11, 2009, October 13, 2009, February 8, 2011, February 1, 2012, the private placement completed on September 7, 2012, the sale and issuance of the ATM Shares and the issuance of unregistered shares as part of previously-disclosed settlements of certain claims may have created a change of ownership for Federal income tax purposes. We have not undertaken a study to determine if this has occurred. A change in ownership for Federal income tax purposes may result in a limitation on the use of net operating loss and tax credit carryforwards in future periods.

Results of Operations

Comparison of the three-month and nine-month periods ended September 30, 2012 and 2011

Revenues and Other Income

Total revenues and other income increased to $1,000 for the three month period ended September 30, 2012 as compared to zero for the same period in the prior year. Total revenue and other income was $1,000 for both nine month periods ended September 30, 2012 and 2011. The increase for the three month period ended September 30, 2012 was primarily due to an increase of $1,000 in interest income as a result of the private placement completed on September 7, 2012 for net proceeds of approximately $23 million.

Research and Development Expenses

Research and development, or R&D, expenses include contracted services relating to our clinical product development activities which include preclinical studies, clinical trials, regulatory affairs and bulk manufacturing scale-up activities and bulk active ingredient purchases for preclinical and clinical trials primarily relating to our two products in clinical development, which are Androxal^® and Proellex^®. Research and development expenses also include internal operating expenses relating to our general research and development activities. R&D expenses decreased 3% or approximately $103,000 to $3.1 million for the three month period ended September 30, 2012 as compared to $3.2 million for the same period in the prior year. Our primary R&D expenses for the three month periods ended September 30, 2012 and 2011 are shown in the following table (in thousands):

Research and Development	Three-months ended September 30, 2012		Three-months ended September 30, 2011		Variance			Change (%)
Androxal® clinical development	$	1,969	$	2,138	$	(169	)		(8	)%
Proellex® clinical development		389		277		112			40	%
Payroll and benefits		543		421		122			29	%
Operating and occupancy		230		398		(168	)		(42	)%
Total	$	3,131	$	3,234	$	(103	)		(3	)%

R&D expenses decreased 3% or approximately $204,000 to $6.8 million for the nine month period ended September 30, 2012 as compared to $7.0 million for the same period in the prior year. Our primary R&D expenses for the nine month periods ended September 30, 2012 and 2011 are shown in the following table (in thousands):

Research and Development	Nine-months ended September 30, 2012		Nine-months ended September 30, 2011		Variance			Change (%)
Androxal® clinical development	$	3,275	$	4,366	$	(1,091	)		(25	)%
Proellex® clinical development		1,287		820		467			57	%
Payroll and benefits		1,455		875		580			66	%
Operating and occupancy		759		919		(160	)		(17	)%
Total	$	6,776	$	6,980	$	(204	)		(3	)%

The decrease in R&D expenses for both the three and nine month periods ended September 30, 2012 as compared to the same periods in the prior year, is primarily due to the decreased clinical development expenses related to Androxal® due to the completion of the Phase 2b study in men with secondary hypogonadism, partially offset by an increase in clinical development expenses related to Proellex® due to the commencement of the Phase 2 vaginal administration study for uterine fibroids. Payroll and benefits expenses increased for both the three and nine month periods ended September 30, 2012 as compared to the same period in the prior year due to increased headcount in R&D employees. Operating and occupancy expenses decreased for the three month period ended September 30, 2012 as compared to the same period in the prior year due to a decrease in costs associated with our patent portfolio. Operating and occupancy expenses decreased for the nine month period ended September 30, 2012 as compared to the same period in the prior year due to a decrease in costs associated with our patent portfolio, partially offset by an increase in consulting and other outside services.

To date through September 30, 2012 we have incurred approximately $23.1 million for the development of Androxal® and approximately $58.5 million for the development of Proellex®. These accumulated costs exclude any internal operating expenses.

General and Administrative Expenses

General and administrative expenses, or G&A, increased 100% or approximately $727,000 to $1.5 million for the three month period ended September 30, 2012 as compared to $726,000 for the same period in the prior year. Our primary G&A expenses for the three month period ended September 30, 2012 and 2011 are shown in the following table (in thousands):

General and Administrative	Three-months ended Sept. 30, 2012		Three-months ended Sept. 30, 2011		Variance		Change (%)
Payroll and benefits	$	953	$	469	$	484		103	%
Operating and occupancy		500		257		243		95	%
Total	$	1,453	$	726	$	727		100	%

G&A payroll and benefits expenses include salaries, bonuses, severance costs, non-cash stock based compensation expense and fringe benefits. Included in payroll and benefits expense is a charge for non-cash stock based compensation of $653,000 for the three month period ended September 30, 2012 as compared to $299,000 for the same period in the prior year. Additionally, salaries for the three month period ended September 30, 2012 were $275,000 as compared to $150,000 for the same period in the prior year. The increase in salaries is primarily due to an increase in headcount and the discontinuation of the salary reduction program put in place in August 2009.

G&A operating and occupancy expenses, which include expenses to operate as a public company, increased 95% or approximately $243,000 to $500,000 for the three month period ended September 30, 2012 as compared to $257,000 for the same period in the prior year. The increase is primarily due to an increase in professional services and travel expenses.

G&A expenses increased 20% or approximately $568,000 to $3.3 million for the nine month period ended September 30, 2012 as compared to $2.8 million for the same period in the prior year. Our primary G&A expenses for the nine month period ended September 30, 2012 and 2011 are shown in the following table (in thousands):

General and Administrative	Nine-months ended Sept. 30, 2012		Nine-months ended Sept. 30, 2011		Variance		Change (%)
Payroll and benefits	$	2,026	$	1,762	$	264		15	%
Operating and occupancy		1,322		1,018		304		30	%
Total	$	3,348	$	2,780	$	568		20	%

G&A payroll and benefits expenses include salaries, bonuses, severance costs, non-cash stock option compensation expense and fringe benefits. Included in payroll and benefits expense is a charge for non-cash stock based compensation expense of approximately $1.3 million for both nine month periods ended September 30, 2012 and 2011. Additionally, salaries for the nine month period ended September 30, 2012 were $664,000 as compared to $380,000 for the same period in the prior year. The increase in salaries is primarily due to an increase in headcount and the discontinuation of the salary reduction program put in place in August 2009.

G&A operating and occupancy expenses, which include expenses to operate as a public company, increased 30% or approximately $304,000 to $1.3 million for the nine month period ended September 30, 2012 as compared to $1.0 million for the same period in the prior year. The increase is primarily due to an increase in professional services and travel expenses.

Off-Balance Sheet Arrangements

As of September 30, 2012, the only off-balance sheet arrangement we have is the operating lease relating to our facility.

Liquidity and Capital Resources

Since our inception, we have financed our operations primarily with proceeds from private placements and public offerings of equity securities and with funds received under collaborative agreements.

On February 12, 2010, we entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Ladenburg Thalmann & Co. Inc. (“Ladenburg”), pursuant to which we may issue and sell from time to time through Ladenburg, as sales agent and/or principal, shares of our common stock having an aggregate offering price of up to $10 million (the “ATM Shares”). Ladenburg is not required to sell on our behalf any specific number or dollar amount of the ATM Shares, but Ladenburg, upon acceptance of written instructions from us, agreed to use its commercially reasonable efforts consistent with its customary trading and sales practices, to sell the ATM Shares up to the amount specified, and otherwise in accordance with the terms of a placement notice delivered to Ladenburg. We have no obligation to sell any ATM Shares under the Equity Distribution Agreement, and may at any time suspend sales under the Equity Distribution Agreement, provided that such suspension shall not affect either party’s obligations with respect to the ATM Shares sold prior to the receipt of notice of such suspension. Ladenburg receives a commission of 4% of the gross sales price of all ATM Shares sold through it under the Equity Distribution Agreement. The ATM Shares are issued pursuant to our shelf registration statement on Form S-3, as amended (File No. 333-163648). Between January 1, 2012 and September 30, 2012, we sold an aggregate of 100 ATM Shares at a weighted average share price of $5.07, for proceeds of approximately $500, net of expenses. Cumulative through September 30, 2012, we have sold 2,775,476 ATM Shares at a weighted average share price of $2.67, for proceeds of approximately $7.4 million, net of expenses. Pursuant to General Instruction I.B.6. of Form S-3, in the event that the aggregate market value of our common stock held by non-affiliates (“Public Float”) is less than $75 million, we are limited to the amount of shares we can sell under this Form S-3 to no more than one-third of the Public Float, during a period of 12 calendar months immediately prior to, and including, the date of such sale of such common stock. As of the date of this filing, we are not restricted by such rule, however, should our Public Float fall below $75 million in the future, we will again be subject to such limitation.

On February 1, 2012, we completed a registered direct offering to certain institutional investors, including certain existing shareholders, of 2,463,537 shares of our common stock at a price per share of $4.50 (the “2012 Public Offering”). Net proceeds to us, after deducting placement agent's fees and offering expenses, were approximately $10.3 million.

Our primary use of cash to date has been in operating activities to fund research and development, including preclinical studies and clinical trials, and general and administrative expenses. We had cash and cash equivalents of approximately $29.6 million as of September 30, 2012 as compared to $4.6 million as of December 31, 2011. All cash and cash equivalents as of September 30, 2012 and December 31, 2011 were held in an account backed by U.S. government securities.

Net cash of approximately $8.1 million and $7.1 million was used in operating activities during the nine month periods ended September 30, 2012 and 2011, respectively. The major use of cash for operating activities for the nine month period ended September 30, 2012 was to fund our operations. Cash used in investing activities during the nine month period ended September 30, 2012 was approximately $632,000 primarily for capitalized patent and patent application costs for Androxal® and Proellex®. Cash provided by financing activities during the nine month period ended September 30, 2012 was approximately $33.8 million as a result of completing the 2012 Public Offering on February 1, 2012 and the private placement on September 7, 2012.

We have experienced negative cash flows from operations since inception. We will require substantial funds for research and development, including preclinical studies and clinical trials of our product candidates, and to commence sales and marketing efforts if appropriate, if the FDA or other regulatory approvals are obtained. Based on our current and planned clinical activities, we will need to raise additional capital no later than the second quarter of 2014 or seek additional funding in the public or private capital markets through corporate collaborations or other financing vehicles in order to continue our development activities through NDA approval. There can be no assurance that any such funding will be available to us on favorable terms or at all. If we are successful in obtaining additional financing, the terms of such financing may have the effect of diluting or adversely affecting the holdings or the rights of holders of our common stock. It is possible that our clinical trial activities will be more costly and take longer than we anticipate; accordingly, there can be no assurance that additional capital will not be necessary prior to the time anticipated. Our capital requirements will depend on many factors, which are discussed in detail in “Item 1A. Risk Factors” to Part I of Form 10-K for the fiscal year ended December 31, 2011. Additionally, as discussed in Note 5, there is a third party individual patent holder that claims priority over our patent application for Androxal®. The uncertainties relating to the foregoing matters raise substantial doubt about our ability to continue as a going concern.

Our results of operations may vary significantly from quarter to quarter and year to year, and depend on, among other factors, our ability to raise additional capital on acceptable terms or at all, on our ability to be successful in our clinical trials, the regulatory approval process in the United States and other foreign jurisdictions and the ability to complete strategic licenses and product development agreements. The timing of our revenues may not match the timing of our associated product development expenses. To date, research and development expenses have usually exceeded revenue in any particular period and/or fiscal year.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk. We had cash and cash equivalents of approximately $29.6 million at September 30, 2012 which is held in an account backed by U.S. government securities. Although this cash account is subject to fluctuations in interest rates and market conditions, no significant gain or loss on this account is expected to be recognized in earnings. We do not invest in derivative securities.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Based on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures (as defined in Rule 13a-15(e)) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), were effective as of September 30, 2012.

Changes in Internal Control over Financial Reporting

In connection with the evaluation described above, we identified no change in internal control over financial reporting that occurred during the quarter ended September 30, 2012 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

Therapeutic uses of our Androxal® product candidate are covered in the United States by five issued U.S. patents and seven pending patent applications. Foreign coverage of therapeutic uses of our Androxal® product candidate includes 55 issued foreign patents and 53 foreign pending patent applications. The issued patents and pending applications relate to methods for treating certain conditions including the treatment of testosterone deficiency in men, the treatment of diabetes mellitus Type 2, the treatment of metabolic syndrome and conditions associated therewith, and the treatment of infertility in hypogonadal men. Androxal® (the trans-isomer of clomiphene) is purified from clomiphene citrate. A third party individual holds two issued patents related to the use of an anti-estrogen such as clomiphene citrate and others for use in the treatment of androgen deficiency and disorders related thereto. We requested re-examination of one of these patents by the U.S. Patent and Trademark Office (“PTO”) based on prior art. The patent holder amended the claims in the re-examination proceedings, which led the PTO to determine that the amended claims were patentable in view of those publications under consideration and a re-examination certificate was issued. We subsequently filed a second request for re-examination by the PTO in light of a number of additional publications. The request was granted and all of the claims were finally rejected by the PTO in the re-examination. The patent holder appealed the rejections to the PTO Board of Patent Appeals and Interferences (the “PTO Board”) which ultimately reversed the rejections of several dependent claims in view of those publications under consideration. The patent holder filed a Notice of Appeal to the Federal Circuit on September 28, 2010 contesting the rejections maintained by the PTO Board. A decision was rendered by the Federal Circuit on December 12, 2011, affirming the rejection of the appealed claims. We expect that a re-examination certificate will be issued confirming the patentability of the remaining claims; however, if such a re-examination certificate were to issue, we believe that our development of Androxal® would not infringe any of the remaining claims and that all of the remaining claims are invalid on various grounds including additional prior art publications. We also believe that the second of these two patents is invalid in view of published prior art not considered by the PTO. If necessary, we intend to vigorously defend any and all claims against the holder of such patents in a court of competent jurisdiction in order to develop Androxal® further. Adverse determinations in litigation proceedings could require us to seek licenses which may not be available on commercially reasonable terms, or at all, or subject us to significant liabilities, in which case we may not be able to successfully commercialize or out-license Androxal® until such patents expire or are otherwise no longer in force.

On March 1, 2010, we were served with a lawsuit where we were named as a co-defendant along with one of our clinical regulatory service providers (“CRO”) relating to the Proellex® clinical trial study. The lawsuit was filed in the State of Tennessee, 30th Judicial District Chancery Court at Memphis by an investigator and claims that the CRO did not pay it amounts owing to it relating to the Proellex® study. We did not engage the investigator and under our agreement with the CRO, we believe the CRO is responsible for any such costs or damages regarding such lawsuit. Pursuant to a Settlement Agreement and Mutual Release entered into in October 2009, such CRO, on behalf of itself and its agents, released us from all claims which could be asserted by them against us. We believe such release covers the claims set forth in this lawsuit. The CRO failed to respond to the lawsuit, and a default judgment was entered against it in the amount of $172,901.29. We intend to vigorously defend any and all claims asserted by the investigator. An estimate of the possible costs or expenses to defend ourselves in this matter or risk of exposure under the litigation cannot be made at this time.

Item 1A. Risk Factors

There were no material changes from the risk factors previously disclosed in the registrant’s Form 10-K for the fiscal year ended December 31, 2011 in response to “Item 1A. Risk Factors” to Part I of Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On September 7, 2012, we completed a private placement of 2,145,636 shares of our common stock at a price per share of $11.00 (the “Shares”), with certain institutional investors (the “Investors”). The net proceeds to us, after deducting offering expenses, were approximately $23 million. The Shares were sold without registration pursuant to Section 4(2) and/or Rule 506 of Regulation D promulgated under the Securities Exchange Act of 1933, as amended. In accordance with the terms of the private placement, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the Investors and in connection therewith, a Registration Rights Agreement (the “Registration Rights Agreement”), pursuant to which we agreed to file a registration statement to register the resale of the Shares by the Investors to the public within sixty (60) days of closing. We filed such registration statement on Form S-3 (Registration No. 333-184159) on September 28, 2012, as failure to do so before the expiration of the sixty (60) day period would have resulted in penalty payments being owed to the Investors. We however, still need to maintain compliance with all public filings necessary for the Investors to sell their Shares pursuant to Rule 144, as failure to do so will result in significant penalties for the Company.

Subsequent to the execution of the Purchase Agreement by the Investors, we entered into an agreement (the “Trout Agreement”) with Trout Capital LLC (“Trout”), whereby the Company agreed to pay Trout a fee for its assistance in connection with the placement of the Shares. Pursuant to the Trout Agreement, Trout had no commitment to purchase any of the Shares and only acted as an agent in obtaining indications of interest for the Shares from the Investors who purchased the Shares directly from the Company, with the Company retaining final authority on all matters. The Trout Agreement also required the Company to indemnify Trout against certain liabilities arising from their services relating to the sale and issuance of the Shares.

Item 3.

Defaults Upon Senior Securities.

None

Item 4.

Mine Safety Disclosures.

None

Item 5.

Other Information

None

Item 6.

Exhibits

3.1(a)

Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Company's Registration Statement on Form SB-2 (No. 33-57728-FW), as amended ("Registration Statement")).

3.1(b)

Certificate of Amendment to the Company's Restated Certificate of Incorporation, dated as of May 2, 2006 (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K as filed with the Securities and Exchange Commission (the "Commission") on May 2, 2006).

3.1(c)

Certificate of Amendment to the Company's Restated Certificate of Incorporation, as amended, dated as of December 16, 2008 (incorporated by reference to Exhibit 3.1(d) to the Company's Current Report on Form 8-K as filed with the Commission on December 23, 2008).

3.1(d)

Certificate of Designation of Series One Junior Participating Preferred Stock dated September 2, 1999 (incorporated by reference to Exhibit A to Exhibit 4.1 to the Company's Registration Statement on Form 8-A as filed with the Commission on September 3, 1999).

3.1(e)

Certificate of Amendment to Restated Certificate of Incorporation, dated as of November 18, 2009. Exhibit 3.1(e) to the Company’s Current Report on Form 8-K dated November 19, 2009 is incorporated herein by reference.

3.1(f)

Certificate of Amendment to Restated Certificate of Incorporation, dated October 14, 2010. Exhibit 3.1(f) to the Company’s Current Report on Form 8-K dated October 14, 2010 is incorporated herein by reference.

3.2

Restated Bylaws of the Company (incorporated by reference to Exhibit 3.4 to the Registration Statement).

4.1

Form of Series A Warrant Certificate. Exhibit 4.10 to the Company’s Registration Statement on Form S-1/A (No. 333-171196) as filed with the Commission on February 2, 2011 is incorporated herein by reference.

4.2

Form of Series B Warrant Certificate. Exhibit 4.11 to the Company’s Registration Statement on Form S-1/A (No. 333-171196) as filed with the Commission on February 2, 2011 is incorporated herein by reference.

4.3

Series A Warrant Agreement dated February 8, 2011 by and among the Company and Computershare Inc. and its wholly-owned subsidiary, Computershare Trust Company, N.A. Exhibit 4.1 to the Company’s Current Report on Form 8-K as filed with the Commission on February 9, 2011 is incorporated herein by reference.

4.4

Series B Warrant Agreement dated February 8, 2011 by and among the Company and Computershare Inc. and its wholly-owned subsidiary, Computershare Trust Company, N.A. Exhibit 4.2 to the Company’s Current Report on Form 8-K as filed with the Commission on February 9, 2011 is incorporated herein by reference.

10.1

Securities Purchase Agreement dated August 31, 2012 by and among the Company and certain institutional investors. Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the Commission on September 12, 2012 is incorporated herein by reference.

10.2

Registration Rights Agreement dated August 31, 2012 by and among the Company and certain institutional investors. Exhibit 10.2 to the Company’s Current Report on Form 8-K as filed with the Commission on September 12, 2012 is incorporated herein by reference.

10.3

Agreement dated September 4, 2012 by and between the Company and Trout Capital LLC. Exhibit 10.3 to the Company’s Current Report on Form 8-K as filed with the Commission on September 12, 2012 is incorporated herein by reference.

31.1*

Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer).

31.2*

Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer).

32.1*

Certification furnished pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer).

32.2*

Certification furnished pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer).

Filed herewith.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	REPROS THERAPEUTICS INC.

Date: November 14, 2012
	By:	/s/ Joseph S. Podolski
		Joseph S. Podolski
		Chief Executive Officer and Director
		(Principal Executive Officer)

Date: November 14, 2012
	By:	/s/ Katherine A. Anderson
		Katherine A. Anderson
		Chief Financial Officer
		(Principal Financial Officer)

EX-31.1 2 v326064_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

I, Joseph S. Podolski, certify that:

1. I have reviewed this quarterly report of Repros Therapeutics Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 14, 2012	By: /s/ Joseph S. Podolski
	Joseph S. Podolski
	Chief Executive Officer
	Repros Therapeutics Inc.

EX-31.2 3 v326064_ex31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

I, Katherine A. Anderson, certify that:

1. I have reviewed this quarterly report of Repros Therapeutics Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 14, 2012	By: /s/ Katherine A. Anderson
	Katherine A. Anderson
	Chief Financial Officer
	Repros Therapeutics Inc.

EX-32.1 4 v326064_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Repros Therapeutics Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Joseph S. Podolski, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 14, 2012	By: /s/ Joseph S. Podolski
	Joseph S. Podolski
	Chief Executive Officer
	Repros Therapeutics Inc.

A signed original of this written statement required by Section 906 has been provided to Repros and will be retained by Repros and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 v326064_ex32-2.htm EXHIBIT 32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Repros Therapeutics Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Katherine A. Anderson, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 14, 2012	By: /s/ Katherine A. Anderson
	Katherine A. Anderson
	Chief Financial Officer
	Repros Therapeutics Inc.

EX-101.INS 6 rprx-20120930.xml XBRL INSTANCE DOCUMENT 0000897075 2010-03-01 2010-03-31 0000897075 2010-12-31 0000897075 2011-07-01 2011-09-30 0000897075 2011-01-01 2011-09-30 0000897075 rprx:SeriesBWarrantMember 2011-01-01 2011-09-30 0000897075 rprx:SeriesWarrantMember 2011-01-01 2011-09-30 0000897075 2011-09-30 0000897075 2011-12-31 0000897075 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0000897075 us-gaap:CommonStockMember 2011-12-31 0000897075 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2011-12-31 0000897075 us-gaap:TreasuryStockMember 2011-12-31 0000897075 2012-07-01 2012-09-30 0000897075 2012-01-01 2012-09-30 0000897075 rprx:SeriesBWarrantMember 2012-01-01 2012-09-30 0000897075 rprx:SeriesWarrantMember 2012-01-01 2012-09-30 0000897075 rprx:IssuanceDuringPeriodTwoMember 2012-01-01 2012-09-30 0000897075 rprx:ProellexMember rprx:EndometriosisMember 2012-01-01 2012-09-30 0000897075 rprx:ProellexMember rprx:UterineFibroidsMember 2012-01-01 2012-09-30 0000897075 rprx:AndroxalMember rprx:SecondaryHypogonadismMember 2012-01-01 2012-09-30 0000897075 us-gaap:PrivatePlacementMember 2012-01-01 2012-09-30 0000897075 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-09-30 0000897075 us-gaap:CommonStockMember 2012-01-01 2012-09-30 0000897075 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2012-01-01 2012-09-30 0000897075 rprx:IssuanceDuringPeriodOneMember 2012-01-01 2012-09-30 0000897075 rprx:IssuanceDuringPeriodFourMember 2012-01-01 2012-09-30 0000897075 rprx:IssuanceDuringPeriodThreeMember 2012-01-01 2012-09-30 0000897075 us-gaap:StockOptionMember us-gaap:MaximumMember 2012-01-01 2012-09-30 0000897075 us-gaap:StockOptionMember us-gaap:MinimumMember 2012-01-01 2012-09-30 0000897075 us-gaap:AdditionalPaidInCapitalMember rprx:IssuanceDuringPeriodTwoMember 2012-01-01 2012-09-30 0000897075 us-gaap:CommonStockMember rprx:IssuanceDuringPeriodTwoMember 2012-01-01 2012-09-30 0000897075 us-gaap:CommonStockMember rprx:IssuanceDuringPeriodOneMember 2012-01-01 2012-09-30 0000897075 us-gaap:AdditionalPaidInCapitalMember rprx:IssuanceDuringPeriodFourMember 2012-01-01 2012-09-30 0000897075 us-gaap:CommonStockMember rprx:IssuanceDuringPeriodThreeMember 2012-01-01 2012-09-30 0000897075 us-gaap:CommonStockMember rprx:IssuanceDuringPeriodFourMember 2012-01-01 2012-09-30 0000897075 2012-09-30 0000897075 rprx:IssuanceDuringPeriodTwoMember 2012-09-30 0000897075 rprx:ProellexMember 2012-09-30 0000897075 rprx:AndroxalMember 2012-09-30 0000897075 rprx:PeriodTwoMember 2012-09-30 0000897075 rprx:PeriodOneMember 2012-09-30 0000897075 rprx:ThirdPartyMember 2012-09-30 0000897075 rprx:ForeignMember 2012-09-30 0000897075 rprx:DomesticMember 2012-09-30 0000897075 us-gaap:AdditionalPaidInCapitalMember 2012-09-30 0000897075 us-gaap:CommonStockMember 2012-09-30 0000897075 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2012-09-30 0000897075 us-gaap:TreasuryStockMember 2012-09-30 0000897075 1987-08-20 2012-09-30 0000897075 2012-11-06 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure 10-Q false 2012-09-30 2012 Q3 RPRX REPROS THERAPEUTICS INC. 0000897075 --12-31 Smaller Reporting Company 17116357

2957000

7070000

4565000

29583000

99000

451000

4664000

30034000

15000

59000

1385000

1939000

345000

1594000

6064000

32032000

1145000

1508000

253000

329000

1398000

1837000

12000

17000

197769000

233416000

1380000

191735000

201858000

197769000

12000

-191735000

-1380000

233416000

17000

-201858000

-1380000

6064000

32032000

0.001

5000000

0.001

75000000

12470694

17228707

12358344

17116357

112350

28755000

627000

1219000

1000

16300000

102000

1003000

1000

48006000

3234000

6980000

3131000

6776000

188692000

726000

2780000

1453000

3348000

51441000

388000

3960000

9760000

4584000

10124000

240521000

-3960000

-9759000

-4583000

-10123000

-192515000

-1828000

939000

-3960000

-9759000

-4583000

-10123000

-193404000

-8454000

-3960000

-9759000

-4583000

-10123000

-201858000

-0.32

-0.82

-0.30

-0.69

12315

11840

15422

14746

12315

11840

15422

14746

2463537

2145636

100

2145636

11173

2463537

100

11173

2145636

2.49

4.50

11.00

5.07

11.00

10.88

1.33

316000

4417000

2614000

709000

1308000

84000

106000

4262000

1654000

1902000

11435000

-200000

18000

199000

4447000

-140000

352000

148000

744000

367000

9937000

-7137000

-8100000

-176511000

191000

15000

54000

2447000

247000

578000

5534000

225000

3000

138000

2250000

213000

-262000

-632000

-5769000

11509000

33328000

207431000

3000

422000

797000

327000

23688000

21487000

2839000

1732000

11512000

33750000

211863000

4113000

25018000

29583000

12345000

NOTE 1 — Organization, Operations and Liquidity Repros Therapeutics Inc. (the “Company”, “RPRX,” “Repros,” or “we,” “us” or “our”) was organized on August 20, 1987. We are a development stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. Our primary product candidate, Androxal®, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. We are developing Androxal® for men of reproductive age with low testosterone levels. Androxal® treats the underlying mechanism that causes secondary hypogonadism and restores normal testicular function. On July 9, 2012, we announced that we reached an agreement with the Food and Drug Administration (“FDA”) for the design of the pivotal efficacy studies for Androxal® for the treatment of secondary hypogonadism. The pivotal studies are being conducted under a Special Protocol Assessment (“SPA”).  Proellex®, our product candidate for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. On October 8, 2012, we announced that the FDA has agreed to a reclassification of the full clinical hold to a partial clinical hold on low dose oral Proellex® to allow us to conduct a Phase 2 study in the treatment of endometriosis. We initiated this study in November 2012 and expect to complete enrollment in the second quarter of 2013. Additionally, the FDA has accepted an Investigational New Drug Application (“IND”) for vaginally delivered Proellex® and, as a result, we commenced a Phase 2 vaginal administration study for uterine fibroids in the first quarter of 2012 and intend to report final study results around year end 2012. Our product development pipeline is summarized in the table below: <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="text-align: center; width: 34%; vertical-align: bottom;">Product Candidate (Indication)Androxal®</td><td style="text-align: center; width: 1%; vertical-align: bottom; font-weight: bold;"> </td><td style="text-align: left; width: 21%; vertical-align: bottom; font-weight: bold;">Status</td><td style="text-align: center; width: 1%; vertical-align: bottom; font-weight: bold;"> </td><td style="text-align: left; width: 43%; vertical-align: bottom; font-weight: bold;">Next Expected Milestone(s)</td></tr><tr style="vertical-align: top;"><td style="text-align: center; vertical-align: bottom;"> </td><td style="text-align: center; vertical-align: bottom; font-weight: bold;"> </td><td style="text-align: left; vertical-align: bottom; font-weight: bold;"> </td><td style="text-align: center; vertical-align: bottom; font-weight: bold;"> </td><td style="text-align: left; vertical-align: bottom; font-weight: bold;"> </td></tr><tr style="vertical-align: top;"><td style="font-style: italic;">Secondary Hypogonadism</td><td style="font-style: italic;"> </td><td>Phase 3</td><td> </td><td>Complete first Phase 3 pivotal study (Q2 2013) Complete open label safety study (Q4 2013) Complete DEXA study (Q1 2014) </td></tr><tr style="vertical-align: top;"><td style="font-weight: bold;">Proellex®</td><td style="font-weight: bold;"> </td><td> </td><td> </td><td> </td></tr><tr style="vertical-align: top;"><td style="font-style: italic;">Uterine Fibroids</td><td style="font-style: italic;"> </td><td>Phase 2</td><td> </td><td>Complete Phase 2 study (vaginal delivery) (Q4 2012) </td></tr><tr style="vertical-align: top;"><td>Endometriosis </td><td style="font-style: italic;"> </td><td>Phase 2</td><td> </td><td>Initiate Phase 2 study (oral delivery) (Q4 2012) </td></tr></table> We also continue to maintain our patent portfolio of our phentolamine-based products for the treatment of sexual dysfunction and in order to create value from these assets in various ways which includes product out-licensing. On February 1, 2012, we completed a registered direct offering to certain institutional investors, including certain existing shareholders, of 2,463,537 shares of our common stock at a price per share of $4.50. Net proceeds to us, after deducting placement agent's fees and offering expenses, were approximately $10.3 million. On May 9, 2012, we announced that we held a meeting with the FDA to discuss the design of pivotal Phase 3 efficacy studies for Androxal® as well as the components of the overall drug development program required for a New Drug Application (“NDA”) submission. During this meeting we agreed with the FDA upon the registration requirements for Androxal® oral therapy for the treatment of secondary hypogonadism, including a safety database comprising of safety data for 100 subjects exposed to Androxal® for one year and 800 subjects exposed for six months, with a focus on overweight men under 60 years of age. The FDA further advised that a one year dual-energy X-ray absorptiometry (“DEXA”) study be conducted to ensure that there is no bone loss. On July 9, 2012, we announced that we reached an agreement with the FDA for the design of the pivotal efficacy studies for Androxal® for the treatment of secondary hypogonadism. The pivotal studies are being conducted under a Special Protocol Assessment. The first pivotal study is fully enrolled in November 2012 and we have begun enrolling subjects into the second pivotal study. Additionally, we began enrolling men into a 500 subject open label safety study in June 2012 and began enrolling men into a one year DEXA study in the third quarter of 2012. Depending on study enrollment and the completion of other studies, we believe we may be able to submit an NDA in the first half of 2014. At the end of July 2012, we satisfied our enrollment requirement of study subjects in the ongoing ZPV-200 Phase 2 study for the use of Proellex®-V, the proprietary vaginal delivery formulation of telapristone acetate, in the treatment of uterine fibroids and we intend to report the final study results around year end 2012. Additionally, we have begun enrolling subjects who completed the ZPV-200 study into a one year open label safety trial in order to begin collecting long term safety data which we expect the FDA to require in connection with the submission of an NDA. On September 7, 2012, we completed a private placement of 2,145,636 shares of our common stock at a price per share of $11.00. Net proceeds to us, after deducting offering expenses, were approximately $23 million. As of September 30, 2012, we had accumulated losses of $201.9 million, approximately $29.6 million in cash and cash equivalents, and our accounts payable and accrued expenses were approximately $1.8 million. We anticipate that our current liquidity will be sufficient to continue these planned studies into the second quarter of 2014; however, significant additional capital will be required for us to complete the development of our product candidates through NDA approval.We continue to explore potential additional financing alternatives (including corporate partnering opportunities) that would provide sufficient funds to enable us to continue to develop our two product candidates through NDA approval; however, there can be no assurance that we will be successful in raising any such additional funds on a timely basis or at all. The foregoing matters raise substantial doubt about our ability to continue as a going concern.

NOTE 2 — Patents and Patent Applications As of September 30, 2012, we had approximately $1,939,000 in capitalized patent and patent application costs reflected on its balance sheet. Of this amount, $1,594,000 relates to patent and patent application costs for Androxal® and $345,000 relates to patent and patent application costs for Proellex®. Should we not continue development of either drug candidate or should we not continue as a going concern, the remaining capitalized patent and patent application costs may not be recoverable, which would result in charges to operating results in future periods.

NOTE 3 — Accrued Expenses Accrued expenses consist of the following (in thousands): <table align="center" style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;" nowrap="nowrap"> </td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">September 30, 2012</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December 31, 2011</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify; font-weight: bold;"> </td><td> </td><td style="text-align: justify;" colspan="2"> </td><td> </td><td> </td><td style="text-align: justify;" colspan="2"> </td><td> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify; text-indent: 0in; width: 64%;">Patent costs</td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 15%;">123</td><td style="text-align: left; width: 1%;"> </td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 15%;">51</td><td style="text-align: left; width: 1%;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; text-indent: 0in;">Research and development costs</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">44</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">87</td><td style="text-align: left;"> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify; text-indent: 0in;">Personnel related costs</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">28</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">70</td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 1pt; text-indent: 0in;">Other</td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: left;"> </td><td style="border-bottom: black 1pt solid; text-align: right;">134</td><td style="text-align: left; padding-bottom: 1pt;"> </td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: left;"> </td><td style="border-bottom: black 1pt solid; text-align: right;">45</td><td style="text-align: left; padding-bottom: 1pt;"> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 0in;">Total</td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">329</td><td style="text-align: left; padding-bottom: 2.5pt;"> </td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">253</td><td style="text-align: left; padding-bottom: 2.5pt;"></td></tr></table>

NOTE 4 — Loss Per Share Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed using the average share price for the period and applying the treasury stock method to potentially dilutive outstanding options. In all applicable periods, all potential common stock equivalents were anti-dilutive and, accordingly, were not included in the computation of diluted loss per share. The following table presents information necessary to calculate loss per share for the three and nine month periods ended September 30, 2012 and 2011 (in thousands, except per share amounts): <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;" nowrap="nowrap"> </td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Three Months Ended Sept. 30,</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Nine Months Ended Sept. 30,</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;" nowrap="nowrap"> </td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2011</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2011</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td> </td><td style="text-align: justify;" colspan="2"> </td><td> </td><td> </td><td style="text-align: justify;" colspan="2"> </td><td> </td><td> </td><td style="text-align: justify;" colspan="2"> </td><td> </td><td> </td><td style="text-align: justify;" colspan="2"> </td><td> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify; text-indent: 0in; width: 52%;">Net Loss</td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%;">(4,583</td><td style="text-align: left; width: 1%;">)</td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%;">(3,960</td><td style="text-align: left; width: 1%;">)</td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%;">(10,123</td><td style="text-align: left; width: 1%;">)</td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%;">(9,759</td><td style="text-align: left; width: 1%;">)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; text-indent: 0in;">Average common shares outstanding</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">15,422</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">12,315</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">14,746</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">11,840</td><td style="text-align: left;"> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify; text-indent: 0in;">Basic and diluted loss per share</td><td> </td><td style="text-align: left;">$</td><td style="text-align: right;">(0.30</td><td style="text-align: left;">)</td><td> </td><td style="text-align: left;">$</td><td style="text-align: right;">(0.32</td><td style="text-align: left;">)</td><td> </td><td style="text-align: left;">$</td><td style="text-align: right;">(0.69</td><td style="text-align: left;">)</td><td> </td><td style="text-align: left;">$</td><td style="text-align: right;">(0.82</td><td style="text-align: left;">)</td></tr></table> Potential common stock of 5,264,207 and 5,260,795 common shares underlying stock options and warrants for the periods ended September 30, 2012 and 2011, respectively, were excluded from the above calculation of diluted loss per share because they were anti-dilutive. Potential common stock for the periods ended September 30, 2012 and 2011, includes Series A Warrants to purchase 1,749,270 shares of our common stock at an exercise price of $0.01. Also included in potential common stock for the periods ended September 30, 2012 and 2011, are Series B Warrants to purchase 1,569,421 and 1,690,500 shares, respectively, of our common stock at an exercise price of $2.49 issued in our February 8, 2011 public offering.

NOTE 5 — Commitmentsand Contingencies Therapeutic uses of our Androxal® product candidate are covered in the United States by five issued U.S. patents and seven pending patent applications. Foreign coverage of therapeutic uses of our Androxal® product candidate includes 55 issued foreign patents and 53 foreign pending patent applications. The issued patents and pending applications relate to methods for treating certain conditions including the treatment of testosterone deficiency in men, the treatment of diabetes mellitus Type 2, the treatment of metabolic syndrome and conditions associated therewith, and the treatment of infertility in hypogonadal men. Androxal® (the trans-isomer of clomiphene) is purified from clomiphene citrate. A third party individual holds two issued patents related to the use of an anti-estrogen such as clomiphene citrate and others for use in the treatment of androgen deficiency and disorders related thereto. We requested re-examination of one of these patents by the U.S. Patent and Trademark Office (“PTO”) based on prior art. The patent holder amended the claims in the re-examination proceedings, which led the PTO to determine that the amended claims were patentable in view of those publications under consideration and a re-examination certificate was issued. We subsequently filed a second request for re-examination by the PTO in light of a number of additional publications. The request was granted and all of the claims were finally rejected by the PTO in the re-examination. The patent holder appealed the rejections to the PTO Board of Patent Appeals and Interferences (the “PTO Board”) which ultimately reversed the rejections of several dependent claims in view of those publications under consideration. The patent holder filed a Notice of Appeal to the Federal Circuit on September 28, 2010 contesting the rejections maintained by the PTO Board. A decision was rendered by the Federal Circuit on December 12, 2011, affirming the rejection of the appealed claims. We expect that a re-examination certificate will be issued confirming the patentability of the remaining claims; however, if such a re-examination certificate were to issue, we believe that our development of Androxal® would not infringe any of the remaining claims and that all of the remaining claims are invalid on various grounds including additional prior art publications. We also believe that the second of these two patents is invalid in view of published prior art not considered by the PTO. If necessary, we intend to vigorously defend any and all claims against the holder of such patents in a court of competent jurisdiction in order to develop Androxal® further. Adverse determinations in litigation proceedings could require us to seek licenses which may not be available on commercially reasonable terms, or at all, or subject us to significant liabilities, in which case we may not be able to successfully commercialize or out-license Androxal® until such patents expire or are otherwise no longer in force. On March 1, 2010, we were served with a lawsuit where we were named as a co-defendant along with one of our clinical regulatory service providers (“CRO”) relating to the Proellex® clinical trial study.  The lawsuit was filed in the State of Tennessee, 30th Judicial District Chancery Court at Memphis by an investigator and claims that the CRO did not pay it amounts owing to it relating to the Proellex® study.  We did not engage the investigator and under our agreement with the CRO, we believe the CRO is responsible for any such costs or damages regarding such lawsuit.  Pursuant to a Settlement Agreement and Mutual Release entered into in October 2009, such CRO, on behalf of itself and its agents, released us from all claims which could be asserted by them against us.  We believe such release covers the claims set forth in this lawsuit. The CRO failed to respond to the lawsuit, and a default judgment was entered against it in the amount of $172,901.29. We intend to vigorously defend any and all claims asserted by the investigator. An estimate of the possible costs or expenses to defend ourselves in this matter or risk of exposure under the litigation cannot be made at this time.

NOTE 6 — Subsequent Events On October 31, 2012, Dr. Jean Fourcroy, MD, PhD, MPH, a member of Repros Therapeutics Inc.’s (the “Company”) board of directors (the “Board”) resigned her position as a member of the Board. Such resignation was not a result of any disagreements relating to the Company’s operations, policies or practices.

Our product development pipeline is summarized in the table below:   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="text-align: center; width: 34%; vertical-align: bottom;"> Product Candidate (Indication) Androxal® </td> <td style="text-align: center; width: 1%; vertical-align: bottom; font-weight: bold;"> </td> <td style="text-align: left; width: 21%; vertical-align: bottom; font-weight: bold;">Status</td> <td style="text-align: center; width: 1%; vertical-align: bottom; font-weight: bold;"> </td> <td style="text-align: left; width: 43%; vertical-align: bottom; font-weight: bold;">Next Expected Milestone(s)</td> </tr> <tr style="vertical-align: top;"> <td style="text-align: center; vertical-align: bottom;"> </td> <td style="text-align: center; vertical-align: bottom; font-weight: bold;"> </td> <td style="text-align: left; vertical-align: bottom; font-weight: bold;"> </td> <td style="text-align: center; vertical-align: bottom; font-weight: bold;"> </td> <td style="text-align: left; vertical-align: bottom; font-weight: bold;"> </td> </tr> <tr style="vertical-align: top;"> <td style="font-style: italic;">Secondary Hypogonadism</td> <td style="font-style: italic;"> </td> <td>Phase 3</td> <td> </td> <td> Complete first Phase 3 pivotal study (Q2 2013)   Complete open label safety study (Q4 2013)   Complete DEXA study (Q1 2014)   </td> </tr> <tr style="vertical-align: top;"> <td style="font-weight: bold;">Proellex®</td> <td style="font-weight: bold;"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: top;"> <td style="font-style: italic;">Uterine Fibroids</td> <td style="font-style: italic;"> </td> <td>Phase 2</td> <td> </td> <td> Complete Phase 2 study (vaginal delivery) (Q4 2012)   </td> </tr> <tr style="vertical-align: top;"> <td> Endometriosis </td> <td style="font-style: italic;"> </td> <td>Phase 2</td> <td> </td> <td> Initiate Phase 2 study (oral delivery) (Q4 2012) </td> </tr> </table>

Accrued expenses consist of the following (in thousands): <table align="center" style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;" nowrap="nowrap"> </td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">September 30, 2012</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December 31, 2011</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify; font-weight: bold;"> </td><td> </td><td style="text-align: justify;" colspan="2"> </td><td> </td><td> </td><td style="text-align: justify;" colspan="2"> </td><td> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify; text-indent: 0in; width: 64%;">Patent costs</td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 15%;">123</td><td style="text-align: left; width: 1%;"> </td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 15%;">51</td><td style="text-align: left; width: 1%;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; text-indent: 0in;">Research and development costs</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">44</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">87</td><td style="text-align: left;"> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify; text-indent: 0in;">Personnel related costs</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">28</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">70</td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 1pt; text-indent: 0in;">Other</td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: left;"> </td><td style="border-bottom: black 1pt solid; text-align: right;">134</td><td style="text-align: left; padding-bottom: 1pt;"> </td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: left;"> </td><td style="border-bottom: black 1pt solid; text-align: right;">45</td><td style="text-align: left; padding-bottom: 1pt;"> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 0in;">Total</td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">329</td><td style="text-align: left; padding-bottom: 2.5pt;"> </td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">253</td><td style="text-align: left; padding-bottom: 2.5pt;"></td></tr></table>

The following table presents information necessary to calculate loss per share for the three and nine month periods ended September 30, 2012 and 2011 (in thousands, except per share amounts): <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;" nowrap="nowrap"> </td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Three Months Ended Sept. 30,</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Nine Months Ended Sept. 30,</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;" nowrap="nowrap"> </td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2011</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2011</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td> </td><td style="text-align: justify;" colspan="2"> </td><td> </td><td> </td><td style="text-align: justify;" colspan="2"> </td><td> </td><td> </td><td style="text-align: justify;" colspan="2"> </td><td> </td><td> </td><td style="text-align: justify;" colspan="2"> </td><td> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify; text-indent: 0in; width: 52%;">Net Loss</td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%;">(4,583</td><td style="text-align: left; width: 1%;">)</td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%;">(3,960</td><td style="text-align: left; width: 1%;">)</td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%;">(10,123</td><td style="text-align: left; width: 1%;">)</td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%;">(9,759</td><td style="text-align: left; width: 1%;">)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; text-indent: 0in;">Average common shares outstanding</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">15,422</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">12,315</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">14,746</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">11,840</td><td style="text-align: left;"> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify; text-indent: 0in;">Basic and diluted loss per share</td><td> </td><td style="text-align: left;">$</td><td style="text-align: right;">(0.30</td><td style="text-align: left;">)</td><td> </td><td style="text-align: left;">$</td><td style="text-align: right;">(0.32</td><td style="text-align: left;">)</td><td> </td><td style="text-align: left;">$</td><td style="text-align: right;">(0.69</td><td style="text-align: left;">)</td><td> </td><td style="text-align: left;">$</td><td style="text-align: right;">(0.82</td><td style="text-align: left;">)</td></tr></table>

Phase 2 Phase 2 Phase 3 Initiate Phase 2 study (oral delivery) (Q4 2012) Complete Phase 2 study (vaginal delivery) (Q4 2012) Commence Phase 3 study (vaginal delivery) (Q1 2013) Complete first Phase 3 pivotal study (Q2 2013) Complete open label safety study (Q4 2013) Complete DEXA study (Q1 2014) 10300000 800 100 500

23000000

1800000

51000 123000 87000 44000 70000 28000

45000

134000

12315000

11840000

15422000

14746000

5260795

1690500

1749270

5264207

1569421

1749270

2.49 0.01 2.49 0.01 2 55 5 53 7 1

172901

12470694

112350

17228707

112350

1902000

10310000

23018000

10307000

3000

23061000

2000

16488

121000

121079 121079 301000 301000

777000

586000

27915

30195000

4666000

EX-101.SCH 7 rprx-20120930.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Organization, Operations and Liquidity link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Patents and Patent Applications link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Loss Per Share link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Organization, Operations and Liquidity (Tables) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Loss Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Product Development Pipeline (Detail) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Organization, Operations and Liquidity - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Patents and Patent Applications - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Accrued Expenses (Detail) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Calculation of Loss Per Share (Detail) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Loss Per Share - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 rprx-20120930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 rprx-20120930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 rprx-20120930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document Documentand Entity Information [Abstract] Document - Document and Entity Information [Abstract] Document - Document and Entity Information [Abstract] Document - Document and Entity Information [Abstract] Document Type Document Type Document Type Amendment Flag Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Statement Of Financial Position [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Statement [Line Items] Assets [Abstract] ASSETS ASSETS Assets Current [Abstract] Current Assets Current Assets Cash and Cash Equivalents At Carrying Value Cash and cash equivalents Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Prepaid Expense and Other Assets Current Prepaid expenses and other current assets Prepaid expenses and other current assets Assets Current Total current assets Total current assets Property Plant and Equipment Net Fixed assets, net Fixed assets, net Intangible Assets Net Excluding Goodwill Capitalized patent and patent application costs Other assets, net Assets Total assets Total assets Liabilities and Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities Current [Abstract] Current Liabilities Current Liabilities Accounts Payable Current Accounts payable Accounts payable Accrued Liabilities Current Accrued expenses Accrued expenses Total Liabilities Current Total current liabilities Total current liabilities Stockholders Equity [Abstract] Stockholders' Equity Stockholders' Equity Preferred Stock Value Undesignated Preferred Stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding Undesignated Preferred Stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding Common Stock Value Common Stock, $.001 par value, 75,000,000 shares authorized, 17,228,707 and 12,470,694 shares issued, respectively and 17,116,357 and 12,358,344 shares outstanding, respectively Common Stock, $.001 par value, 75,000,000 shares authorized, 14,946,339 and 12,470,694 shares issued, respectively and 14,833,989 and 12,358,344 shares outstanding, respectively Additional Paid In Capital Additional paid-in capital Additional paid-in capital Treasury Stock Value Cost of treasury stock, 112,350 shares Cost of treasury stock, 112,350 shares Development Stage Enterprise Deficit Accumulated During Development Stage Deficit accumulated during development stage Deficit accumulated during the development stage Deficit accumulated during the development stage Stockholders Equity Total stockholders' equity Total stockholders' equity Beginning Balance Ending Balance Liabilities and Stockholders Equity Total liabilities and stockholders' equity Total liabilities and stockholders' equity Preferred Stock Par Or Stated Value Per Share Preferred Stock, par value Preferred Stock, par value Preferred Stock Shares Authorized Preferred Stock, shares authorized Preferred Stock, shares authorized Preferred Stock Shares Issued Preferred Stock, issued Preferred Stock, issued Preferred Stock Shares Outstanding Preferred Stock, outstanding Preferred Stock, outstanding Common Stock Par Or Stated Value Per Share Common Stock, par value Common Stock, par value Common Stock Shares Authorized Common Stock, shares authorized Common Stock, shares authorized Common Stock Shares Issued Common Stock, shares issued Common Stock, shares issued Common Stock Shares Outstanding Common Stock, shares outstanding Common Stock, shares outstanding Treasury Stock Shares Treasury stock, shares Treasury stock, shares Income Statement [Abstract] Income Statement [Abstract] Income Statement [Abstract] Revenues [Abstract] Revenues Revenues Licenses Revenue Licensing fees Licensing fees Royalty Revenue Product royalties Product royalties Revenue From Grants Research and development grants Research and development grants Investment Income Interest Interest income Interest income Gains Losses On Sales Of Assets Gain on disposal of fixed assets Gain on disposal of fixed assets Gain on disposal of fixed assets Other Nonoperating Income Other Income Other Income Revenues Total revenues and other income Total revenues and other income Costs and Expenses [Abstract] Expenses Expenses Research and Development Expense Research and development Research and development General and Administrative Expense General and administrative General and administrative Other Cost and Expense Operating Interest expense and amortization of intangibles Interest expense and amortization of intangibles Costs and Expenses Total expenses Total expenses Income Loss From Continuing Operations Loss from continuing operations Loss from continuing operations Income Loss From Discontinued Operations Net Of Tax Loss from discontinued operations Loss from discontinued operations Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax Gain on disposal of discontinued operation Gain on disposal of discontinued operations Gain on disposal of discontinued operations Income Loss Before Extraordinary Items and Cumulative Effect Of Change In Accounting Principle Net loss before cumulative effect of change in accounting principle Net loss before cumulative effect of change in accounting principle New Accounting Pronouncement Or Change In Accounting Principle Effect Of Change On Net Income Cumulative effect of change in accounting principle Cumulative effect of change in accounting principle Net Income Loss Net loss Net loss Net Loss Net loss Earnings Per Share Basic and Diluted Basic and diluted loss per share Loss per share - basic and diluted: Weighted Average Number Of Shares Outstanding [Abstract] Weighted average shares used in loss per share calculation: Weighted average shares used in loss per share calculation: Weighted Average Number Of Shares Outstanding Basic Basic Basic Weighted Average Number Of Diluted Shares Outstanding Diluted Diluted Statement Of Stockholders Equity [Abstract] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Statement Equity Components [Axis] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock [Member] Additional Paid In Capital [Member] Additional Paid-in Capital [Member] Treasury Stock [Member] Treasury Stock [Member] Accumulated Deficit During Development Stage [Member] Deficit Accumulated During the Development Stage [Member] Statement Class Of Stock [Axis] Class of Stock [Axis] Class of Stock [Axis] Class Of Stock [Domain] Class of Stock [Domain] Class of Stock [Domain] Issuance During Period One [Member] Issuance During Period 1st [Member] Issuance During Period 1st [Member] Issuance During Period Two [Member] Issuance During Period 2nd [Member] Issuance During Period 2nd [Member] Issuance During Period Three [Member] Issuance During Period 3rd [Member] Issuance During Period Four [Member] Issuance During Period 4th [Member] Shares Issued Beginning Balance (in shares) Beginning Balance (in shares) Ending Balance (in shares) Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Stock based option compensation Stock based option compensation Stock Issued During Period Shares New Issues Issuance of common stock (in shares) Issuance of common stock, share Stock Issued During Period Value New Issues Issuance of common stock Issuance of common stock Stock Issued During Period Shares Stock Options Exercised Exercise of stock options to purchase common stock for cash ($1.33 to $10.88 per share)(in shares) Exercise of stock option to purchase common stock for cash @ $4.80 per share (in shares) Stock Issued During Period Value Stock Options Exercised Exercise of stock options to purchase common stock for cash ($1.33 to $10.88 per share) Exercise of stock option to purchase common stock for cash @ $4.80 per share Stock Issued During Period Shares Stock Warrants Exercised Exercise of 121,079 Series B Warrants to purchase common stock for cash @ $2.49 per share (in shares) Exercise of 3,675 Series B Warrants to purchase common stock for cash @ $2.49 per share (in shares) Number of shares issued during the period as a result of the exercise of warrants. Stock Issued During Period Value Stock Warrants Exercised Exercise of 3,675 Series B Warrants to purchase common stock for cash @ $2.49 per share Exercise of 3,675 Series B Warrants to purchase common stock for cash @ $2.49 per share Value stock issued during the period as a result of the exercise of warrants. Stock Option [Member] Stock Option [Member] Series B Warrant [Member] Series B Warrants [Member] Series B Warrant Range [Axis] Range [Axis] Range [Domain] Range [Domain] Maximum [Member] Minimum [Member] Equity Issuance Per Share Amount Common stock, price per share Common stock, price per share Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Issuance of common stock, offering costs Issuance of common stock, offering costs Common Stock Option Shares Common Stock Option Shares Issuance of common stock offered cashless exercise stock option. Statement Of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Net Cash Provided By Used In Operating Activities [Abstract] Cash Flows from Operating Activities Cash Flows from Operating Activities Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Amortization Of Financing Costs Noncash financing costs Noncash financing costs Inventory Write Down Noncash inventory impairment Noncash inventory impairment Impairment Of Intangible Assets Excluding Goodwill Noncash patent impairment Noncash patent impairment Other Noncash Income Noncash other income Noncash other income Gains Losses On Extinguishment Of Debt Noncash decrease in accounts payable Noncash decrease in accounts payable Depreciation and Amortization Depreciation and amortization Depreciation and amortization Share Based Compensation Noncash stock-based compensation Noncash stock-based compensation Other Noncash Income Expense Common stock issued for agreement not to compete Common stock issued for agreement not to compete Issuance Of Stock and Warrants For Services Or Claims Series B Preferred Stock issued for consulting services Series B Preferred Stock issued for consulting services Increase Decrease In Operating Capital [Abstract] Changes in operating assets and liabilities (net effects of purchase of businesses in 1988 and 1994): Changes in operating assets and liabilities (net effects of purchase of businesses in 1988 and 1994): Increase Decrease In Receivables Increase in receivables Increase in receivables Increase Decrease In Inventories Increase in inventory Increase in inventory Increase Decrease In Prepaid Deferred Expense and Other Assets (Increase) decrease in prepaid expenses and other current assets (Increase) decrease in prepaid expenses and other current assets Increase Decrease In Accounts Payable and Accrued Liabilities Increase (decrease) in accounts payable and accrued expenses Increase (decrease) in accounts payable and accrued expenses Net Cash Provided By Used In Operating Activities Net cash used in operating activities Net cash used in operating activities Net Cash Provided By Used In Investing Activities [Abstract] Cash Flows from Investing Activities Cash Flows from Investing Activities Payments To Acquire Marketable Securities Change in trading marketable securities Change in trading marketable securities Payments To Acquire Property Plant and Equipment Capital expenditures Capital expenditures Payments To Acquire Intangible Assets Capitalization Of Patents and Patent Applications Capitalization of patents and patent applications Proceeds From Sale Of Property Plant and Equipment Proceeds from sale of PP&E Proceeds from sale of PP&E Cash Acquired From Acquisition Cash acquired in purchase of FTI Cash acquired in purchase of FTI Proceeds From Divestiture Of Interest In Consolidated Subsidiaries 1990 phase-out period Proceeds from sale of subsidiary, less $12,345 for operating losses during 1990 phase-out period Proceeds From Divestiture Of Businesses Net Of Cash Divested Proceeds from sale of the assets of FTI Proceeds from sale of the assets of FTI Payments For Proceeds From Other Investing Activities Increase in net assets held for disposal Increase in net assets held for disposal Net Cash Provided By Used In Investing Activities Net cash used in investing activities Net cash used in investing activities Net Cash Provided By Used In Financing Activities [Abstract] Cash Flows from Financing Activities Cash Flows from Financing Activities Proceeds From Issuance Of Common Stock Proceeds from issuance of common stock, net of offering costs Proceeds from issuance of common stock, net of offering costs Proceeds From Stock Options Exercised Exercise of stock options & warrants Exercise of stock options & warrants Proceeds From Contributed Capital Proceeds from a shareholder transaction Proceeds from a shareholder transaction Proceeds From Issuance Of Preferred Stock and Preference Stock Proceeds from issuance of preferred stock Proceeds from issuance of preferred stock Payments For Repurchase Of Common Stock Purchase of treasury stock Purchase of treasury stock Proceeds From Notes Payable Proceeds from issuance of notes payable Proceeds from issuance of notes payable Repayments Of Notes Payable Principal payments on notes payable Principal payments on notes payable Net Cash Provided By Used In Financing Activities Net cash provided by financing activities Net cash provided by financing activities Cash and Cash Equivalents Period Increase Decrease Net increase (decrease) in cash and cash equivalents Net increase (decrease) in cash and cash equivalents Operating Losses During Phase Out Period From Divestiture Of Interest In Consolidated Subsidiaries Proceeds from sale of subsidiary, operating losses during 1990 phase-out period Proceeds from sale of subsidiary, operating losses during 1990 phase-out period Operating Losses During Phase-out Period From Divestiture of Interest in Consolidated Subsidiaries Organization, Operations and Liquidity [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization Consolidation and Presentation Of Financial Statements Disclosure [Text Block] Organization, Operations and Liquidity Organization, Operations and Liquidity Patents and Patent Applications [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Disclosure [Text Block] Patents and Patent Applications Patents and Patent Applications Accrued Expenses [Abstract] Accrued Expenses [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Accrued Expenses Loss Per Share [Abstract] Loss Per Share [Abstract] Earnings Per Share [Text Block] Loss Per Share Loss Per Share Commitments and Contingencies [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events [Abstract] Subsequent Events [Text Block] Subsequent Events Subsequent Events Schedule Of Product Information Table [Text Block] Product Development Pipeline Product Development Pipeline Schedule Of Accrued Liabilities Table [Text Block] Accrued Expenses Accrued Expenses Schedule Of Earnings Per Share Basic and Diluted Table [Text Block] Calculation of Loss Per Share Calculation of Loss Per Share Disclosure Product Development Pipeline [Abstract] Disclosure - Product Development Pipeline [Abstract] Disclosure - Product Development Pipeline [Abstract] Disclosure - Product Development Pipeline [Abstract] Schedule Of Product Information [Table] Schedule of Product Information [Table] Schedule of Product Information [Table] Product Or Service [Axis] Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] Products and Services [Domain] Androxal [Member] Androxal [Member] Androxal [Member] Proellex [Member] Proellex [Member] Proellex [Member] Products Or Services Secondary Categorization [Axis] Products or Services Secondary Categorization [Axis] Products or Services Secondary Categorization [Axis] Products or Services Secondary Categorization [Axis] Products Or Services Name Secondary Categorization [Domain] Products or Services Name Secondary Categorization [Domain] Products or Services Name Secondary Categorization [Domain] Products or Services Name Secondary Categorization [Domain] Secondary Hypogonadism [Member] Secondary Hypogonadism [Member] Secondary Hypogonadism [Member] Uterine Fibroids [Member] Uterine Fibroids [Member] Uterine Fibroids [Member] Endometriosis [Member] Endometriosis [Member] Endometriosis [Member] Product Information [Line Items] Product Information [Line Items] Product Information [Line Items] Product Status Status Status Product Status Product Next Expected Milestone Next Expected Milestone(s) Next Expected Milestone(s) Product Next Expected Milestone Disclosure Organization Operations and Liquidity Additional Information [Abstract] Disclosure - Organization, Operations and Liquidity - Additional Information [Abstract] Disclosure - Organization, Operations and Liquidity - Additional Information [Abstract] Disclosure - Organization, Operations and Liquidity - Additional Information [Abstract] Period One [Member] One year [Member] Period 1 [Member] Period Two [Member] Six months [Member] Period 2 [Member] Subsidiary, Sale Of Stock [Axis] Subsidiary, Sale of Stock [Axis] Sale Of Stock, Name Of Transaction [Domain] Sale of Stock, Name of Transaction [Domain] Private Placement [Member] Public Offering Net Proceeds Issuance of stock net of offering costs Issuance of stock net of offering costs Public offering, net proceeds Number Of Subjects Required For Registration Number of subjects required for registration Number of subjects required for registration Number of Subjects Required for Registration Number Of Subjects In Study Number of subjects in open label safety study Number of subjects in open label safety study Number of Subjects in Study Proceeds From Issuance Of Private Placement Proceeds from Issuance of Private Placement Accounts Payable and Accrued Liabilities Current Accounts payable and accrued expenses Accounts payable and accrued expenses Disclosure Patents and Patent Applications Additional Information [Abstract] Disclosure - Patents and Patent Applications - Additional Information [Abstract] Disclosure - Patents and Patent Applications - Additional Information [Abstract] Disclosure - Patents and Patent Applications - Additional Information [Abstract] Schedule Of Finite Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Disclosure Accrued Expenses [Abstract] Disclosure - Accrued Expenses [Abstract] Disclosure - Accrued Expenses [Abstract] Disclosure - Accrued Expenses [Abstract] Schedule Of Accrued Liabilities [Table] Schedule of Accrued Liabilities [Table] Schedule of Accrued Liabilities [Table] Schedule of Accrued Liabilities [Table] Schedule Of Accrued Liabilities [Line Items] Schedule of Accrued Liabilities [Line Items] Schedule of Accrued Liabilities [Line Items] Schedule of Accrued Liabilities [Line Items] Accrued Patent Expense Current Patent costs Patent costs Accrued Patent Expense, Current Accrued Research and Development Expense Current Research and development costs Research and development costs Accrued Research and Development Expense, Current Accrued Personnel Expense Current Personnel related costs Personnel related costs Accrued Personnel Expense Current Other Accrued Liabilities Current Other Other Disclosure Calculation Of Loss Per Share [Abstract] Disclosure - Calculation of Loss Per Share [Abstract] Disclosure - Calculation of Loss Per Share [Abstract] Disclosure - Calculation of Loss Per Share [Abstract] Earnings Per Share Disclosure [Table] Earnings Per Share Disclosure [Table] Earnings Per Share Disclosure [Table] Earnings Per Share Disclosure [Table] Earnings Per Share Disclosure [Line Items] Earnings Per Share Disclosure [Line Items] Earnings Per Share Disclosure [Line Items] Earnings Per Share Disclosure [Line Items] EX-101.PRE 11 rprx-20120930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 R9.htm IDEA: XBRL DOCUMENT

Organization, Operations and Liquidity

9 Months Ended

Sep. 30, 2012

Organization, Operations and Liquidity [Abstract]

Organization, Operations and Liquidity

NOTE 1 — Organization, Operations and Liquidity

Our product development pipeline is summarized in the table below:

Product Candidate (Indication) Androxal®	Status	Next Expected Milestone(s)

Secondary Hypogonadism	Phase 3	Complete first Phase 3 pivotal study (Q2 2013) Complete open label safety study (Q4 2013) Complete DEXA study (Q1 2014)
Proellex®
Uterine Fibroids	Phase 2	Complete Phase 2 study (vaginal delivery) (Q4 2012)
Endometriosis	Phase 2	Initiate Phase 2 study (oral delivery) (Q4 2012)

As of September 30, 2012, we had accumulated losses of $201.9 million, approximately $29.6 million in cash and cash equivalents, and our accounts payable and accrued expenses were approximately $1.8 million. We anticipate that our current liquidity will be sufficient to continue these planned studies into the second quarter of 2014; however, significant additional capital will be required for us to complete the development of our product candidates through NDA approval.We continue to explore potential additional financing alternatives (including corporate partnering opportunities) that would provide sufficient funds to enable us to continue to develop our two product candidates through NDA approval; however, there can be no assurance that we will be successful in raising any such additional funds on a timely basis or at all. The foregoing matters raise substantial doubt about our ability to continue as a going concern.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS140-4/FIN46(R)-8

-Paragraph 8, C1, C7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 46R

-Paragraph 4, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 2-6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

+ Details

EXCEL 14 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\S,S8P9&4U9E\W-C,S7S1E-S-?8C9E85\U-S9B M-3=D8SDQ.#8B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3E-/3$E$051%1%]35$%414U%3E137T]&7U-4 M3SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O M#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D]R9V%N:7IA=&EO;E]/<&5R871I M;VYS7V%N9%],:3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E!A=&5N='-?86YD7U!A=&5N=%]!<'!L:6-A=&EO;CPO>#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D%C8W)U961?17AP96YS97,\ M+W@Z3F%M93X-"B`@("`\>#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S/"]X.DYA;64^#0H@("`@ M/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I%>&-E;%=O'!E;G-E#I7;W)K#I7;W)K#I7;W)K#I% M>&-E;%=O#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D%C8W)U961?17AP96YS M97-?1&5T86EL/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E M;%=O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X M.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A2!);F9O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$6UB;VP\+W1D/@T* M("`@("`@("`\=&0@8VQA2!296=I'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!#;VUM;VX@4W1O8VLL(%-H87)E'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'!E;G-E'!E;G-E3PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\S,S8P9&4U9E\W-C,S7S1E-S-?8C9E85\U-S9B-3=D8SDQ M.#8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S,V,&1E-69?-S8S M,U\T93'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)FYB'0^)FYB'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S&5D(&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA&-E<'0@ M4VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M&5R M8VES92!O9B`S+#8W-2!397)I97,@0B!787)R86YT'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\S,S8P9&4U9E\W-C,S7S1E-S-?8C9E85\U-S9B-3=D8SDQ M.#8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S,V,&1E-69?-S8S M,U\T93'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R&-E M<'0@4VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S,S8P9&4U9E\W-C,S7S1E-S-?8C9E M85\U-S9B-3=D8SDQ.#8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M,S,V,&1E-69?-S8S,U\T93'0O:'1M;#L@8VAA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5D(&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%SF%T M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#8\'!E;G-E2P@;&5S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$&5R8VES92!O9B!S M=&]C:R!O<'1I;VYS("9A;7`[('=A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!F:6YA;F-I;F<@86-T:79I=&EE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF%T:6]N+"!/ M<&5R871I;VYS(&%N9"!,:7%U:61I='D\8G(^/"]S=')O;F<^/"]T:#X-"B`@ M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\3PO8CX\+W`^/'`@3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE28C.#(R M,3LL("8C.#(R,#M24%)8+"8C.#(R,3L@)B,X,C(P.U)E<')O6QE/3-$)W1E>'0M86QI9VXZ(&IU M'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2`Y+"`R M,#$R+"!W92!A;FYO=6YC960@=&AA="!W92!R96%C:&5D(&%N(&%G3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T M:6UE"8C,36UP=&]M"8C,3"8C,33L@;6%R9VEN.B`P<'0@,'!X.R!F M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)VUA#L@9F]N=#H@,3!P M="!T:6UE6QE/3-$)W=I M9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P'!E8W1E9"8C,38P.TUI;&5S=&]N92AS*3PO M=&0^/"]T6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE2!S M='5D>2`H430@,C`Q,RD\+W`^/'`@6QE/3-$)VUA#L@9F]N=#H@ M,3!P="!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W9E"8C,36QE/3-$)V9O;G0M=V5I M9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q M-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)V9O;G0M2`H=F%G:6YA;"!D96QI=F5R>2D@*%$T M(#(P,3(I/"]P/CQP('-T>6QE/3-$)VUA#L@9F]N=#H@ M,3!P="!T:6UE6QE/3-$ M)V9O;G0M6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE7,@=VAI8V@@:6YC;'5D97,@<')O9'5C="!O=70M M;&EC96YS:6YG+CPO<#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y M.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA#L@9F]N=#H@ M,3!P="!T:6UE&EM871E;'D@)#$P+C,@;6EL;&EO;BX\+W`^/'`@ M3L@=&5X="UI;F1E;G0Z(#`N M-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O M;6%N+"!T:6UE2!H>7!O9V]N861I2!D871A8F%S92!C;VUP2!D871A(&9O M'!O65A3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE M3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[ M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE2!S='5D:65S(&9O6QE/3-$)W1E>'0M86QI M9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@ M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E65A65A2!T'!E8W0@=&AE($9$02!T;R!R97%U:7)E(&EN(&-O;FYE8W1I;VX@ M=VET:"!T:&4@6QE/3-$ M)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM M97,L('-E6QE/3-$)W1E>'0M86QI9VXZ M(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E&EM871E;'D@)#(S(&UI;&QI;VXN/"]P/CQP('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@ M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E6QE/3-$)W1E>'0M86QI M9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@ M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2`D,2XX(&UI;&QI;VXN(%=E(&%N=&EC:7!A=&4@ M=&AA="!O=7(@8W5R2!B87-I2!T;R!C M;VYT:6YU92!A7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E M6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2`D,2PY,SDL,#`P(&EN(&-A M<&ET86QI>F5D('!A=&5N="!A;F0@<&%T96YT(&%P<&QI8V%T:6]N(&-O6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E M6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'!E M;G-E6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD M96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S M(&YE=R!R;VUA;BP@=&EM97,L('-E'!E;G-E6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P M+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`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`P:6X[)SY297-E87)C:"!A;F0@9&5V96QO<&UE;G0@8V]S=',\+W1D M/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)V)A8VMG3L@=&5X="UI;F1E;G0Z(#!I;CLG M/E!E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,C@\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[ M/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^-S`\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R M/CQT6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F'0M:6YD96YT.B`P:6X[)SY4 M;W1A;#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R<^,S(Y/"]T9#X\=&0@6QE/3-$ M)V)O'1087)T7S,S M-C!D935F7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[ M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE3L@=&5X M="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@ M=&EM97,@;F5W(')O;6%N+"!T:6UE2!D:79I9&EN9R!N970@;&]S2!T M:&4@=V5I9VAT960@879E2!D:6QU=&EV M92!O=71S=&%N9&EN9R!O<'1I;VYS+B!);B!A;&P@87!P;&EC86)L92!P97)I M;V1S+"!A;&P@<&]T96YT:6%L(&-O;6UO;B!S=&]C:R!E<75I=F%L96YT2P@=V5R92!N;W0@ M:6YC;'5D960@:6X@=&AE(&-O;7!U=&%T:6]N(&]F(&1I;'5T960@;&]S6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT M.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE M=R!R;VUA;BP@=&EM97,L('-E3L@=&5X="UI;F1E;G0Z(#`N-6EN M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N M+"!T:6UE6QE/3-$)W=I M9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P6QE/3-$ M)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A9&1I M;F6QE/3-$ M)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W!A M9&1I;F6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P:6X[('=I9'1H.B`U,B4[)SY.970@3&]S6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R<^*#0L M-3@S/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG M/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z M(#DE.R<^*#,L.38P/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q)3LG M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@=VED=&@Z(#DE.R<^*#$P+#$R,SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/BD\+W1D/CQT9"!S='EL93TS1"=W M:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!W:61T:#H@,24[)SXD/"]T9#X\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/BD\+W1D/CPO='(^ M/'1R('-T>6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&IU M'0M:6YD96YT.B`P:6X[)SY!=F5R86=E(&-O;6UO;B!S:&%R M97,@;W5T6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,3(L,S$U/"]T9#X\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$T+#6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P:6X[ M)SY"87-I8R!A;F0@9&EL=71E9"!L;W-S('!E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T M9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXI/"]T9#X\=&0^)B,Q M-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^*#`N-CD\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^*3PO=&0^/'1D/B8C,38P M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\ M=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXI/"]T9#X\+W1R/CPO=&%B M;&4^/'`@3L@=&5X="UI;F1E M;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@ M;F5W(')O;6%N+"!T:6UE3L@=&5X="UI;F1E;G0Z(#`N,C5I;CL@ M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E&5R8VES92!P'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3L@ M=&5X="UI;F1E;G0Z(#`N,C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT M.B`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`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`@("`\=&%B;&4@8VQA3L@=&5X="UI M;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM M97,@;F5W(')O;6%N+"!T:6UE3L@=&5X="UI;F1E;G0Z(#%I;CL@ M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E28C M.#(R,3LI(&)O87)D(&]F(&1I28C M.#(Q-SMS(&]P97)A=&EO;G,L('!O;&EC:65S(&]R('!R86-T:6-E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S,S8P M9&4U9E\W-C,S7S1E-S-?8C9E85\U-S9B-3=D8SDQ.#8-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO,S,V,&1E-69?-S8S,U\T93'0O:'1M;#L@8VAAF%T:6]N+"!/ M<&5R871I;VYS(&%N9"!,:7%U:61I='D@6T%B'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D(&EN('1H92!T86)L92!B M96QO=SH\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T M:6UE6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&UA#L@ M9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`R M,24[('9E6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`T,R4[('9E6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E6QE/3-$)V9O;G0M2!(>7!O M9V]N861I6QE/3-$)V9O;G0M6QE/3-$)VUA#L@9F]N M=#H@,3!P="!T:6UE2!S='5D>2`H430@,C`Q,RD\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE M/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W9E6QE/3-$)W9E6QE.B!I M=&%L:6,[)SXF(S$V,#L\+W1D/@T*/'1D/E!H87-E(#(\+W1D/@T*/'1D/B8C M,38P.SPO=&0^#0H\=&0^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[ M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'!E;G-E6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E'!E M;G-E6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD M96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`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`P:6X[)SY297-E87)C:"!A;F0@9&5V96QO<&UE;G0@8V]S M=',\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)V)A8VMG3L@=&5X="UI;F1E;G0Z M(#!I;CLG/E!E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,C@\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^ M)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^-S`\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T M9#X\+W1R/CQT6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M:6YD96YT.B`P M:6X[)SY4;W1A;#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R<^,S(Y/"]T9#X\=&0@6QE/3-$)V)O'10 M87)T7S,S-C!D935F7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA#L@9F]N=#H@,3!P="!T M:6UE#L@9F]N=#H@,3!P="!T:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM M97,L('-E6QE/3-$)W9E3LG M(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D M:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS M1&YO=W)A<#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A M9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W9E3LG M(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D M:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS M1&YO=W)A<#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$ M)V)O'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG M/BD\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXD/"]T M9#X\=&0@ XML 15 R8.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $) In Thousands, unless otherwise specified	301 Months Ended
	Sep. 30, 2012
Proceeds from sale of subsidiary, operating losses during 1990 phase-out period	$ 12,345

XML 16 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Current Assets
Cash and cash equivalents	$ 29,583	$ 4,565
Prepaid expenses and other current assets	451	99
Total current assets	30,034	4,664
Fixed assets, net	59	15
Other assets, net	1,939	1,385
Total assets	32,032	6,064
Current Liabilities
Accounts payable	1,508	1,145
Accrued expenses	329	253
Total current liabilities	1,837	1,398
Stockholders' Equity
Undesignated Preferred Stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding	0	0
Common Stock, $.001 par value, 75,000,000 shares authorized, 17,228,707 and 12,470,694 shares issued, respectively and 17,116,357 and 12,358,344 shares outstanding, respectively	17	12
Additional paid-in capital	233,416	197,769
Cost of treasury stock, 112,350 shares	(1,380)	(1,380)
Deficit accumulated during the development stage	(201,858)	(191,735)
Total stockholders' equity	30,195	4,666
Total liabilities and stockholders' equity	$ 32,032	$ 6,064

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	9 Months Ended
	Sep. 30, 2012
Issuance During Period 1st [Member]
Issuance of common stock (in shares)	100
Common stock, price per share	$ 5.07
Issuance During Period 2nd [Member]
Issuance of common stock (in shares)	2,463,537
Common stock, price per share	$ 4.50
Issuance of common stock, offering costs	$ 777
Issuance During Period Three [Member]
Issuance of common stock (in shares)	11,173
Common Stock Option Shares	27,915
Issuance During Period Four [Member]
Issuance of common stock (in shares)	2,145,636
Common stock, price per share	$ 11.00
Issuance of common stock, offering costs	$ 586
Stock Option [Member] \| Maximum [Member]
Common stock, price per share	$ 10.88
Stock Option [Member] \| Minimum [Member]
Common stock, price per share	$ 1.33
Series B Warrants [Member]
Exercise of 121,079 Series B Warrants to purchase common stock for cash @ $2.49 per share (in shares)	121,079
Common stock, price per share	$ 2.49

- Definition

Number of new stock issued during the period.

+ References+ Details

XML 18 R22.htm IDEA: XBRL DOCUMENT

Calculation of Loss Per Share (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended		301 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012
Earnings Per Share Disclosure [Line Items]
Net loss	$ (4,583)	$ (3,960)	$ (10,123)	$ (9,759)	$ (201,858)
Average common shares outstanding	15,422	12,315	14,746	11,840
Basic and diluted loss per share	$ (0.30)	$ (0.32)	$ (0.69)	$ (0.82)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

XML 19 R24.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended
	Mar. 31, 2010	Sep. 30, 2012
Commitments and Contingencies [Line Items]
Number of patents requested for re-examination		1
Default judgment amount against clinical regulatory service provider	$ 172,901
Domestic [Member]
Commitments and Contingencies [Line Items]
Number of patents		5
Number of pending patent applications		7
Foreign [Member]
Commitments and Contingencies [Line Items]
Number of patents		55
Number of pending patent applications		53
Third Party [Member]
Commitments and Contingencies [Line Items]
Number of patents		2

- Definition

The value (monetary amount) of the award the plaintiff seeks in the legal matter.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14557-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14326-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 11

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

XML 20 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'

'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'

'+ "\n"+' '+ "\n"+'

'+ "\n"+'

'+raw+'

'+ "\n"+'

'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 21 R7.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	9 Months Ended		301 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012
Cash Flows from Operating Activities
Net loss	$ (10,123)	$ (9,759)	$ (201,858)
Gain on disposal of discontinued operations			(939)
Gain on disposal of fixed assets			(102)
Adjustments to reconcile net loss to net cash used in operating activities:
Noncash financing costs			316
Noncash inventory impairment			4,417
Noncash patent impairment			2,614
Noncash other income			(709)
Noncash decrease in accounts payable			(1,308)
Depreciation and amortization	106	84	4,262
Noncash stock-based compensation	1,902	1,654	11,435
Common stock issued for agreement not to compete			200
Series B Preferred Stock issued for consulting services			18
Changes in operating assets and liabilities (net effects of purchase of businesses in 1988 and 1994):
Increase in receivables			(199)
Increase in inventory			(4,447)
(Increase) decrease in prepaid expenses and other current assets	(352)	140	(148)
Increase (decrease) in accounts payable and accrued expenses	367	744	9,937
Net cash used in operating activities	(8,100)	(7,137)	(176,511)
Cash Flows from Investing Activities
Change in trading marketable securities			(191)
Capital expenditures	(54)	(15)	(2,447)
Capitalization of patents and patent applications	(578)	(247)	(5,534)
Proceeds from sale of PP&E			225
Cash acquired in purchase of FTI			3
Proceeds from sale of subsidiary, less $12,345 for operating losses during 1990 phase-out period			138
Proceeds from sale of the assets of FTI			2,250
Increase in net assets held for disposal			(213)
Net cash used in investing activities	(632)	(262)	(5,769)
Cash Flows from Financing Activities
Proceeds from issuance of common stock, net of offering costs	33,328	11,509	207,431
Exercise of stock options & warrants	422	3	797
Proceeds from a shareholder transaction			327
Proceeds from issuance of preferred stock			23,688
Purchase of treasury stock			(21,487)
Proceeds from issuance of notes payable			2,839
Principal payments on notes payable			(1,732)
Net cash provided by financing activities	33,750	11,512	211,863
Net increase (decrease) in cash and cash equivalents	25,018	4,113	29,583
Cash and cash equivalents at beginning of period	4,565	2,957
Cash and cash equivalents at end of period	$ 29,583	$ 7,070	$ 29,583

XML 22 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred Stock, issued
Preferred Stock, outstanding
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	75,000,000	75,000,000
Common Stock, shares issued	17,228,707	12,470,694
Common Stock, shares outstanding	17,116,357	12,358,344
Treasury stock, shares	112,350	112,350

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References+ Details

- Definition

Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References+ Details

XML 23 R17.htm IDEA: XBRL DOCUMENT

Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2012

Loss Per Share [Abstract]

Calculation of Loss Per Share

The following table presents information necessary to calculate loss per share for the three and nine month periods ended September 30, 2012 and 2011 (in thousands, except per share amounts):

	Three Months Ended Sept. 30,						Nine Months Ended Sept. 30,
	2012			2011			2012			2011

Net Loss	$	(4,583	)	$	(3,960	)	$	(10,123	)	$	(9,759	)
Average common shares outstanding		15,422			12,315			14,746			11,840
Basic and diluted loss per share	$	(0.30	)	$	(0.32	)	$	(0.69	)	$	(0.82	)

XML 24 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2012	Nov. 06, 2012
Document Documentand Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3
Trading Symbol	RPRX
Entity Registrant Name	REPROS THERAPEUTICS INC.
Entity Central Index Key	0000897075
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		17,116,357

XML 25 R18.htm IDEA: XBRL DOCUMENT

Product Development Pipeline (Detail)	9 Months Ended
Product Development Pipeline (Detail)	Sep. 30, 2012
Androxal [Member] \| Secondary Hypogonadism [Member]
Product Information [Line Items]
Status	Phase 3
Next Expected Milestone(s)	Complete first Phase 3 pivotal study (Q2 2013) Complete open label safety study (Q4 2013) Complete DEXA study (Q1 2014)
Proellex [Member] \| Uterine Fibroids [Member]
Product Information [Line Items]
Status	Phase 2
Next Expected Milestone(s)	Complete Phase 2 study (vaginal delivery) (Q4 2012) Commence Phase 3 study (vaginal delivery) (Q1 2013)
Proellex [Member] \| Endometriosis [Member]
Product Information [Line Items]
Status	Phase 2
Next Expected Milestone(s)	Initiate Phase 2 study (oral delivery) (Q4 2012)

ZIP 26 0001144204-12-062136-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-12-062136-xbrl.zip M4$L#!!0````(`$=B;D%UWNDS:C,``)SO`0`1`!P`"TR,#$R,#DS,"YX M;6Q55`D``U;2HU!6TJ-0=7@+``$$)0X```0Y`0``[%U[;^,XDO]_@?T.NAPP MV`-B1R^_TMU9I//HSFUWG$W2TSVX.S04B;9Y(TL:4DKL.6`_^Q4IR99D699L M^I5XL+,3BX_Z5;&J^"J2[_\^&MK2,R(4N\Z'(Z4N'TG(,5T+._T/1]\>KVOM MH[^?_?4O[_^M5I,^(0<1PT>6%%!(EZ[^K/WX>/\E+BXUZG)=J:O2?RG*B:*> MJ+*B2K)RJLFGFBJ=?_T?Z6DL71J^\4@,\WBQ-`&J`$0"6IOHK1B\H3;51;S,ZWY'E()HAI<>D.J>JZG^ZCM%'3MUTAUR@#)@HSV]CY M/969551W21]RRMH)2WX"R<;96:J%)P62F9LG8>(DZTS5+QK/JW0ZG1.>.LE* M<5Y&J%0Y^?'URX,Y0$.CAAWJ&XZ9PH(+L&?S8^KJJM(J*A'FB`M8R"/(9,HZ MMTSGQ"`F<6UTTC-,OX9&GFTX!JC3^!I^QQ69;N#X9)P6&T5FO>\^GT2)O&5J MLE+3E$FQ@!`PI'GEHM2<@A;"^64@(2<[&IF#_/PL):<`=IX1]?.+A&DYA1P# MFS2_#$]B191T$8K-_`*0D)?=]\B<_)"24R"@M;YA>),R/8,^\9:-$G*X&-D% M^O/C"U-J9I1,NT\IU]M[U).XMI]&JE)L$R<><3U$?(QHTOIX!?[8@](4#SU[ M\FU`4._#$;/Y6FS;]1&UCDYBQWCA.CX:^=(#,GWF:4*W,7$<9I2,0_L86^P*^C4BV(+_:$?RP`T.RF#:>IJ,M"^7OW4Y-H# M\I@$E)V20$9QP!NT*BD.%.C4-%F\XG3V2FC*3@KMYX,/M;+!UH5M4-KM/?BN M^?OY"-.?#U`_HA^_&X2`BG_E0ZK-R#@2$>HS7/$'"TC"0`&;.,(B61C2P^%S MU/6^94\AC[>@LSE;(XSJ\Q&XV-?P6?X>CM->FZ:P3"PV9+,)>HQ M5B\#@IW^)7I&MNNQ"#!J0\>NS\!S.]K=9TPL"ZDZ- M43+#6[7J@H"ZF$2'/2HBA0E87$XNK*BS*"D"/0 M@\H*5=EO/@!ST#5^(BZV#DHK0&ES17I0VZS:GCL6<4?Q*F1%M9VD?1Y[;M]U M#`O3X=XK;UHD6U'>`L&^:15^")XHMC`(YL&P47+T>$?P,U"\LPV3C\/V0POG M\C-==,IG[&UKP6$K:=-;2:]$-PY[3P<=.&Q6;66S:O^TI]0*5=?9-T6IL$(U M8>Z@$*45XMH-R.O5B"EW!Y4HOXH](.@5>XD$>P>ER-_88G]U/39BC]99[@VG M'R[`?#5&>!CLR:I)@7I,LV1X764!):YT(JXIG93<#GI77>^P<]"[9?0N*;># MWBVW#//JMX'7LWRSWF[\L!U=??WHC2MRE76G@_+NN?+NWU+'GBCO89EEL\.) M/5RBVV: MD8'@(WN'L/N-3Q6WU;XE0I)WO2U%A!._CG9+!Z#N<;N5CJ1]'>VV9\ZSR.#> MFJ?-W``!/K#@:;X_UHNUPNHL;+\O(J6^\3 M@M-&M\G?N.+E4G5_"53KM5D]L` M,B'6[:[PR\W:K?N\>V++Z`Z[9K:YK.ZP=P*^.3C[2`#__M>_W/Q+^>_K7^\^ MHQ&Z;#1;[=_NT1_X[,>WFW^QS[^]X&=3UW6ST6B8C_\W.&N^_WSU7O_T2;G^ M_/Y4:5\W&\KU]>=WRNF'SXT/G]XW/W6:-ZFW2P)&F0F>#@R"P`JC[T-N@^@L M4@.>&(./T^+?K(Z<&K\]7,Y4%[WR<0IIU6O[Z;&=1P9E4J^%GZ$!SQ*9;X,A M>^3&)4N2GBG//EXBQQUB)Z_:L@)*57&21E_,N1E M8N\MA$_C-W(>QQZ2(J6\9X]:S+T,3Y%K_WQ_DBW+"+%OY_#!8A^O;:-?KL*> M85,4UI@J'5<9DPD7O:Y"_U*NZJF#2B-.596E20&>P/J83Q\>) M>@O)0B8&7/3#D0RNH:4H3:W12@F\@.H9?PIG,K$SZ.# M,M3$#?>%4/5&L[$K4E47*D!;6PWK'4&>@:VKD0>3'`1%N_X`D7-*D4\C#R!" MJ)U."F8)J@)!EA6GWE!602E<:'JSJ:<`K4ZZK"A`J[22M._"I\;&=S;T>2`D MIG=\->,6"9&"TL@TRGQR(F"5E5`CJ]'E8-TXT&?T\9.-0H%"\M7(M`/6C7QR M7>L%V_FCG*I2T]IIN94A+!)H63DJ':VS(T!+Q245FXV^*T(O%:NSP.XZ^DK, MA+E$*'-3SG6$U8B5=GVJ#/];0,WD#V[2.V-L@#P$^GQ%R:A0/JG5P)2VS8;< MK@Z&!,CZ@HTG;&/V`*5`X:@-+0LGG]C*B,HK2Z@R7I;`"@+)B*`\@,:T4QKZ2=E]9$LN2+ZT#K=+D MYVQQ"Q%"I]5J9HPSG]J*@$I/UC1-5YI5`:7VD,1IB-9.3\=GR2P/HK2>5`.1 MW2>]`J+$(YBB:#LUN<&:N[,J1JV4EI;NH5<'MCDV2RNKK+0;;?%L)ACEK3QP M;0L1&NZCEFN?E2*#JKJ,69!GZV=A-N*EBKO?"N2*$1V%_-1R;&PK3.5%)BQ` MGG5IN;B71BXH/*YJ-R52^"N$?549=&P%LE`CR/'`6V%J74:0-Q$Y=ZQE3;GB M`L(BHJ(`+K_H4`5A>HYQ9Y`NX8UJ\4'4'2)\QVH9028B%1*(V0RG+LO*O%G. M/`1B,<^3[:8PA]N`YX$_8(\B(*NR?'/W'EF_E]V%*"`J!EZN*#AQ+:\9T"T@*0%;>IXA#MJ([20>!J'I+;G;T`E0AN141E9>3TE+5=DMNK89( MA%O*"$IKM#6]2%#I6)F5L54161S)4Q5;:MP;YA0D+B:O>:M>(:$5<%00334< M7[#)HB#H/4QFG#D+@#DQXL5SS7:KTE-4D@#NW;%AL_@ZO4TLV6C$;6*IK"Y-+=-/%D!*+3-],K!#O[@4+*OKL,>[ M:+=7L&->&9B4%8^FNG4=%CACL#C0D`=!B.3T5O$<8CDV7B:`N9(] MQ?66IK6"O52FM8(]5*95M1'UMBPW2Y"DR"`F"WM,++1%07LEY+N@+34U$PA7 M2&\U8)64K-G)++.M$5@EC=04+:LH&Y+8HNZ^U7]_X5(>BQLF=^.N7P@ZK=V>'6#,(9B>\U*?3O.4 M&0$LZJ$ZS>SJ29I$9?*5#+#3$DV^DHGIC;:^3NX7#HD453#]RK-H76ZH2FD, MX<"7C<[9-),1Q4X`2AIIJ^L(4,G:C$XNIBH`8R6]K75:C6SD^08P5E+NFIX] MX+,%.2["R$Q@"R"KFDE-Z:@-)1N?OSS02TS-L`"RIOEOD=_M/1HC09#;:KL` M<#&$[")`;FXV56?5=1U(]EQJV-U>;D:AC&7/?(B!EM]6'U'/)3!$@+&"2RSL M&&1\XZ,ALB$6BX&[`VM&R<*=&?7\!+LF-BS!0RCB[RB*)1; MD($PK[O',A#FU?=8!N)ZC3T6PA*]DJ;+V8-6ZQ3$+7I)YG`=^-/D\5]=4E!% MFDJ7.5V!Z[6UMMY("T$TS+0(_*F,U^'74P2J45[1FZY`>44?)HSGZIY#'.F- MACF+Y*.RP>7$E\XE?V40![BD<=S*1X-BDRU+8COPYT0W%%I0?@P-NX%$KFOJ M%-$"PJMB++2U(HSMS6$LM,I".2$N2F,*M1)]L<#GJ^R<((^V+N\$\/EZG`^\H:OJ3@"?K]SY MP/66WEP?\,@:RH5+K47+YR$0#7XMFKXI\&O1]NU(7I#&%X#/'F()@QB3KR"% MI6!*P),JCN0J/B*U@%M5;VH-+1%06`[RS$D=04P&3Q1;&.:%+,PFR23,B)Y! M`'>V$1PLX<3MH/!A.O#[[B9DP^$KK0YRLM;=>8 M7/-3[/OEGC;TQ/?^&?S:W]<]F,X&O69R_LQYB('$D]GS(5NH7-%;/@!U1#]^ M-PB+#<];8YH[UU;K>G*J78#Q;#.\E'5R14SI]>3YA\9QL@/.VK,<+#8%B-0[G>;N\/ MA]BISF%=TTHSF'+Q\)7X^$\>>]#M76,'BH`N\:`K,;&%V7NB"@AFP;$C(8[O MDO%W@GUTZ;XX8F+Q]Y6R\J1<$TELY-:!4(6 M?WQDQ#3H0.!69TM.[]C-DBD\O7,U8ON=`::#D*U+]"3H=)&6N>QQ(=GTM54> M@>JXBK+XW(3&KK[-F8GP+*`E#M+"N,_F)C!5-E.UJ2Z#*]YQ018;?2.'"FHY MI9G9UL\G)`3*PHN&,Z?4A$*I;&V*GKWB:AZ',9*ZA9OW:S+W+JVM82Y\)RUL"QT8X6:1@ MS47&O45.*L>.=S31W-PBG[V8Q%0+,D1>-;U/JM]J;Q53[WW-`6J&@.QK2K(JZ)D,7/B(5[%&M6 M3W7FC::R]+/0^0-F(9<6*\[_IEC8O#OGN;1\:D4RO<3LVAWL!P3Q=45^Y\Z- M`YBH:V.+A8=/-HF$=0I:>ZZ,*^(IS=K'@&('L05`?L2.22M,GQ,'O)S>E&&J M`,F\?AJF_>)K@[QH3-?4 M=@!RY9%H(_NPP'*PD\HT7?!*1$@(&,_!@&[F:;MBHJ(1+KRW1%/G^\(U(:SL M$>26KF6?DUP296+GDUZ-$#$Q7>9`2W%7N)"@:'0+=S+43>.KO)/7:56&.+?C M92`(?F(QTD6/#E4>[ZCS,!*1@> MW",O(.;`H.NP?T5OY\^$YA,NDOZMZZ-X/4O0W:O:?#>?I)9%!>`C3KH]X:B4 MEI:]!"V?6HG.?!(G(7+(!-VC4FH`DD-];9@7=IBM1JGEN_5BKFY"2KLY/5-417E#)O37R/L1=)NR)D=U:WAKJPH)9]!GP^=>&1T M.ED##F->H@!![J4#/PH4W-;D7XU?%EXCTM3U>:1O.%&=4^E_05ZX M-WXG#0W2Q_!!]GSX=_1.ZD%=IY+"?OMX".)VT(L$O!O.FCB4NEQ``+S4.!CDTI@8W7I M;_X`322LRN]86(OAC"=?E'?'R>3[N_L?QXG$5!JGD4IU23+#"YI7-*#S2[D! M223^A_1B4,C!U0"F"*XCG0=]D)RDRL>2TFFWZM)W)+%G0PRPS\F-#R!P]NKB M$W:]@4&&ALF%P,?OG&&0IQG0L$(FDF11M\>%:Y&@3R7?E7QP2;XT<,F0/=[& M58\PWME3WF#-$AU3,#+)PM0E["VH^D$+0R#=@$@>`9=)QE(D+\ED)TR9FSN6 MXH?/([PM'70/@VE+%#PGC%U!GD-$6'.`YQIB;X`@?DV&L3#F@CZ"(CCX$Y@TB]P#&9;ZQ+ M74?ZSP`DTCF6F`L_EEZ8N,*[>JR0$GP!0.8`?H,$C3Y!O)<(^6(@KUW7XA0O MP0JDY,VN8#!_2YCK]>5YRER9U$*#HJ!?3'CLEX>?739[1KT>6*$)3>,'%NN( M6?:)N$!'F8+%:FJZMDM.I2?;,']/:7;<.JQF+MC8;/,E5V=^<`(AILP4X`E% MQZU9VX(L>-.``CYX+#S3EF!,"W-`UY;8E@ZEG$R2^8>[%/.AX3,6"OHB<<:] M*V:^N-U`CLBVT2AIZ2YW#AFGP)NUAT"U4=KH!LBP_4'D'Q@:T-TA=^C`"'OO MCZLU^`!(YRX$@='SDD]LJ!.Z$:Z)Q.VCV&`),I$'!A5[DU`?(K<`^I"O9.,A ME!DR0M1E4;R0D=M-`+5BJ+6'GXB+K7"0@AP+O)@/PS^**;?-KNF[3P"H/=\\ MN05>GDL#Q@LS3HOU0P;#RTY@8&9$W!(CIGH!"]:WP4:91-B3A&%^SR`^T^-T M$I1CKLMR8:C/G*PQZFC+&I$!-UNBAYXN6]OM&6$ZZ! M#;">_V_O6I_;-I+\]U3E?\#IO'5V%47Q3=&YI$J1[%MOK2V=I21;]\4%DD,2 M"0CP\)#$_/7;CQD\"(`$*$`B%6S5.A0)S'3W]/3T=/?\AM:@J3!!Y1QH.T6D MP%^#E1,,N&]Z-/#`YE+0P(>BE>UI>MSJLMBPPX2B2<',#`<IU)W"JV-X>F']P<@#"9'=OQ@3+T%MMGZVP_:F!S24S#( MIKYRQ7M-?2K2M38!3797.L9R\$@N_;W2IU/Y=T"&HVB`*4#.MA*`9Z_"E<*; MILEH(G`K_(,FR>_V@/K-9L:V!W8W;"E5V*:8>>5M26]8-T+)7ZJ5*OSJ[2?X MBDW%NT*3I%Q2DTYG%C%GWK308+2SQX*(/7T@=!G\TIRFJNJN#ED2LKO.'OUA MG`,VE8?/7*];O+\OT%C8YP=:(L4T_.:S8>*VP!)OW7<;%)UY3JG3<^N4+":6 M'4V6*OQJ^SA&3IZB&-07?7ZO88+2F,A)&.R^_A[9?64RE]7,%KF0228OJ9OZ MVXY7R_0<+I5_RDZ7I"JVRUQK;_^W0[[IN\KW@I6T'_`(FR'8,^C@\6BN/A/> M.N"O]RKXN_KPKXN`I3:RU'MFELJ;3(44](PB`]71@&D4TZ7H(-W^@O&EI6Y8'OR? MX[L@,(RFV(XWLTW#QI@4?;_`4\NFO@1#?#K&X_4J"N-F!?8??93SVE5I#AG6 MTBC"00%#?%YH][H)A,R`>FP%1DKG0R#PZ+T.$\5WM0=]#?\LC,D"OD6\$>!8 M!8%LWSLUZ;YKPYH??R+O^^_*2N59VD"$C+R4?%H4-VU1LAP&+L6 M^"`&-AN]0;?1[P[Y)U(4=;4O@@/ MAYWJZY!`'YK69Q@YG0I*.T#'*X4:AED_R_LO4$\A.+`?\";D?6XH#TQ#KZ#1 M1V,)RFBNM3?M5K.K+0W3Q-3M3>=KT6=^5H%P($[5J*00-19B:O+K`X8*] MY<1WW8UDH]I_J?W8]H1C)#@/%@%<9/PO-C@)X`Y5BL5&Y&1X`*L"XJ%BQYX[ M^A*TGX\L40_Z[DS"EXW$J>N/EX;K4@:7BX':L25,.;2>U$+X*W71;K60T=\% M6GJ8.+;+J:V,]#OFZ"@=@1/N/.U=?,HU'C68]=X"IR#*1N?J#DQTX;#Q;H9R M^9S@';2H51I;F-><'T9ASGP'!:+ITWLJ2.>D8DC&%!:A4[SO=+[6_G7J@`KK M8]=VL*(RY0IYZN2.58TK3HFQL7K0AG&C4AJ[UPSF;&40R<%A!UP,"M[07S,1( MQ$8EY1:&LYD4[H`I%=`MV:H@A1K)*&-WRMZ#&R-3ZC89`3E.DD73`)N/'YCP1N]#-F22D5T]B2<@%5S<(\J!X/@>3&=&UW)F!57F^ M$QVFR')&LXR&,:*OO$);).U%\+4<;7#Y(L&GJ)'=6UI11&IM2$/(IF89_7)F9Q/SL7M,_MA M84<\=NQ*"4M-I?@L2TY9SS'(:P_W7="985%B6;#/;-KHN@AG&5O]>;\%%*H2 MC]"3DZ.K43.6)7A_%YCLT#&B]9HF6CV=PC7Q%JM9R,0/,S9F*X9`CNQF:`O5 M[O4;@^Y@KRT4@>WFVT/EW"AUZFU2PE;2H(3CVVU%!GBA3[&425U]1ZXBC^(; M>*8Y4M)L)`0]:@[4CS3G='=!YH@^B/!H1H/WN:`3NL1NTE;R6!G^H#-\4S"L MZ=O?YGDPK%1V:WG&Q,"X$#MLI'&^XZ!2FJJ>7R/PV3%.?73&#/S1BX:9*+`# MV@S&8AKX4YMN2]P5`(]M83_`&NZ`B&'DJ(8./8#`@@+_?,13]1[;T:DZ.!E5 M3ZD93RUHQ.TD6.[Y@MP#$@Y(ES1\1ZFK&:E>^TW$8FP@<7@<)&!C>,V@4K&` MBYDZ=Z7I)K!OT76DKO8V$EZ!'8M-1=18'VCQY+17N/S@>1>0Y3OI3=N^29$Y M/-@5'8P9+$4N;UY('8(BP8!$*1L2BO=@YQ5,9)!X+P3/XU#`?DAW89^$QTL# M3S_4DLD$G&/P?5&='9UWGUCD#[\L8K(ANC%X2+,-%!3VK`:>+R!+9YK2N0;A MLB\!:@PR=*E16HGPAB22^-3VQ_#*V/99B1G#;!V3`Q7[<4/PW00&(V+:(GB> M)9_KB6/"Q5%ICN484"=V#.B&XLCL-/'G:%B%,Q_U^9\M)=F<>S'^%-Q$WN5E MPY8W1MU1HP7>(JT:9"RI+%*&^7%TU,=(T&M"$.R.F)E4MX33SX`OQKI)L]E= M"`&;VNL9A[MT0G=O8&_]48]Z>=,%EV?/)I,[AF2Y?P&3 M_M(*KN@1>8!;;P7FLZ-M548M"6GX&MX6`!C?^FO)RUO0P9),3]%7Q?4 M7]SV8Q?D%TPH&@Q&M:'V-40%[]5H=H"C/&?]LM6YT&`K![_/?#P`BCZU84_= MU%4AA^6.&OH\\)K'8OR[,>,O^=`D)FUM[9/[A$U/'`85W!HO.!YBXU$.5,&W M%)NP?1=TW7U7J'C]&07(!>U$`-A1JJX\V:AO/S^@\O;-NO3T^DTER!,P(P^. MOOKQA/^;MQ94DG3*O0%OL(RGE7WNV;R4I6J=EBWL0R-W5`[_1L%K6N\P!"!, M"V]S2:,DZ6V\%,.O0YY78B+%R5GY]O/RFZL:JMC\V*-<.N>0I,_&B(`KK&1\ M)BI2QV,,JC>G\/&I=$K_Q7CR^0K5QIM21H#=[O?*Z>B$6SH=E=?72!HR-EG!< M3$29,DXP/2R%Z9P?O<(,6\^L,.68F50?*EV'"%:XD#-6A6=9:*R*-!P9RW:W M@`%+%>%37/9CE5JO7ZG0GMF.;A+8:?:SI\8=5A/E'F1NZDFC04U0QL8462.= M[4`5;#(RQMW.Z`F#7(SQ5R2V3K^(^[V-\=IBU%PNS(FRA!H1K1#D)J0ZR1@CY67>-"5591$IA#)=*`A"M61NOM:EQ M;U"*W1(>/SI>4P26PQE8C(.)@[G0+)^B-EC,%E3?Q"IO;-_#7#.U-E7EX"IC MT-2N#--751\9]/BN>DEURL]P.8^JA^,&N:!CM6)8,E6]!GJ^EN0LA;>PJ4XM M*#I`O!ND`D&6HM3:#+#=U#Y9F%)7N10,ZO7`$UPM96/](=?I*#["0$08D&1.FYS&: M&4]8-#3QB-A-D6XX77SHJ8R-N,\A8?/4R8NT8/L@E9([TN7/=-1$^Q#H;A/U M]J58?QV2_8*VX1`$6T%"XZ\RLND)JCK%5X($GSFK]PHE6.O@D>E@%8:X_%CX M*TTCUU0<3D9*)5S['9EQQ3,W&*S)%,>!I)='\MVWO4;__`D)]4U,P\-EM-L8 M#0HDMHZ7T7:K\:0:B>/A=-08]HL$\7

@!%$12( MV_U&KY/MMQU+JKO=:73;!9)]A\I&KS'L#8Z?C7;CO/?=/E?-NO+N7S@$4(J13 M!B4WZ:DU>Z;U&YU!K]%I#!1Z!6?"]+D+D3CS)KIS#[\%#MO0@R2UNS=]I8T*5)^-XZ)5W8U#)$L0?M M`5;@K:`[!"^TWY0D,"TJ+X_5VK!.CAJ=86L7K@+BV_$=Q#(EBT?W6\U6NZE= M(*IB-)V9D2O=@PL4FF3@YRP&^H,1N%YM>JO=&(Q:#<+Q(78VQS"3N^^_2^.O MT^R--,-U?>8+7PUP!?E"G#90,C9A15.X$:FGXS(K+6*77@)1!D&PN'CQ)!T. MG`MKP%'*X8D_%G7M(@'8YIC%R)J/EN.#VCEY"Y_BI" MM$++EM^F7%J%*21 M?&%JZ&.!@[44IFEXOJO=K5="ZZ0\"N3!&H4VREVCJ)=]\B;-T-24.B>39`S".."-[[A^>Q3\8B@ MPX%7@"DH?,LST0":!$8ET7GDJ-!X;[0HY8^,`8TF@7?BZ$>* MYB*8+E&J6<:J::1FCOZ-D/5MIJE.1$=%,I.7MSGB=P:HB/>?'(W4D5RMA*Z& MA%LB,!>0 M.AQ$T'&3Q!!`)>'8@KJ@"::S4('>%=.&-"FH,?YB>]+A8R:5&#Z**?5^:3@3 MW_!P?H3.:H?]OQ;[80S\O,&``A>/#Q*)!@T7WL]-.'$X\@[RYX1/IO0=')Y% MS!/I'L/4QFFTT;72FV"866JDY0&@'8&E;9L=$J](FD]@,]J7FIF\$LC^(G@5 MU&$$'\F828NZM4M4<$]:[!B298"^M8&TD8*R'"._O'CP^LI(*FIWC9M&%/3K3E2G=F/,*AC[&6@0(+##P!$0EC;SA!OU' M5)\:=A>$1Z\ZD\`BI/DQQ6MJGV9A-60C#N=X;\QM8,:E6R%G^"7*3)DA)86Y MCG#HU*"<0K8(P*>2N_WR!1CQ%- MDNQ&L);HRLO2L/I]GEB*D"YS&N`W,@J8*\0?&D/H"P6S'P%/T>]UPZ3UAZ!5 MEDO<(DK[J[LVXXEA]PCTKF"YZ*/"D97=&"&&FQD6Z!/Z)G@ MK0HQ#/H-B3#^)$R9\`X`D38=?/!JS/@@@0E``9#""/9D'G#?:]F$A@D#@Y@O MMC.IRXUC$/!X-I=Q"UHT?`=/&HV^"N8.XANS%76FJP-M_&[3)&$<@AXR^8:;+?J2UASW-=B6PD:V?\@ MG+TDIC<0W`A;C*UQS(WA4M`*;3@:``+H5^B`C.X$WTSUI8Z03:`C.ITMX-_E MD*02?^,[KJ\S.*4.GHSGF4S:14`D$O_9]W#_]%68`DT256'1T*(@P_N@.ZW6 MJ,&=(D=H'\="84@;GBO,&5]Z@GOH.0-T.MPF'O;@'5UD<9%6D$STF.]!<4+W M=ADL/KZ;-3)*CD23[(H#$&[4BW8%N?'>@K45I*V$1BXBCL!,)VTFL%\ M8'.#!<5-+&D;]!./$LX/UI(&4&)B&(JF_\K1)[CI30?SRYQ=L2F(]U;XIKB> MR6NG/X6GKN[0=7W*G#R@B]*__ZYZ:Y$R[[C;`SB0)0G9?7N@?#`U(5[TPO0M M0C^\*].?C=A\EZ8S.;+FH,"@E'6W^+8NR[\Z_9`9?,;KT]6@.Z5/V<*7J#^A MT9*'H>I>CI6;IZK)WE>JYVUHJX3(;">N58_^NO/U#8O]0I>KETM%MA/QDA>L M'RV/VR]9?RZVRI^V!:];S]G&SAE7Z0-5V;,MEZ^7;,DZ^TJE(NW?YQKVDN?$ ML;5;[1RN1A#YKF7?NJ%X'8J__WWIN\8X#;LK?^@D/>"21/IZF#L:_#_&OR_!O^OP?]+$]L+@?_G#P6F!Q`WSZ,3*,N%-94X[4<3 M33R8\P$U''D-1YXC=/+7"/_5<.3/*]D:COSX1[:&@GXM4-"O4(*U#AZ9#M9P MY#45!T'%2\?(:SCRHV&TAB-_=9S6<.0OEK6JX<@/BHT:COSP?`-ZL88CKX3F M&H[\B.'(T_),A3)&F'1R5L[C>UG>SH=V\^21OLDWKIU;1CRZ>#3<;^J$TF=* M=*AGW.`A-SAX>*E[8FX[QI^4;:&78\<;N(63GV29_W^?)AXTSD0W#Q-X*%H=A0X.0!^2/A4]/Q)G.I6]0Y9!AEKN<7R, M0,(11S0X-KOEG3:?+GUYX54W*8J=)=;R'\G5MIYL+212@K.\EGCW7X1WPQB+ MZ4;FPOUV/8M)E-#AL+;UTM1=]WIVBRC\))E/+@*43<05W2!_0WGNNP=;RD;S M89)1V[_<7IT0?.I2-]T?3TZ[)S^U6]T6_D\QDD5CP,470N>%WAFGT?W*L)#3 MC[;S5#3EX\G/YT'U.>D[?EYN;9$/E[:I?'R MR;HE5^GJ.T7DPF5,IQHZ_1$P/[E"P,NO0=)XO@;9+<)+D/PWN^07&! M_H.1ED_PL8L/?!XP!XWMTRLQ01K;VRU"OQV:@RU=/96<7")#`T7#7)P>=3`` M?>WP6$#YXCH?)LC+TW79Y.859Z]7"KE!^7SY`AVVDN.=WEL)1.456^>\"%%J M=E.!^%X&):^P>OV8.=G>83FDY9ZXW=Z>M/U&"5PQE4'C8,G!_?-U&#+>V$JG MTMR-+2A187((.L7:M.,BW8^8BM@9%66G?=YK'2X[WG#,I>A-4M.R^^8^UG><-:PL=/E4Q[,&KU8T[@ZY7,13')#'NC MSO`U2&;[Y.?IT>NTAJ^!U;*G1W\PZG7:?PG)',KT8+_V::UMK%T?Y*V0-W0I M9*56%IS/;ROA?",RHC+K@./>[(V4WUX=?TT7S$]?O/3-V5O<2;.28YR2M&W8V\I/1Y1=A-)U(24S6MQ00Z MW(O6K^I"3LI8Q*ZN*R,ET4XG*K/7J`.(A6N=42OBQN[L-';DF/R_3\$5@KOCA.%H?_A_W_#6 M:/]LBZZ(P1&_I,)+,L,YGGV6^71 MFC:+2I+KL-,Y'T9W?L]&:X5RO9ABO2#=KW)G7P27.=[HQO23=:FO$.&4WJ4; MD%E33IA^%1-[;E$KV1,R?[80@VVC5CQT6#7)AR:>'&%4'A8[W5;[ M_.!8+*[DU178#(]#.HFUK!J)=(]#&F7J2H&I-&@?AWB>JBRY15*).-B/H1^O M5W3/FXH!Y$KME>X4#GKGYSNYW$)T7@W8F^-=13KYM?9EZ*_0^RF#=]K*[AYV M&37;E_5R\C/`[U#%,O<@^?G8+6LC7"V_H6+LQ>ZNM392S5><@(IIKVY2EL!W MH=X:BM(N`9!`(#P,)_G)YJ'VW;LVQ/:+=B0J'9TU/DSC2L/][/Y&__ MA#^T1_K*6Z_$CR?`#D'HG`L``00E#@``!#D!``#M75MS M&KD2?M^J_0]SV-?%@'%R;"K9+0)VBBK;N&PGV;=KX\X]??_GPGV;SKT^WE\Z0NN$<2.!.Y.U,T0!NF?(_83X`YG>/?G>-VY]AI M=WK=;J_;=OI73K-IUNI7#$O8;O7=T:F^G9/>\7$5[9SVWG4K:.?D?:]S4D$[ M[]J];F<_[7P#CP#?:>HD;>JT=]+N'7>=FY_?U)F`KG=R6DU3QP+#]\]-^9A\ MGR`.CNB&A']LS()@T6NUELOET6K"_"/*'EK'[7:WE19LQ"5[*XZW2B^[:=E. MZZ^KRSMW!G/4Q(0'B+C/4K*:/+G.V=E9*_I6%.6XQR/Y2^JB(`H,6KV++9^%-9^5Y:COR%NEN- M^9(ARK:!2MJ*:)@B/HFX"'GS`:%%2P+8`C_@Z2<1I,UV)Z'DM^3CO_N<0\`' M(6-"L[0!'TW`CYK].[]*KRBF\8;!`V#M?+8!P$$:,@QDP4_!R:@"/E\C#4=I-KN01?`@O6-CT@@/$-V[X4< M+:Y!W2\48M:RH3;6K`-42:[@+K?9]07>G$YB@1K!3$YA:L> MY&$*`DLOTD2W:,DK?4`/*H8Z9YJ;-=.^OCV@\SDE1E1DBM:"AZR!]G7@ON?A M6(<;L3(:D0%:X`"I9E-%$K6@I-!<^^9/]PP0#]G:J(/D%*X%'WE&)E2<%%/1 MK)J+(3R"3Z,ETEV`'N"]**+C;0^6U MX'H?(":^\\`7V)7[EGS1`%E4-DN>=!M^5U(L]%BQRP;4R>W=(W\8*V'?J>@U)DX&E`=RS1NGL4L7G(O$:L"4VFS[]KWC842.]W)R/*!$*!H*71.E*5$% M;P/A`U)F;EK!T!,3Q-8C@8RT M8!#O8LMH.)V"&XRG@QDB#V)-D1R\$'C<,$QV8/"&JI'_/3=GN0?O'UI8:G`%$L;G-C8*UYS! M//,3FOYKU5BX-7B?KZ1U(>:SV/>&,%&=4-/+UIQ%`W`24D^M(G4("[&FQS'D MQ-L&93^+R;(0:?D+!S0.*X\.5.JGIJS7!*TE'FK+D<([Y279V$(\<\1N047\*-\T4-S1$HA M5W=BU:"D1-JUKY-5.ETEJ],(:KDWQ^06*"F3NEOBAV8R>7)NF+S(D?OT7"F* MC2I\<]R;P9@ZA>YZ^*&=8N?])3FSSSSZ4\HIC"I\V4:.:^2BM]90FNYU\#O:=_])\0,KA#[#H$DZ0[A."/[MIC-0F.81*[X MF5L7P(M.0LN4]WCZHMY;HI9ZDUP&+K-L<^7/ML?>Z4D3HM_C%^\5[*JD:LVF M$@ZS)/2A^NH01U8&(8,HM1J]33`B`THX];$GG\RZ"R<<>QAI-@U>4VNMV7\5 MG&:I:BN\XU/(,0&9^XN.HTG4XN^?C]R6<0M5=6_3'Y0`ZI/AAYJC75"V:5*T M,5)N/5FVIGK37Q8VPXRY!;L(3\?@7K.+D%?)X2+<<\)FXU%=PW"6+VN?\RIH M4\6N`FCLNZ2T-9F62HXCE?CY"IB+N?'PE"_[9O@L@,:^>ZF;2LM+U@Q/0C%& MZE^0U@B^&2;S0+'OWF=^+-E^0UXL=.,/0'SYLMBKK?#-T%X&1/OV##;F1;>P M")D[0]Q\V-4+UYMF`W`L?*)ZTSNO:0!IQLRP$V^)U)N_0B#L6^`+!TN\;3PU M)*U0I-:D%0-A>#+]\'\I\P88IMYN!ENW!VM:S2$?(7N!N3FW;XV/!EC^^M5/ MA$.U)Z%;%+Q!.'+CA^'DNO!AA5<\JR#O`_N4APR2,RC/SY@9O:E0+/\3'E0H M;JSJ&ZU[_O-NIMIG^9.?I%7?H.#YY=%BA;0BA_V#N#IHTXZFMWR_[R&HL5>^ M`FO&A5$5]>/&#)G]/N.OZ2?`."4$_')=I4"J?HP4VF_C2_[Q0=D7Q%N-8#UH M,T7!^,6`G#G$AY9LV^8!L3W MOI[T/YR?]+!G^P[Q9E]/?G^^/?U\\L___>__^L?_G)[^^]OC?>_:MZ,Y]L+> M#]9F2K#3>R?A:^_FU^F-0T*?]OY(^NJQKC[T/WSJO:QZURA$SQ39?P8]]H@U=][#_X;GK]@VNL/_MX;G/<'O?/^Y7!X.3SOC7[T3D_UOOH'P>\X_]6/ M'SZKOW-Q.1@6PW\QW?F+'P\'.IR[23WV^ MO#B_'%ST)NU_Z@L3W>7%Y\-\:L!D^&G[*9=X?[Z@`/?8-/2"KR>O8;BX/#M[ M?W__L'RA[@>?SLX&Y^?#L[3A2=+RHU/B!2'R M["T5[Z:(KO_ERY>S^*^L:4`N@YC^WK=1&"\,2KYZPA;\?Z=ILU/^J]/^X'38 M_[`,G`U?K(T3;CZ3[>#C6?+'$RXN1&WJN_@13WOK'W]_O-LG(UYXYI#YV;K- M&7)=]B7.PV6X6N"O)P&9+UR<_NZ5XJD08OI]SOE'SO/?>&]G-;AA/V./CYM3 M!T]1Y(8-\K;?=T.<^G-$O'883;JNQ6?D\GFY-,IGKMPZ'KXP9:DWD*48CY@CR>WA*/ MK6L$N1,_('R)NG)1$,2+]$EO%R?G[Y?OH1GV/MC^_"S&J-G905B>(,J:O.*0 MV,AME/]\S\V!N6,VXAR/W!!3CVT1;[@\U_M=-,?>TRO#_>J[#MN@;_Z*2+@: M>^?,%^Q.?)&\X8:$\Z^6Z-P2KYJ"J\:WF`%^AX/76]=^#.\\A%-MA M>1S[7;3(7DV9*_JKR?@U"6S7#R**)]1W(CN\QF_8]1?\VQ.RP(Q8=RYH==48 MNV,Z0Q[Y%9NB8[;3Q3\$;#C>$S8P'3XT'2=>^)![YTU].H];E,92]3O-Z86- M!"_D7TQ^&BT6+K'7;#0"L?P7&@,WLFT:8>=FN6`K!PY*L[Y+WQAC5\BU(S?1 M^O3>#X()IO'J5YI%<4^-,9OMM9DAH>ZQ.4G[\SD)Y^L1>.5[(?$85S;!#0WO MTA^(H3%7B7CQ'^\9CAQ"O&2SQ.%&9?);_KU&[,K8^??MW,=<[F[[M-#&CNWK M*0I>8B,["DYG""W.N)S/L!L&Z6]BR9^>]]?^]=_6O[8V7#&$^([]&*1?<=$+ M=N-O6^+&UGDB*1,\/F%-L(EZ1H!!6TL@9M M*$3B3TL4M!%Z7CG%7`LUTZZ0$QZN<_&6'0EGFUC#-L0K"OQL92N0V;Y@=Y@] M%JE:U]GX66O2S0<`:XMWPW7#8JZ^C(^"`+/-^"4(*;)#R3*>;VA=M"+XHCAA MO05]C^U4\GT@HK^**/I]I*"R'6J(_ M#6KKM^/1GAXA>PRGHI^8%ST$^HS2SU<35S$@'@.G^UQF/`! MRR>,F,SZ8EPQZBU)`0#.W+CS0N3-"'.,$FB,OYNE[48\`^B[[SOO9.O[%BA* MA]SJGQ^!QG21P)E;"9_*]NHJI0*E%@N@@3&[ M1[;M1\PSF*`5C]UIF'"%!%;?9#Q!(6O!>B@$`DDY_$1N'YY4LB"0F,KJFXP>-+`=*;#!F4R5C$"9 M2$Q&&1I0G!P:G"DW87UAMA0D*%7QUH+65M]DV$$A9F&8K@@%&/N!3WK?TU+( M;E-K8#*D4$D;11#@K&O;])@)(LZ==X46)$2RR(^`PAJ8C#94THP$"9P%[)EB M%$1TI35=]AM;`[/QA0IJ*08!)SJ4R7E]"M$,WW@AI@M*`GS-9&R3D/D'T9SG M`V+G.J+,H-FED&BP?N?6P&2(HI+&FP&=CI`+XR-D7PBEC$1K8#8+HH(&BT&D M&OEH7",JB[=&)-<:``E@-!`2%`)4K+YG^51:0\FU^5L37::M+L==IFV7:=ME MVG:9MH>5:I=IVT:$B^V!8QI/1R=VG;9WFC2#7J(.CB8S5QL.G"!,GN68OV`4 MA:\^);^V9I)2=;N$1G-XJZNL``:<<$P1JW=!$)564T)D-'>WKHHV$.#$9HK8 M'$][4E&9C;1MY:& M=E"D:OIL7$VY0ZB$5]USMZ3U\23V"IA/=?'%>,AWOV)4%]OM8KM=;+>+[7:Q M79A2[6*[S2SCC_@->Q'6J:.PV_1HXK4%C,.)S-X3.ZXZMF92FB:0:VDT]EHD MTF+A[W,-9^S[*^2&*[7D\PV-1E3U!;_'-)PQO^;IEJ'[3I$GO6FZU]9HG+2$ M^`OXAG/(<.>]X2"^%9&X/G<\'X[]1J(($8G1"*B^/B3LPSE<^,XP![QL(@[& MWA-RV3]3Y5UL,9'1D*>^:J0`X)PEQ*5('GS/3PJX>K.TR+-0,P(*L_%.?;U( MV(=S3I#"T3!-19K3$% MI=EJ!!5TIH$'CMNR?J,@"+<8Q^G6J+("!&1F:Q-44)@*#)Q%<1=AA@:HX7@P_81D[ M6XX?<#B>/J.EM@KEW9@M6U!=F6I4CN\O^&I3YE%QC8AQAWQ$%W%\N#E5)([L]Q@FTZQS1\: M>D7>#-]YZR)3;'&;4.+99"'-$6C^8Z;+.%191YK$#B=N\(#?LSSZ'OO13O)N MJ`1$'N>8SQ)EO*WI3YFN.*$_B-I`#B>C<<,6GR52_6?:F:Y+449Y.VS#25*\ M0=1C`V;SC-,W%!";!UB(&X727%\%I>D:$OK:T0"B2&0\H+Y^8C)[95R-WIAQ M,<,/$9?#^LG%;"JL1O"V;%>F:TKH:[0*LFT4ZFAT'`_4!A0<]V.V!D4EC=53 M_@8UF*BQ@//U.E0FU;]D3];`9#BL?=W+<"NBSP?,42_W-'"7OZ[+<9>_WN6O M=_GK7?[Z8:7:Y:\WO(PG6R+?"GTO+O94_R:]U)6Z/7%X03 MH5@C17BBLOJB52J(Z.7(N&KN>!J/0EUC?)>FI9L2[5KB M12#@S+XL=THS;[]Q6WN0EY-DX6U@FFQ'?&GGC341.9O=4B&.-YH>N!.*S0G]_]\D+? M$!F^I5)+Z#D031C+9:3.*"H,]@R9X;LF]22?A]'$[EQ"]K=^1,N+?DME^-)( M+D$!=K@CRXS".'W]$3,X`0GQ$Z9OQ,;)/'_$MC]+-*)Z4JSM3Q_/E9)# M2`+0DLNG1+(H97>(9+%ZP._QG^1A`YT.CN<:B3X>.'>)!#S'PZV&#O/TQW.9 M0QL.G(L^TE$7_W$"WM6-Y,VF-;=0<&:C)\]VIGEQG?9<9#/#OO,N.[S/@N,_X8$G&.,".^ M``.<@X^Z.1]0\N"+A%RLET(08&9+;7V`3\$II9CC3,`Q6K6O<'@7>+TJ"$>5 M?6/R^+66Q+,0CB_UQN2!9CVQYT`<6]Z-R8/$6F+/80!V`IR$TY7)_GMMS5;1 MUU&'E/4FCG!%H6>F54WA\Q#$?D3&1:(L^V,YNMK2GR78;A!,H.EB5X-,G)>X=`?,.WH"@6O MMZ[_'MQY#J'8#KMLHBZ;J,LF`A*=ZK*)NFRB+INHM5QGOOE-J/]&V.[Y;?4[ M6ZWNO,W;?R,[)&],LEKOPI;OK)W\HW:2ILM#@Q-MJ9;2;C+`54W@0N7E4(&9 M?$@\QA-Y,&524D!G-KSJ$\@3#1BX2,$;(G??&I./3U4]*0GSMO\M2 MI/<;F\W7,J?>8DG`,0SNY@M$:!+?O/-"Y,W(BXN3+?!F:;L1?PKIN^\[[V0; M/2O2>)E^S*:8&1P,984$QP*);]>FXE*]Q+K?V&QU3',:+Y8$G'T\9__>+#F\ MB`2OR1"]QB\RRU!):[8ZISFE:PD&3A&G:[R@V":Q!3+RG*Q!(HL9B*G,IIF9 MT[M")'`RD].7;/-5Y&2GUW+:]IC&;'@=I M]\X(!,X#Z6E62GK?TW/2S+);GZY+0@9C>N4B(LT8*-6/V2P\@S9\62'!>->*!^)V:3_4RZ_&4D!*>@U3[?3%28O/%T"^FR(:,S MFPI84A6Z^MS!!RA&M\MI&GXB)368H3.;0=B2!G?P`8K'[;$ZH7B!"'\)"E.* MG;4%DA8\4Q[B5>O0;%W6EI2N"QQ.U&T?P\BV>0IZ,$$KOOYP-].V:82=>X)> MB!MO4:5&@TZ'9LNWMC0:=('#"=;IGU8VDGUEMOAKPYD])3##B+]9T`;34+.[$&`)/Q&M*U%#0<2WZ/ M[]T3WS**WJ6U!@`S\!K2;Q%60$LU]6V,G>"6284G#(ZGE6:R?B_6`&"&7$55 MET,-Q_+F(EB/3HI.8W$763=&8-CSSJ MIL`&QZK/+D;;M(Y,*1+-C;V0UAH"C+:I5*/>Q858X43:LDYFR8<-E;36$&!< MK;Y6A5@!A=,R[#)7(J3D)6+6XOH$4%.G^X36$&`@K;Y"BX'"C*)MEY0)71_- MIZEUR2\P^V.U]5C5H34$&%MK%5\'.,Y_!]^F/:&7#Y&D]K#NTEP MJK,KS6ZL"^BOA%=%!6<#+>9\Q,8HI2LV'.-GLTOKNCB6T),V',#58[N' MJ:MQW)62[4K)=J5DNU*RAY5J5TI64*=^DT6?5+Q8OW41QR.BSP&K]AUX_S`"=D@5DW^-#VT9J3.V_J MTSE:`U4:2A(J$Q:3_8J=:)UFN<.7THA2T1JPJ^32%1E8&D`ZF^L`-I>.'CHS MK#/#.C/L@/O;."U9HGBGMJAY.T93VXN*`A&HA`?.8##RG+2LC'">*&E:*M*O M_=*M2-I2W13"@#:#FM(/D+=Q&U/4`3Q/]E7J+Y$K?^,\W\KH(P72<5W@\.VQ MWIXL&6O8=?%2+LM\*Z.O`)25Y1[K+;Z/FO*VF47!$R\ZY2"ZNF+N]\RGZ[*0 M@EVW?"?M5-%O>R^NA+.))#9MO3V@.1:P(USLJW;54@%\Y1Y=30M:FM3!W.J: M9E2=AK=TLWH]P/Z_X>!?JX4_8WTZ)!`_SZXB,?-"09V)4Z`J!;[V=/%[B"GQ M\"UYH3YQ`KD6"AN;>12@8?D+D;5H;=QX#",.*?$#HA!\05,SE?D;%KL`5_NF M`C^[B50F7-+(;#7\4K'S8N;;-Y@?>(Q]N<1_LGOP5$8>'1#>/J&?P=Z=WW>E==WK7G=YU MIW?=Z5UW>M=@+NR5BX(@?8I`?H0GI#GN5GFE*=$^XU-']])A5RL MET(08"90;7T`.:YK2#$'"-:E=Y+768MQMN+SNR^/5TB)C![E%0_O`M=.!0', ME&@B(Z25`T&C&2'`BB8TF''03N6#>ADAOY5/-/@,;@8UI1\@6TQCBCK`)I,L MKV,/*](8\LV,OCPN'=E%H<(]WML6IW*7WMW4C#[U74V>.>;AN`V;>QJKI%RR MEI\GHFGI@.U@CIX,%YP:-AGF^&G6>/I,D1<@6YICH$_FB[A1(5\"AF0)FQ% M@<0?(HZ$+='1RW\P\?I=#%ZF;T9XT:F0%+X94H;<[-/;Y;51`E83!9MZ\L^`P-.A4%1[=*\P2*/HFET8/8MZDJ[ASXP.#4' M,]4;GD(TPS>\!,6"$EY:;4IL$HYL.YI'+B]$D1@SNQ023=?OW.Q[UI5&03.@ MH=_#1:+)A5O4[YA9#F>\M1XWORQBNSYA^-O-?(]]4A-YKX*V%0/P-8 MU8F!5&!-P8MB(66@=;Z<)#TS!XG4@AU_:]@(HR(Q M\LY"[85>#JC%LCCK#S_B`#.L_&@PR3F M^Z#$5,FU,^U3H*YJ'9ISN6OIM3)8.+5T=O'K:UI!:6E.H>YW`6]Q$S%!SN M,Y,W_I)51.,SN22'%3N\C,.5/U]$X?HP;'>K4U9':J1_=M6(436%O,V.G M'HL[@;6;);.82(`GE-A"G[[%3QHIC%LS,M"N.,`\Q,5`S$DX7]_/O_(9:H\U MM1G6=F)BD@\J@V(ZM$U$Q23?D8;%5'2'CHMIRJMH^&M`Z2)C+?NO.CKH0F-= M:*P+C1TT-/9D8P]1XNN&Q;+M38?$RB\I*CAP7*:4L=^]8(%M,B7845?9%M&` MB8[MBEN@'0D..#.H605!"Y?5UM0!(F;/KX0Z$T3#E3RRL]O.:*Q,.K@+;-<" MYN',@72T?,?^C*+%*[&1J[N3[-(8?">KJ=VD`!*L$0TIA_* MDHIXT:^F-*YV0=8V@70&(PTEV M@N-D74T!KUNW]0S50>6"=C_+'#]AZM'[]`"_1G'A:CT*HZ,T\3=2P M2J3HX%P;YBG(6YBK:S1',QP\^='L-505+U?2FGF>J(8B2R%37"`N.$$[XQ][ M00%F__D_4$L#!!0````(`$=B;D&Q]$,7@#8``!AD`P`5`!P`"TR,#$R M,#DS,%]L86(N>&UL550)``-6TJ-05M*C4'5X"P`!!"4.```$.0$``.U]:W/< M1I;E]XV8_Y"K[=BV(TB)%&5;U';W#$52'L;0*JXHVS/AV'"`0%81;110!E`4 MV;]^\@%4X96)3#SN3;KWPTS+4M[$/5GWG+SY_LN_/JXC\D#3+$SBO[XX?GGT M@M#83X(P7OWUQ8^?/QR^??&O?_N7__&7_WEX^)_O/UV3B\3?KFF'K_\EMP]D0LO]SZGGO];1M@__)#$@?=T M0#XF#W1]1U-R_/J`O#XZ?DV.CM^=G+P[.2)G/Y##0[.O_A32+[3^U6]>ONW_ MSIMWKU]#?.?MNV].`+[SYMMWQV\`OO/-T;N3XVF^\S,-8IHU/O6F_-3;=V^. MWKU^0V[F_]0I:[IW;]["?.HU:\-O]Y^*POBW.R^CA-$PSO[ZXC[/-^]>O?KR MYIFDJU>OCXY.7I4%7\B2[QZSL%;ZRTE9]OC5?_YP?>O?T[5W&,99 M[L7^WHI7TV5W?'IZ^DK\*RN:A>\R87^=^%XNA*'7+Z(LP?_KL"QVR/_J\/CU MX,';($TB^HDNB?C\N_QI0__Z(@O7FXB[+?[N/J7+;A^B-'W%[5_% M=.7E-.#UOSUDGY#U_Z_BKU\07NC'3U>[6D0-V^S5-CM<>=Y&5A)Y=S0JJWKQ MZF]D!N]..?KC;ZO>7?//MEUL-N5IK2YIQ'R$\/"&IF$27,;#7&U8@_I\FWMI M/L+KBCV0WY^3W(L&>5RQ!/+U(QW6MCL[J#9E0DV'M>G> MC_`_7[/OUSRCCSF-`RY_\F^YI4;+I0;R/D!T38E?JRSBG4&2UG&FF_3QD/=M M1Z9S2K-DF_K4J@'D[U!WRKL;X!3O=%D-/).F\>&/MR_^MLLH*O9$5D`J M-9!?RCK^WU^D/]/!RRM4F!?CX3Z!@H?)AC1WR3\#T*!TGG_(9:1G:5U/O-0O MW65_[(%:E'CE)RR;W>2'-9(NTV0]5#A*EY*AK?7*6"NKF6=&_9>KY.%50,-7 M7#[Y'X2.'AX=E[DK^ZN=*Y]9M1U"V2H"H(,=;BGCA?\[K(*A>]!\C^&3!AG(=0 M7.@,P"H9NJ)O[AYA-ZB^8,.4GJZA7A:XCV@ZJI0[69`E%0&?,4;L-YSQV*(O MFB_Z)>^H']3=;#LF9I8)ZUG57&@"Q*>%DB M"N-QS2FO+?@VI=_0G%.$=1?KNF,:AG>2\>;,JY9'X5[=X;YX*(38"?XYY+DU M!Z?S'8>''6&N9F([QN?BXN?4XYL`;I_6=TGKARB`U,L`<:[I6/,7+_Z=R`+P MS$+VSX`_XSR$8DEG`%:9T15]<[%!SO]]HJN03_O%^4=OK1IT=18%XH;"S>8/ M7,S;[LL17A">*FZY:\"<21V&(I(N=JM\T@3NO+0Z9]U;ZD57<4`?_X,^:7G5 M+`M*K+:CBE^^*$A$2<**8G'+(8^-Z36=S[`,4X1QFV+=,3P7Q\ZW:5H;R>GG M#)7%@9BF<;<9!D71V@`;;_;05<<->#>3ZU#TZXOP*@-[PGO>CNY#&-'TG'UM ME:3Z;JY>$K23:SJI$%]1C)3EL/HW-YPU[MHF<1>V5^N,V7:?UA6P,V>-R7J= MQ+=YXO]V>^^QGVVQS?EN9SXFU*>0.D/8?%(/097V""LBS`Z(-"052[1<\WF@ M,<]#0?``YZ@&I.E(6/L98\OUI9?="1SE!GQ!>!KENRWY3>87?_WK;15%,00@-)%=>C\(HI@,QK/3UN*#O84A7.U M$%6RJQJ?"#RZ#F-ZQ?[8M22O*8S!IZJKF@C@Q8@HATTL!QRV9=AXEU&HUHIB M)=V:(0Q'N;,LHWEFD-$V"@)2K>5B:_^N*(">C/;[>7M[^?D6BTT#W8-D3G

(V)TRP/SI^VPPH:E7/O;M"IW^W27UD>EUUCO84GFR*.NSG7 M'<1PU#OWLONS..#_<_G[-GSP(N9-=I:?>VGZ%,:KG[QHJQM^F=D#4M,44"N* MF($X&RG^4#$E9SDIC8FPQB'O:&`^_P/=FV+QVGT@F]8-%'!@B)>3.[H*XYC' M6[(DTIF9,.YO!H%%2-G?*[%!2K:5_C4EW$;\X"3])J4;+PPN'S/U)]]ZHQ`^U7M>ZW55H6)Z*\O$.FM"#, M!*LCM0+Q(7RD01'=!R2>P6OCGG):OV&[POZX;_>!O4$/1]PK?B_0*KR+J!00 MYL/EHQ]M^9Z8[Y,D^!)&7[,R)6:&9&=)2E,<8@\$=>YM M0M:1A?]@=-EX.2V4JOSC9A.%\EY4XB<97J(\$)T M9!@^"U:FO[AIKS*+Q,]S+5V#3VSU&2UXZ%^'WET8A7E(,]8YB]VB]TD4,*'F M'77^9+`B9UP%('TL8#7#I6(J>I"J,9'6Z(MY8^!=G;V_NK[Z?'5Y2\X^7I#; MSXOS__CWQ?7%Y:?;/Y/+__OCU>?_PE(78%B0Y+?E65,>+$F&(B#FB_@:(QR1 MZ%]IKLJ"*VOZ5@!*IRM&#O!\$K^1B&RXV-\;[(")KN\GVSC/;KPGOB/58!:X MVP`R$5:YW$J,BX*D*(F[SF/O]D:61,OLIW(8-*76QG,KQ=8%,R@)TRT-VK*@ MYZ'"!I:*2L<[HH27)1W=)AHAK9TOUR41.>F.SV:#<`N/Q;@<63WT1.P0$"T+ M,;-NJVP;-\LVRZ[=24Y[%TVC&5-J(]I-ZS-N.FV>1B,;&A)C59(J+ M4UZ#`?RY0(!W[&IBQV$/7]E.5#DT-77#ZJ),*>1T6=]N]J[2L)L=.YSMV#$G M2\EI:GET=,P&DBEYX/8'Y)N#HZ,C_G\D MDY=P>-O\/DGYJNX!B9.8DC#+>)HK=@KB73CR+!H!>)>DBFL=NR(51`,\^K*_ M'*7WE$NS*.2!EK:;K>G1RM4UJ$=4[%SM"/OOM'%__-W!Z]=O#[X[^DZ$_?'K M@S??'1U\>_JF+"PY<4#8GS?4S\,'&CW)HM\='!]_>W#RS<[RY)NW!R=O=I85 M"M7-T4[)S-V6;PY.W[`6.3FU;LLW!V]/3@Y.WYZ.;4O0@QX*MK?.='13'7!J M,`C$U2M>=..%P55<;&K230PJ+""G!95.M^:H=B4)+TJN8E(41IH3'.(YW]%_ M&,;$G\EST[G!&7P'G7S3AWIKZDT;YW`,_9Q2+]NF3T:I0T=A0%YVNMI^-D`6 MFC6!,`QI(X?/DTQR"SP6?5'9W4T'H>L!=Q0(D.141WF3E\H0AZ/D M!67Y12+VE-_FWHI>QDS\-VF8T0NZ#/TP/_/][7H;\=_O8INRS*1IH:'P!)4# M4GZ2IFB]QK,O0D09LJ^6%/622L5$UDQ:=CB=_$QM(F%[%=B!A!U48&>SP#:4 M4VC@^3V=$[R=$#L)'E+"IU/%IN1/)HF8"S=6"S:X"S5F"S3N+&\HEQZSVN(& MG<=MH_52UYRVN'3$R/7WNTM$WGOL'_SI^R#C*T2,_+T4$T8J9W$7O,P7NIP[ MO&&V)Z3;U*'#&CW[112'-!S8/V**1BI-U,#DCER"0G+I5(;!7A0=>["6NF^\ M=)&*VU`#,22_H:EX`L!X]5M9`=J"N`92WQHY,R6+E$AC.P+/C!LJ.TP'#(K;+` MY+!R@-?%7\R1]3#/#^J'&9SA[!3.HW)5/[#61SHB1\V&U-COS!NZ;T)9])'T M"`P''>>)G&'PM#!0N6PPD';J'?G:=G/ICH;,7:6Q#F#LG.TY@7$[\?D%&\): M.IQ50]R)0R,C?48[8E&/9.T9BUH80]Z<[R=KNGMAU^#>$Y4%Z/WX*J?;5^+S MDJ3R^C'R=2=NNFY\R?T,SL/><*^-]O:E]KI0AR/I)_I`XRTU>7^Z5120EAUN M-N.B+(+.0PM?L=@VPD5(3JF"LTDF161"[JKVQ0V*A2,:$C5+@NZ9;CK9WB(M M2Y"B"-85U69^\NW_2XIY)?4X/V%W+7<&:'N3[C/07MD3H#M-4?=44G>$[W@7G_?>K% MVF>*VF7AL[J:HXH\A/!"1)9"3>MZG,THBRCYD'7U;.]J'L?MTKTI74=(`]OQ MK,@#6\$,.>?Q0+.ORGT@H2N)-=4SE,>S\ACZRVQ,+2L/&:+ M15A'0=C=;C(K"$@AZN=S4XIZR0PG1N)1UH])S!\X]O(P7DEQU"B1R@)0AM1. M=[\Y6RU:)`DXZF/K^$R^&LK,--Y"4K$GFIL\U(+B_"<*7R(_.C:!J[!;VO3AW-[.IHUER(Y+SM$Q7RKWXQ5N M:7LSG1UH%Z<'H)V4K%X.6IA@S02/0%&96L7KS>?Q'[:O-*!"NP/MYP'@Q!2- M61X<,6?.@G48AUQ4^,,'_7SNLX2A\2KV:#-5,V( M`72.QXP:K8D>(UX`S_;P[&&?/"S*L6_?E(_*#'K>1^U^]ZR$N*F^DDB3G0GB M')`YB-V*2_$HKB3&.DGS\!\>?TV"3X6&<Q(S66\;L M@N))K*.8@3'X^9(>*(HC#]Q*[H/:VY&](>[1#4M(`@L/2>+OL23S83%B+P02 M^#,I)KSI/IYB0!HL$;@(LZ*Y:;!WZB/-%\O/WJ.Q'/14@R8,O?!Z):):0T4D M"*N#;PIAM6">4AN,<\^VH`IP1N48I(+SX\+3$3/JZ17%B'>`[X%UN<.WC7!_ M%_%%L0UFL>PL:*`Z$WT`\EVPJ9JD]2)2IS`1L>5(L&`1D[)VKE2*\M@Z-EO[ M=.V]ZM8$M%?"\*&C;:-S$3OH&V&3*F7KG;`I91(C-7U/ETE*+Q_SU$O2((R] M].DJIVL^>CZ7#YSQZ>CEDOK,U?-[%@#T*C[S_63+P:QNTC#VPTVD6_R9X6,H M:>Z$3:5+AN5G2.T[1'Q(S&OM/T7DMWBG(K_&WYK>?X_L/HB?8<[8=+Q;C7B[ MW/]^2?`A3T&9JIS;HO=2&N?(1?"*V7Z[:N M+^3H`7-G.D"KG3N@W(8]V_-H#4BEGDM\FCH]D_)`JG2^[VNT$ELM!ZJ/=0>[ M4HI*OHHE1_U.1G-X9RP02/X9I9XFWDW[V]K-60QM/5C!Z^!Q6ZW:)(:3FDLO MY>\C9^5[`.^]+/3Y5M(PVN;:J[S[+`'EJ!]$:\=^8;%_:H,(([DG6YKAJ)8] MEKWC@2PC1W,;ABR;Y1$10WVS1W)=\YL8=#;D2I/@9D2!H_S/-%S= MLP^?L=_16]&/V_4=31?+UJ7&!@>BK*L"%(4!,)OQ6%9!BCJ(K(2/NMIWBZ.? MK9H2L%<`+J[MWF;L[]B(HBXLQ/AR4JA+@.)T2M;@M42J@\[@^L=)8.>^B8-1X-%0MJB1"EXHBU;)Y M`,6V)GRYT("T$(RB%F<>3QD/=J[AW#C9&`_``>GHXY6A>/20"DX^=E?7,T'C MCTS<)U'`@O3R]VV8/QF,A\SL`:7"%%`SY/8/$?`:]+?. M:E\I_4460[N0;2)WD9[OK`>#YLW.6B3`Q>U9$(1\I<"+;KPPN(K/O4V8>U%O M#.OM`..Y#T`S6/;E"3?@&Q@+$^1('PGD,.P'`LD!H\!J\L$DJI`>L>UE1%=I MK$=LE4'3>,06-^(G=1DRMC6!H7T3%DOC_>+(!`TNZ#+TP_QBFX;QJG(='QO= MK&B_Z-M5!-D+V$)LJ>F^`E+40&05M2LP1278'<58K"6^&F:)-;^G%GA!^Y-! M0=SJ8(9$,,(TW7GD95DQ@V@Z1=>RP9B>ZW!:G[(9O:!HF MP2)6IZ(&1@#,,G*]=4"^*%_F6M*",!.DA')*%,=9/A^*(&%9&Q-]L:<5$0@$ M+IGLC3)I673>,"V;B&DT'H'@=!P[2=&(@J#1ML:*7 MIDU*3$U39C&@/ZV:H5*UYKXI6;G1?('>DQ%.B^4D=372VX'5'^NMJ)HXVC^P M'],^V"M6F+%><]XP/+B->Y$^!,F;_-[-0&_'5&^* M0K,([E4:5(!/)785PQ@66NRLDTQR(T=?]_*I^"SSXEB75TX>.=E M-.#;IVBVRBZU\G8C/8VUU`6]4.=\JVRK9B`;P M*_5B]33NMP3LGB$8S6IO.P(1+,AU9/8;RXZGFI7*#NDC_2+^2;^H;%0!Z`JS M(:3N>)>6C1%'D6SRJPZE.=;:\T!HNX$4OU9/;H+-!-HY\SKC=>F)01UTWQ8$ MNUQM0ZOVVK4%I]"U0@C7"*EHV.,K10N0A5`(6U=UHA>8BE&.2<-D.!R0A&[V M&"I")W70!4'JE/C'A4@;L\M'FOIAII]FLJ\,7RKT4.T3#%FBJ(KLZG)*1>PP ME__&J2A3CJ1`ER=DP_R^9YER/2=9)BGQO>R>?/6GXYKLQX#98%JT1(IPGH&BB4>2()U-2%KX!: MH-:)TW/0/RO$,\F?8YHW29,,D3P'9:Z?^3;)W5B14RR(]POKSUZ:>G&NU:W! M54$MG0^#.31M*^O"TJT)(5OSZ^.#HNU.^0A`RK._W.(T(^_KEFU.S'`5D M#\+T[7-R\.UWWSR#UC':=#=-\Q27\'&!EP0))7F"_=DQN>A+O(QXA)781N*N M)_XOM-*V7XJ/O43;YC%"*6M[/X;+Y/0RO^]9QJJ\KB9DD=>#')B9NBSQ=H!G M4C"7-/V/V2!C9-RN163@2X!_.`$WT$`3_>X70."I"#E6Z#V@WRX+/970<+1; MD&4AY&/TD[D+/CKM"H;.T6=')(Q).X1POB\8H=]DW5D6+'7H=K3UXS8Z`LSC M/0-=SI`/\PQT&Z_7T(1PO5]0QR^<\G_B[_SUW/ZP+P.H]%7'FK^U^#?D.Q&& M^@>IY*T?MZG@S5\6..YZC84RI-\>LB7P4PQD?P&-3G$>U?&2X.?_`> MP_5VW1N)]7*`L=ATL/E+%__N1.;8V9C-7[NK)0%_[S`V^[UKY2!_[X:#K=]; M_KL;OW=78[9^[XZ6A+[$NMS553X_>+;F#Q]K?GZM&?B5UDKW%3EY/F)ZLW(7NYPWE8NXJAE.57&H24ZUN]KK\8NY;%D895G/2<>- M9CO-/5<>S!($9B+-5Q4CFF7[5;7JGCF\9;4>$M3F2/4,0'D4[YPUZXW+=]R`"`N7'KRS@Y%`P;!_W6X>($A/V2FYH7G!3D4,.')_ MI#EWXB9-'L*`!N^??LQ8SQ\OV("-:76\.O/S\($E"M2$\@,J`Q2"05!;>_1H M+J.PK(:\?R*\(CY>V%5%]G6A"\2=`_,X?X!60YH.FE41-5-&<\HA8->R3M(\_(>8AU@L/X2QQU#$ MJ]XI\B>I9EE!_B\*,M MOTWV^R0)OH11ZQ>K@K:J!Y*RE@!;;-[9\QYW7P.159!=':2L!(GK(W&6;-IX M.;<20*[6<_ M1#$L3A@Y7+J:",?#B1T^E0['=,5?!05S&)*DZ@AN,E$9OG!T^]X+XXP/UFFV MB"\?^;A\&V;W4ATNZ)UN=K3?%I",)D":D2-LB#0BBYC4S7B'S0VQV#H$4G``,]6I&")"4-N!!D\S] M)`!^D.A]\^9\W!E/'>^4B0*M@Q![F7C]P;N[%N:8,ZY-T[;C+R)45Q=T;`:O^K)Y?* MNWOX'47>*J5R#V*,UV2(]C[QPK5MHMJL'P//*) MO<%P%,;S>WZK2-;8R2:7'[GJ1J%W%T9R)^57?/,;72ZIS_XQ6>YO:F1_OMMF M84S%7"FKZOCT[5MA?GQZ^N9KM$V$SZ]E8/<2V-*^OJ7'4`1F)5,7&'@X8X&%G2.=RW&S_-Y#XNSSNHT$_M-@\PV5QN;PHM MV5RU0V5S'8`1FRLF[K#9$`>CPVXOG3M61%<:,*4;EO"-E(%(JZ2%E9.8DJDDPYRRHK=$[(CB,-@"M=-KSOUS0+TF.*W5FQ M/>5&[D[AZ\&^GVY9$.U'DU9B9U0AJM@90C82N[(N4E0F]V?(ZDBE/EYODSH@"?`?"X"F=#]GZ%LV"ZBW>":%3-HA(G[P#IVA1A M>_>'^S=B*%#V'H:>7HN3W(ORWM[%F'B MT.UZ#RN;`9;=+!(P+$@AL>)64SMLB(4H%TS;6&J5/]VP'R=G8S=^6?R&%['1 M#'4EF,*A@V:B'J4]$16(AE M5:]:]%$*43*:Q^]ME*)EBRD0'4!,=*%U'X8S8F``J*!.Y4*M&W%7A%R=D7\F M9YM-%/JBA#L"80^.;WBK@"LNQ?`TX%!%0\6K7JU0D`I0(M+$IS3(/C"0MUY$ M%\M!:85%+9"R806N)2"%->'FA-L+SD&F%D93'Q.A%!,"&4?)R'=S\[^]]>;_ M7*+I(R`F4.6PIUM+0ZRY!J^%IXN[W+PB#T>C;0CJD5*7>P!Z_/)2KU%;?TB1K%HV^5 M.DFU4OS<8GPK')^>'I$-)^=ALLWYLXQA$KB08DSX`]=2CJPT>CH@XD&H/QV_ M/CAY\XTXE;A?`8[DC5#!5KS^9M1*6$G+0!W0)3'#1,`!&7R_.X;UD1;/Z%:*=Z^*O$80_G655F=8UHW$'A-"?)[6I[TP\VN<%$Z(5L& MO#76JW[2PD_W?DC2JK]BNW+'PK?!Y*]I30A3P>8@E1/#_-:'NDS)PPTN;?L8 M#[=ZY(B?*2[X>4\C>3E"$&:;A!$8>[88'B'&E+$E-U43R';$='&CW20;[-S< M6#?%ACKWMYDI4-8VN88[9(YNWIT1EYO[YL;OEW-%4W;/P$RQ>5=7&;[&Z*%: M:U"ZIBJS@_0`1$RX*FA&/63%&=2:'\55^71=,,9H&Y; MI.D>%1#]W$[U;KWBOD=AB#^+8XU'\"HL\21+?BWE[O[*`S&X8'^9+)GRD:9^F!G/'7?;8NVN40#IV5,C+FHL MS,C.#E\X3.&4_R;6>@28I``CMIJ0+\65C"YHQ-R8T+;1Z#BDW3RC(1".')PG M<9Z&=]NB3CM[W?)U%`4WXT M)L[X[`#>??M0>+"8KZ:+CO9*KF`/'G87&)<7^LJ_H.P?AXTH>BM$'V880#8? M>S0O@!:[XG?UN3F\T^^V&_8&R!J;)G-N=KJ=OT:6HA&;PJ/`<,I*7? M'L)H5GOU;,%)73XF.2WOCC),3FHF2.E'PVU]@B$*EW?#X6LU8X)C\ M1<[AV<$\2+!Z_RXJZ/KW#A[`<9AI22$LBZ4AAY4F@!S6N-V,GGU1WBW/RV'# MV+?P_B8-8S_<>!'9H6!9Q4P,MNN6YT4!R=X^$C39V\,`%[=#3+(-PLWM#U-L M>W!_,X!N*]*F1'GW1)8[=(YNLYH9FYN[',;O;L`YOQL'_'_X(>('+^*"=R-. M(#6OC]6HBU4UT"=\S>%U'S6-`RDSE1J(K(*T+IA&/4(['"@G8MA]9[)?MH'X M`]U7CJ,W#@`%/U!LR<_.$\9VY#01H'23/@I9.3H].1*BPO_FU]WMK]?BC..% M..)X(^8QMKG\Z#3'B^?\&H!$S=M8K:>2=T=/Y9>(_!2YD3.9V[Q4M&=R7!FV M]?K/^HXZVCMW)_'_&ZO:6$'B;_FPSNNZI,0M8HIF4!$SJ1`SM"`F1/<%T!.4 MO=S\W0!<-KY(5UY^JFYR%F*9^P/Q] MJ@9IL:Y2[T'YE@+?\<;SO^N094E!F#_->4S",*^':8!:S>4VBEW=XF1W63O9 M5Z]I'L@4>5+2-'/G*1GS3'3D(LQ\UB\SC?Q,'_/WD7Y]?_)//1=UZ6XF'<_Z M:+90T&S_)?(+_Q81'T,ZN07<9FIQ?I:*/&<#/!O-U0C,I/*K5A(.B5?(-S55+IFD/";6H*]EFH!I7Z&B"T3T-&,8*+#KT6V?M00``_M,I3%_ MVF]2FI('3@Y,7L4\EZ\@&W350VH#E(MA8)O!6;Z7>UF^%XW?3X,#@V3VB-CC'3K.LP?>+:K3Y_4OPU$KLL2=,@,4W3MSR8[(&J8#2!%!5-&XW@XPOGO'E1B(*.M"ES^$[)%/Z0J9)A9YX MP8MUDQY6;8,8[3I-+5!\=K: MQ#H@6!VCI$DG:EF1:Z34:;]YU*)WPO-B=5IV)D/EG,+T]O"#N`>G,7QG(OU] MR]R[?##<[Z\*4TK?TV!;/$D;;/W\*EXFZ5JL4'_F ML[E&E#6O!)+#-M!:\548%^]'B`A>(/@9D">R"/M`H$>\/DYMP0]G' MT":CP`"!"H0URUJ*84LQ#`EI+_L,D)#>2E`DQ`":3D*ZEF[=DY`!(%U9J)T5 M!(Y4F+))+16&5,*0BN9D_'LO"WTV:+\((W[-[P#=L*L1141L0>L4I6/M2U0G MYG6*"AV4F+%-<.Y%_C;:G6IS8P$-"1Z.+`UBKEJCAM!VQ.46^WG`(H^JI(IE MIJB9E[.O`^HB"DM@S<"KS-[KDFBT=\34K-&`R:)?A"%Z[C4`4`(+:*HYHND@.35+-'AR"./. M<>['(KVEZ4/HT[/'4/MX?5=QV+O&N]Q532\N6$(N"[*.A15%8K:=UW+%ORB: MS>6X^;7B4[L.?(^X,KP[[A!7Q38X'_FVB+(9+Y*U%[8RLS;(#AMX9G8Z;A@M MLCPN1UWTWXZJ,R!`8*R:``K:*J-_Q!P$JS)-'KWH![J^HVD'`[M*0S2Q&S6\I<#;STZ=S+Z2I) MBPN4%*.H`94`LL@*FC*AV`^Y,K*K@M3K0!F,30LS081I,C/]AP!J*EGH2"%% MSUZ!FIIH+3^32N9';TT5GU2.=`=7A2>?)C"-1)17I(E'E$'S')@3?,S#A/6Y MHQZHLLBP$2776,%ZA-=4OD;([Z[Z?W_:)*LD]H(P6^N'<3H3*#G5N]U:,=K% M3K4XYG#/;?^-"#\K!##R&L1_C:3]P3^"C#^RP`EC^B&\2Y,PR/0T["X,14"5 MJ\W?O2A'RH*8I'//9R.B3>XV&+FT\5RCE2Z81Q#J,@Z2-;K3MRJJ4P>>24NT84FM)C,/9H@K?&'77D@J]*5W:K7#,Z7^5T;;!9I-,* M?F5:X;QJZTAMRQ$W(,("=W7:50QV*]0SH4!8I=810K%.K6'#^&DV_B+#MF_E MH2@$/#6V/-82@=G1)W[:WNMP$FJLIQU>_+RY/2@.PL\(AL"D#A^%?9UYA< M=]![&SF8*7J@Y4++WB[UT%%WDE-PU?>9]N]4G<7![I6JLX#]?_:77E3),S-M!AK8DT3WL>(K22W>&]?]YV MLCS\]VP;"N'PX$2"K3A9.(U:CTESQ5//BYCV;`IM%`-+9EONM3(0^=CW@A\Z M1=P8VNLG=_")>BGVSE#3!CW&GUI5Q&8];^L,S-&$^/PE,2'$OA@L(:KN*7X_ M5@2?$#H_;\-'LD[B_!Y[V<&X25^[0HE6='90HAF:L)>0LJ[+2Y]N/7Y&]C9/ M_-]Z#J2J;8`O(54YWG4?IBQ[0'AI?A1=E$<^Z#D*0Z+'`'W%IS:(NJ[XU$40 M8/SOO\^WABV6GU,OSEBVIML::V$,R0@3**VPJM+A0.X+9/]9,44_8SD<5U+' ME9CA`F6.Y`KUN&#E].;R//%$^7*I*S'`'2=6N%R>^Y4%"2[DJCI MA5F+MU=#-:WZ2)3VF@7A15&H!EYAJ76S^]*$O* MPH25)F5QC&3=PO6K+-MZ+)*X]&4B68B9\^P_DA*,GV3P=YH_&QQF0Q+[6"K= M/A`X-HI@@ANH]!&X/F3I8>\()?FXY8K$NK7MW=^IGV>?Z._;,*7!AR3]1%UTB@L16)6V)+2F#!K4C5'T*#1P#B/2V!I"6S)@*5S M`C.1I6<*S4BIIL#6CL=E3SR"R9BE>M1$S4XZ)I2XJ_@VWP9/II)6%L>2L+V[ M!I)U%1-1V@&%ZO6[2MLP)LF&QD0ZFWE+FC^QO&,.)$,DR54L@S3(!,QM!4QG M0*%)3(.]6DFI4Q=T([E(SSXP*&4BS2]#K`\&M<-THPI@MY>;0>K8`B4,";?"FJP#GL,1'&306C5V"D MR*^_($"#U),!U&N*BCWOIGED@4F6?(U5_NELLXE"O]A5-&YCZ?"J$9YD&-$, MNI<:9+4B7N6?2;5FQ[>1SM0HA[W-XO[.T7^JIK%]*>(9M0W&XQ)C%5?UYL1( MN<5XBN)#&(A;SKRS*:9^9O4O16@O(XA0$TW2L5TIP(>[*O M@,@:7'FP8@S(I`1Y"`W2^A$+%)@X#UN8,E+]PH4A'>'D1N/0M<%M!D;F@!)C M"*<9D'V"B`8H2E%X$QMW7V M/0BM$JA^0[";.PT@V+Z_CC+(&8\F@45C(E#/"8_9+:5P@.#N+#55@?K-I882 M,),\Z490%L8NR)0N%^^5*K3ATS2P5)1`'#T]7V"C%6PN9$Y(F7)0:"T78UYX MDY7+F?(BH5/OC>@U`7O[3>MVQ[*Y"(]BK:0HC[/'88#[A=MXIT,<:48;A_BP.*F^Z6^F&417`.F((2Q4YI;E8 MD*U4X([2#`18`Q94@*%KT?,`9*-6,\>@,WIF(R%=^F:A'Q/D18Q@21S3R"XU M4EA!9T=*YY5=8&GACG*9@]@[G]+(X[=IHJN4>\Y;Y4_SQ0]X$J7G<6<>I24Q MW*K](K^GZ9`-[#V&@"OUO1!:5[YQ`_?VI0_#@;7:/HVWD"OH9J'>7#LWBO-) M5LW/O5UDF5,(V[OO92:KY_W5P&_DFX"2[/&63'GL\*\`MX1$%&% M*POL(S$>UE`FD"CMUMV?+T[+Y7@TH`BK],:ZHUBO-Q6=,2^1>6DBJI+CD(:)U".@AJI5/.@W!1)@/FZC=O]7@CX3<@(,VW6:J:8<;.5LC&;TFD:TNQG+TT]S2WO MRJ)@&\X[W6QMZA6E2%$,\QD>*W_/2H^[7N2!WW2LCHCZ%F-E.`#>U1;G8<"S MDO"!WE)_FXJUN\M'/]H&-.`7RYTGZ\TV+R:OFR.QLS6_*THSJIFF?LC[W29J MD%927*F7["LF9@]=5/*3NL&NPDU9\P6QG%N-(:6EX\T M]<.,WJ2AKUS.F_.38)LG9VVVN62Y-:55?IB(+V/LWP1MQS+_.F`B5`#?\*)X MBOS/T0AF^TG=HM2R2:FDBU('MIR"V],ZO[#7-\3.KNK3[,YCJ4B8KXN[_\X3 MYG6\HK'/?!TY,3FX9H2]?,,;0;?%;U^K6`FIU>OX+.8\+7+8TR;NSW'^\[2+ M[<["Y](P&#L11VJL:H/B.($=T7UHOJS=N-AK!R7]!@":4:D/1+RMB\\&BHG0 M/ALP1NH(A09,TDQY7Q,L0](#7B#-?C7QQLJM3V,O#9.^Q^([RT->"ZUPN+6N M4I8C9<&Y7H+C_^8YQMJ!\N M0QKT/U*OM`&]FUWMN#)$*H7G>X3>\-9U>_X6#SEQ9%B"B#N?'!%4^-\M*)G`5+.U5Q M6DLS%4&*D%9^3Y-5ZFWN0]^+3%/+E@U&>MGAN#K%K!9V(\TT7 MMR_Q%FHZX["^Z-(5A"-"_T.2TG`5ZR._7@@J\)NNM=X5DO^.&?;H+AH%O:&7 M:&'?&8.UJ.\*P'E6#:_[[ADPLG5@]?!:<]:[9VWG&O6F@>>':>1ZHJ.HQBXL MS@/+A17&ED:8KC(V!6*$A)5'A8O7V=[N4R* MLOB<[G6:4T:6*:A#O,J#XR[0W34(0Y3`!$-/[&`)0X.C.GVH$W0ZF?A$?]^R M43\-V#CH$Z6/WCJ,.UM?`4%MCR0E.D#]XK*S)LRN5$IV^]>D(W.H9OZ!C/[1ZNO#6 MWHIFM\EV=9__Y$7;KHW?YK:`JVDF0)J1)ZYFJ1B1PHI(,R+L<%;7AL"YH$MO M&^7D[]M`KA9ZX@0U\59>&&0@#O$OZ M7<$+N7)GS+WF"IXI\6QE)*/^RU7R\"J@H500]H>F<+"_^O6:KKSHDGT_?U+L MANDJ!2`&W"TR,#$R,#DS,%]P&UL550)``-6TJ-05M*C4'5X"P`!!"4.```$.0$``.U=6W/;.+)^/U7G/^AD M7]>Q)3O9Q+6S6XXO6==Q+%7LF>QY8M$D)&.'(C4@Z7@<7;N+>$]?[/1[0/WR+0M]]_>O@-GI"\P=$!L/17P>CH^%H M<#0\/3X^/3X:G'T;'!RH??4WC)Y1^:L?WG^2?^?D=#3:Q7<^G7XXWL%W3CZ> M#C_LX#L?CDZ/AV:^\P/Y(8HKGSI9?>K3ZAD,-G^ISZ?#D].3S[MYE,C MJL./;Y\*'CX_/[]_>2#!^XC,#D='1\>'JX+O M\I*G+S$NE7X^7I4='O[[V\V=]XCF[@$.X\0-O;=:K)FZ>L//GS\?9G^E16-\ M&F?U;R+/3;*)02K7@%N"_>]@5>R`_>I@.#HX'KY_B?UW3`"IK^\(POR/3Y^(C5_LN*H-6_;NA?A@E.7J_# M:43FF>SO!JS]7[]?ET#\&87N#(7OO6A^R/Y^J-3483MQ[Q(W0:SQ\?0*AY07 M[`:3*,:L[?/`C>.LDRD*K-C83D2>N(06>40)]MS`J/SEELV!N:9KW!R=!0DB M(>7V">E+O=F$.?'N'BGNQRCPZ01S^4=*N^%9Z(^I'LAY-%_0/Z$PIE_,1=`7 M7:]Y(%@M.U6+;YD#?.[&CU=!]!Q?ASXFR$OT<6PVL47Q6NI:M\@6.O2"*4X+N MT4OR)8B\WQ61[U"@K:GNFBUU,_P0H+,X1MO1ALHWM@;PS/.BE/X[<5]=)D'H MT]^0%/DWV'W``5UOT%9`-_WNUA1QZ9*0GNKB"2+9W&@.*K_EK8&A<_@<)[FB M0Y\.L80*0`^N6R)3\W-;@WV7/L3HCY3^>/G$_F\.(;_EO9FU[]DXBSLW=R_% MZMH$9TA;[;Z^^\G.$&Q9^RV!O6EL0B(_]9(+](2":,&^/<$+1"NK;ON5FC(F M;G'PC!>(9#^P.?,&TSVXSW;AOI^=\=R@P2&]]7?,\4)[0KX:Y#^=+18!]I9B M&(&H_P5CX)9#^/)E00])RJ.%7]^88.=NX*7!+U^-,6D=^2,6&+K9KI M$O(6S6F:O^,Q@T7[`UK0ZJR1`2&Y$"&:T1'E,UOD9V:+''[,P"]_?>,^(,[9 MMVC8_%QJ*Z]T^(_!+B2D70!'_F783-1*[9W*3!=0DK20NE!_1W+?1XD;-)*X M4'-'LMZB9KI=U]N53A&)43.=OM4T*&NR*:>V(M\T2&>I1>&8<$/%*`E(=XHH M])F=/_\M:\#`W41VFQ1YI4\%[/XF(K)9G_W&4?G(V4.<$)=9,?,&`X8Y^XRC MW89SE,_H2C(OM9-I/D;>^UGT=.@C?,A@L!\R/`='P^6UTE_HK];"W--F:P2N M%G&&N3Q%[LY(63:7>*N6Z(\;Q)7OO98E#A>9#?3`>\3!FO,IB>;-];:2*>(B M&43$1^27=[1L&E,AHT6^GFY9Y6=4!)^)<16X,X[.2V6V2_H7"GI\J6RSO$^T\"#M*)C!$3'%=WKNL'_(9=8,JP5-2<[IN:>N,S=[.YU_A`%'#I*99R/^TQ! M%HGW5+SBSN=])D6`:L7+)Y!A3/"@)9I32561D%7"AL&NJ8_UG5E?F$@C^M.OQ&BT025XG@4M5$/IL?LK\G6^1>*#RJT$9#W778!D&&T9E M-9R,0KM\\8*4F=:^1I'_C(.Z:T2=ZE`F2%VZ5;$8&]4=.`))YV%G"&M^T=LO M,VGY3A'[,^D6XGWHO),9OLO1U_+#CVH3SA#&"-3D4*N#R8;)N8!7_=3+K^0, M80U/6O1)>T`-.`N.1Y400(7M57@LZ&0=QH MLRU2)JP%RP#I8G#FACJH33H7-(,JNW^H*>V,8"U:$HJXIN M$^3&*7E5&J:;A9T1M-VJ`:7U,-I;+.OS)^R6ST(JG+O$G:'+D':N!<$QND!3 M[.&$GO_2.4L3@OR+E-"-8[6&@/_VC3LC:*^K!OW%#&Q^+-H^]:]-!6IMR)T1 MM/-6`_[K8?"#W/;G="T[E[2XV7!&G3&.&3!SA$'SK1 MAT[TH1/;47`?.K';^>>F#YW82[^ALM60KM!CDJ'UL^/L6PI)1?,IKX$]"K50 M!F2!9;6,-0_&/4N3QXC@/]_V?U+6JQ6!@S*:LUT#Q`;#:QW(ZSA.M2G.*P$' M8[2E=PW"!K-K'4!QH@'%FL!Q%VU)+B,Q=[CNQ"U8@V5:H39P<(8.XVIHVAM* M.\6ZQO(LJ`4=K=&0YCH8Y@RG'>)7NBYS:D"'9;3B]0T"/\O8'G.JMB"+T^)T MQ/;3A-T*#G[FLOVAN'3SFZ-4O>[.2^]3G`9'?'ZFLY8\[OC&8O.QRIT'[3$! MUA(IW$9P:O07$(J]GZ^__LZAOW/H[QSZ.X?^SF%[!'Y'3RA,D4K"IFK1/;I' MJ!'=@AN#&^QE[Y8MT0G]>DHE@>\$ZMBHYVU3;@MH^QZ]N@%+ZBUCK5P0V-*O M3MJ&V#9:96J[C<(H?S(WG.5=6,`LIP:T)5Z=5@$`&^Y65HI0.%]`V]>UE\M2 M;J3VER60A!9X5#(J[)/-G41!COVKC&BVF-I4`LQ3$NTP@$IJ`>= M\4A(&F^X2O!8<+C\BD*Z?@04XID_QV'V;!2[1Y&S+:D)G?:H`=\*B&P8WMG. M@:GG33OCU29"MF/B5(-.@M2`;!D<&XZQ5;5HK,O0&9`:,%H'P88,E/G&GIW@ MF)TES_23TEZZ[*Y1*.)57ADZ%Y+.SDL-C0TIK\I(+W#LY6"1_X;U%B7CZ;W[ MHDR_N!GH_$C-.X(P&XVEM087.8N8#\`F8U+N1 M.<1VV-'>AM47-(T(W?G2199H+MC&>3I%'=7#^Z(8S=!TN MLX;2"7E"<.CAA="KR/S'X#-&-9G!3**W(1_%+7HNHHM"^J.7^_L1`?RRAL9L M=$JMP*8_!9_<2KT#;@.[#1[@:T!L;`K[3J$(K@IMSZH:;-"Y=$M)N M&J]"B+ZX,?:8X0X':2*,R9#4A$]6I*:(S*H4[0[?I M_`&1\70C9$'A0D*W*?CD5>K]H0DV_L/;^S.%J^+.QH>!OI&U`YWKJA'9[?K- M&K<%%R$PC M"F-ZC%N>2.#RIS7,J:Y0OP]@TL^@)M0F9Y#UX4S=#/[HPYE^XG"F?/"RJ3X* M$7N2H[Y7*]7;MR`G#@8[XITJX+@C2EB^*Y%//*8XU@0.E`ZM-T;R/'Q#;)LJ M](VHE`6.A^(2P_.+V!3?@@,;YTT&*9O">L!!4YK,RJ#8X*U62F`A);>F-'`P ME2:E]0!L<$8KOH^0OYA0_TR"?`!K-00#8LMZ?9.GFEZ=BU1UT MM0YT8);V]KD.@!WOFA>123?.FX6A8['$#''V6K4H@'?,9$%>,HZ./A\?90RQ MWS@L<9L;>BB?82:(X,@?A_SY5UX).A*+H_TR56HP0#?(&H3=/T?ZA*TK04== MM2.L!`-VKZO#&*W18)`5JH&'4K5CK0P$>JG38.XJ2HD^<6^UP$.B6O%6QF%L MWPFZ0VF;C@HX[*E%/JJAP5>K8"E4R[Q;SE7;N23XC`X.=Q7!36U,%MF@IJ*0 M!&KLM7M$L'MA2P(2:\4WMF4!Y_+,_T^:YXZ)[R..53+KR`]NC'QF#4%AG#'V M'5%UQ#A!=X@\80_E:\UWY$6S,&M%]ASMMC_=P:@H?C_;A3)LL$5FXS&?4XM; MG'RNO47/V9_$>P&5!CH8"B69HY0@V6%SK$6;]?(6':!CC39);P,.]@$1/<[?>F];R@4M=3">2(]Q M";:MO32RPW6@84AH1XR#*O/WAN0VA($U,0T"!^,T-PV68FG,&)0N0W\_38.C M_38-C@JF04.VP3*578Z-FF0J?D0)]BC8/E"J#Y3J`Z7Z0*FM*;@/E-KM!&3$ MQ;,C9^3&'IZV!$>U=?#LR,FWCI]Z2FLQ_#3>G<`Y?FMU7V.GD('X25P[@?/W MMF&K".)G\NN$/;:VHZP$PYB/0-!A;TY8OY!6;)50&+O.UR7+H+$HOUZ2AHYM ME(6.%E)A42@\[&4\[SZ%=C(4?UG>!X@'65U9Z,@?Y;'%$]Z&R^_O++^GY(BV M+@,=^:-Z)BL)#!UZ8)`GZP3/CIRQ]RKJ M1QE2%ZU9P#YT^Q`9U`:<#6E]\DO&Q`,=5&UO8K4D0&Q(-T.&M#(1M=;LO*9SO>_,\IOA>1-3(` M6WPS:L<>7N=N_'@51,_Q=>AC@KP$T'%K+8N>O]9&M=Y-2]]-JTZ)LA--[YW5 MJ1-G[YWU$WMG-32B[)D_5E%P.QRQ;E'"IMX)B9XP7<._O/Y*CXK7X?I!ZS,O MP4]T^XA4%D7]QKKBR'6C]/B9/C@+LB4W"V&"-8XVXXK+>PF7!93NRWO`L&97 MDYW(F$+:KSJ?\^X7TFU'@H#"M!CRF$%'%/R=&]!_IF?T?T+K#;\2L/N;R8XB M!-G>M-<%\@O&J=LH]*CFLI7W/F(Y@T(/!Z@TY=Y'YC8HV_XTL&>?R8ZX`U79 MD`WH;!Z1!/^9,3V>7N'0I;H)9U)+M*`:M&?A+ICG]#F)5BS8>EV'3U2Q$7G] M07""+J)G4>#+9F%H_T:XOE&O"QLN-*_G"Q>3W`QZ32D-9_@A0/FB?_GB!2E[ M\?)K%/G/.`A$O46G'6BW2\".I*LF&RY4LYCYE:+SET3Y'6FS,+3C)UQOJ==% M^YU+%S;BI;/&Y0M338KCQWQH7*`'T4Y:6A?:_12NRRBIIOT-;A=ZT`6BPGHX MYS;TB_LWD76(7PO:%1:NUTB48D-<2.:_\*6:/UAT851;`=KS%JZ/\/4!FQ!Q M6WN4RQ<&4F^KLJP#[;/;I1U+027MDRAV8=E9^:NM,B^$_LK;]2HBRS3D\9B< M!RX67DAKM0/M'`QX8M)5DPV9&ZDFV8.:Z`+E_Q9TMW2@5+`WJS<"[8(,:=C1 MT9$-V24W$5,E(_S$G%"$TY6H'K1_LB:-JGVA@K"U!;@3R]<&RI5Q$VOR7Z@' M[=>\)?XK".VX_MZ$.2%HX6+VAVW*9O MXC_S/!8+%$_<5S9O,F."YY&4"HC=!QQDR[)67U)I$/K-@2WU)57H-EQEJWL/ M&'$!A7ZPP+"/H`9JCL<"^G\^8J M"M'[(\4$?7/)[RAA<^D=\E(BFTZ4ZD._E]"0X/K>HHS8BJ/0!EJJ1#II)J^3 MP`T3NMRR:.<%*Z+32;B-0#_2L-V>(H1MQ\EI`W/5@T.GFU3K0K_^L-W>48?6 MCB,059B'D!]?48TRE^GQM-$LHMZ*,^JDGV_#CJ*'VX:3#E/>0X+3A$<]BG[_`F9*2E*#,(1!1"I/K\#P*XRC`/IO6[M*' M&/O8E=AG6[3J',-:;[>\NN!)T-\23%"?3- M/:R0L4QQ*U-;USGNI#U71JM\W\)%:T%@8\F,H/G"O;2N<]Q)NVW['L%%:T-@ M8Q$H/?`E!#^D=!.TO(]7[`^;%9WC3IIIVW>&>JCV+A>3E?@KM^+\%XC^L=D: M(FO0.>ZDW=;DPJ*B`AM,N(7#W'>T2(GWZ,;J.Q!I9>>DDP;=ACU%":X=$8G% M47$;)6CEN:4XEQ2K.">=M,FVGRVJ(&V(+:0=>]G+QU-%WGE5G)-.FDV;\2X" MV=XTVH41KZXN(W8*YZ23)M%FO4,/=GMK*+QU*[O<#'WV#[O6?G(#-C;RUS.J M[K^RNV#%9IR3CF2Y5;!HZ>(RMY7L6IP%OJTDC[`)M/X[QN244UGP+> M`)MBG+-N;4%;=LY,U:BM#DPVJ]S(E"J^=`J3BE8[`).'BNKYZ!1J`P]Q7?US MAK(:4#M'ITIZD`Z,6!4QSU/".HW*(RKZK0&,WJ;4M,/=O5'>C"W.6&^N`CO' M_Z5+0GJPBE>OL(.-\*H@"L.85P5@K/+5J"Y^5\:;0*V<025"8N>P89YG.$\V MRNZ8LO?N:%6O&ZNEDG0*`TRK'8!1I\E"2Z!=&9^ZK/#N1W4QVSF2F740_9'2 M'R]9GLX8;-!6!5&Y*.54@;@DY:I17?RN##"!6GF7&`(D=@X;T^:O^SQU]#Y9 M5RVV.M]YC\A/EYET_-1+KL-I1.:9K!E32L-;N1&[+<5:>K!SMFAXZH:9%'Y& M6]-;']V4KL&`ES5BDT5)"[6=PYM[_H<9P/MM2GKK3U6AOK@Q]FAGO<`!B[!M M,"ZU6MP[,U1SG/L\+-_6S>7VX@(]H2#*TAU.\`+19I#Z".1X/JE\1##,M-OH MXIZWS587:"PUT7O376SO++PS^X0*%646>__AG\]_>-DYQJL'[CC]6U03M`ZP0S"/*"&MM2B`5Q_.SHE*2J(7-_B&Y@^( M\/9&Y5(.;)2=4,EE7NJ%!TT&QN&!@D)!@%[$/)1+.;`YNW1YV!`>-@47GX@, MU7K$QW?L@4[?):_G;H)F$5F:8CGKE7XC#FRVK0:K6".,QM)LF9T`-V'"]#/YJCA.`HQA+2 M:HHZ0QBCAV'*.,@L25%9V5W<*`0."VHY0]A$4>V/_SQ4L/DCQ1LE=JV6RC:^ M>2%G"&N?D6F9OY]YD[^+"]Q2R%OTDK"WE[T$^=]P@.(D"NMN`:1UG&$G;"P- M>.+"V=H*M]LKLZ+KSS+B/`K9@?L&_Y%BG]E]?1_GR`KJ,WB?UE`"]&H,%E'=\X9S')@AX@ MJN8,.^$RKLF[#%$GW:@FZ4.`O?%TRGR_9KLV93L&N@%)'_Z#Z.GQ.Z*=C@J2/24ZP^P^-;O1YY"G6-T9=L)XI$.E M!K).NDM5Y;\.[Y+4?U4E3,\])Y&K!W/O*M8[6& MH*.T;]P9P9K/FG4B,[C;O[T+/]?LYM'$$:R9K5DG489F[DU=N'Z@D1!*T!LT M6G%&L$:Y9GU"$^"J9WS:;Q_A"9T'\R2Y^4]GBP4]`RT]-K?L':S];8TD/$V; M!O4(OL(A3M`-?D(;3WZHNP;+&NF&CW`;@GB&-AT5=,C6]G.X":MP4N:U]Q?^ M^?R%;4KKH]_C^_P^8I[[_#Y]?I\^OT^?WV=OCMZ")>!&P25"I7IG\O\T7^X4 M8=J0QJ"*[Q8EER]>D/HXG*T>?!1T")7JP$[%JF36=P5%@':D-%[:EU@(>ACK M9!*76E8J+:O;33@5M:PBO`1)LE3R/.FD%;MAT>"KKFZY4P'5VRBVSY\2#[U= M8G_M$@UF(]'63+TRD!VB::_6`M9)W[6ER+D]>3D-\^^U9%6`+`MZ--2=9X60 MNGBX74K\G>J9ZHC=RQ9NY+5X5&D"R#QABE=%B)T>H+3)*`Q1H#=&ZVL!63F, M#5,N*AM.N^/D$9$FS@;BBD`FCS:<*P.#]48UYG#2Q+V$HQ/`',,&RH*K%OFY.!Z(\?V>51@H3=Q6&?BX+,N-7`H5(4T;VCW9PU0-EP[WJ+D M.J2K-6(SM6#352H':?!0I*9^FU5%84%2KQ\(SQX3Y)_158UNO=9!44PWXS2) M$S=D-V*5ES\%3#=K$-)6TJI+-(9KP^B7O`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`'-T;T/_\/4$L#!!0````(`$=B;D'$V29K1PL``'YG M```1`!P`"TR,#$R,#DS,"YX&ELZWS_I.,C6:+O?E_,7.L1UXQ#)N/79EV6!J*/ZT;DU6EIM)-&0(_N;L*#ACE$'+=]:]^P1ST:86_63 MM];)B^99XP7T MG)XWZZ+]BA6,14G8:J+IJGQ\V3AM7_^:HN(73-TXN7474" M,3Q?JQ+V%,^0)1&?8'F/9EC,D8VO*E,IY\U:[>GIZ>@'HVB"Z9'-9C4EY?BR MH0:IBY5I-XS/VGB,/%=>5;Y[R-5V5BP8U50T^9PO7ES7=&I)2/$$2.ZG"+VNVC"7NL!8TF-H]S2-%I?$&K@='! MQ,P##09RO+"G9GK58F`@]!$+:6;QVPQ,%!%;F'ETDV*I;[((8IL9H,%`#@#( MY1P+(S2ZQ6"6D'.>H@1:#%HS"S$D;RF+*X!416H,"?VBF\[4\"@\@ZBE$DD(7F]?X?F$PHT19" M%K*JZVP\?X#\`#_2KHC6\(A9Q'D-MG0IMY[2(A@C>"0B`GK1F#$PC\ M2@!<7_?NVYW[0:>MK@:]VVZ[-82;#ZW;UOUUQQI\['2&@P,4B?#V$21H.<62 M@%%%<-ED-(/4V`4DZ\V&Z'^\5M"Z,/&9X98K,8>\3!YQ`ITDA1F&TWPP#(;P MYZYS#Q#T;JQ>O_/0&G:!X+4",)A"/YPRUX&ZNO/=@[3>HDX/^B6_9C-P=XJI M@*#[*"3`*<9M!NXL"5P:7(-A[_I?'WNW[<[#X.]6Y]^?NL/_'(#+$?KL!+B' M*#.DY_M!>DB./B[72$QO7/8DNM0A4.K*!'))"C,@O^V2'*];@X_6S6WORZM- MCHGP9H^C+>1F:"[V@^95CY5[)K$8LE4!MXJCZ/$)HN2'UG_-J&`N MIMT22.8.I/-#I]!Q[JH)\(2,7-P2`N^$!<<=Q5KQK8>QS809G46 M%*9S0#7'8>U7UNR-(9 MS>BM/&$I%7MFRS#D_TG;%^8T">6KTO6HZCS4=N M\N/VWF+,".ZXR*)2X4I+]-OX:PZ83FR"=61R("+#9.U`JO M&X9H0'.EJ^T,9E@2:Q\Q'`[9*&6)1"!2'(H)-H-F;D4$(@]).S8EKH?&5VC/X`P$OZL\F1J7RQD6CHMX`"W9+ MYPCTZZ*.Q(;"\[I3"S<%P]5ZJS`T@">,2XL:CRJD[<'W3SG<,K^4S6!1=]60 MKZH>5>LGU4;]:"$%=0?\A73;S[7D%-SR*!4GN50EGFZ($6GUF=D MK&%7BO!)=2TJK]<9F_RS;#&P!==[V&`Z-Y''B"A?>+./&:9C&+GLB#*N[O:P M)'%8(X\5*R9]M8?VY!F./.K77/YE=2V@J`'Q,R%YU(<\ZF(?U?&3(KETATSZ MJICV;2>5\B0CE_,-+I61+E42K)_O8T'.5!C1+O?5G'W8)J\U42F=M9!BQF6> MMLK3*T(>=5%L-&8?!,!,I*=:_\F9-P^5$!`/WEH)=[M">*J(:WO* MBK[6TJ/X3I^(C?BWARZLH89F<&DAF?U,&8R=JKEZ,$[KQ"^([]MA%S5U:XJ-L<.D<\2%%"' MQ8?`^D3O-C>7*/VH)4E&-0*]N6+SNV/$A52*$G7-X`LLG:@%04SF9MHB:V()EC=8Q08K!9=B,[H["C]J\1AR`%6R0(/TO!K]#%\VQ],!5- MA=C*4S2UJ,/9`KF)L1QO*-$HA@ACU\6+A,WQAG+9K'J%Z'%(DH_$AG<@MM7/ MWO#E-0R4">/!!HO6@HA-EXKPO7#'?,)DCQDLALRXHPX(N%'2GN)/.A0T(]A M:#!!DO8;6TMD?3`:U/9(SY`FPN?YTL"+%"N!9?=XH1:SL`U%P1UQH5!@X6;# MJ`,I9"7R9^]==YG%P]XRRU-9I"_`E'G))7V1I/0\5?F]IV+>&\-\XK^0',0#AN$`-?\-XP]X M0I2!ZZTMVMW<'%'G"4QB)ICOYOOS>]F%B:CG+#.\6E&4R(L]-JYF3ZQVEU:> MK)BZ2S33]53:\CBF?K#1\5S<&R?/V.C#%M%J=SOMRT]DIL#);6^$4R>B+@]V!3;19W;8`MSE<=[_>I3];:G(IZ5L"S*=B3L>^I'&`;8]KE_TG87M>@[6'TS4S\EYX1GT>-?\@LED*K'3>H1I_P2' M7P;[G-AX8UW^)VH)X@G!G`?T)5AG*7H^(3N5[RRL/`,EPX=XBM].6L8$.);+YA'%("39@<>UXBBS/ZM*D$R$=> MGM$=+O$$RQV&Q9]52XD6?6*V]3%5_Y]+NO$K@O+ZH%8,8=0&2X9X@6:$IJTR M;F?Y4_VL^9M-H6SY'U!+`0(>`Q0````(`$=B;D%UWNDS:C,``)SO`0`1`!@` M``````$```"D@0````!R<')X+3(P,3(P.3,P+GAM;%54!0`#5M*C4'5X"P`! M!"4.```$.0$``%!+`0(>`Q0````(`$=B;D%GM3!^2@H``/.%```5`!@````` M``$```"D@;4S``!R<')X+3(P,3(P.3,P7V-A;"YX;6Q55`4``U;2HU!U>`L` M`00E#@``!#D!``!02P$"'@,4````"`!'8FY!9_+*1.(:``!8V`$`%0`8```` M```!````I(%./@``"TR,#$R,#DS,%]D968N>&UL550%``-6TJ-0=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`1V)N0;'T0Q>`-@``&&0#`!4`&``` M`````0```*2!?UD``')P`Q0````(`$=B;D'$44NRFA\``'P]`@`5`!@` M``````$```"D@4Z0``!R<')X+3(P,3(P.3,P7W!R92YX;6Q55`4``U;2HU!U M>`L``00E#@``!#D!``!02P$"'@,4````"`!'8FY!Q-DF:T<+``!^9P``$0`8 M```````!````I($WL```"TR,#$R,#DS,"YX`L` A`00E#@``!#D!``!02P4&``````8`!@`:`@``R;L````` ` end XML 27 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 9 Months Ended 301 Months Ended

Sep. 30, 2012

Sep. 30, 2011

Sep. 30, 2012

Sep. 30, 2011

Sep. 30, 2012

Revenues

Licensing fees $ 28,755

Product royalties 627

Research and development grants 1,219

Interest income 1 1 1 16,300

Gain on disposal of fixed assets 102

Other Income 1,003

Total revenues and other income 1 1 1 48,006

Expenses

Research and development 3,131 3,234 6,776 6,980 188,692

General and administrative 1,453 726 3,348 2,780 51,441

Interest expense and amortization of intangibles 388

Total expenses 4,584 3,960 10,124 9,760 240,521

Loss from continuing operations (4,583) (3,960) (10,123) (9,759) (192,515)

Loss from discontinued operations (1,828)

Gain on disposal of discontinued operations 939

Net loss before cumulative effect of change in accounting principle (4,583) (3,960) (10,123) (9,759) (193,404)

Cumulative effect of change in accounting principle (8,454)

Net Loss $ (4,583) $ (3,960) $ (10,123) $ (9,759) $ (201,858)

Loss per share - basic and diluted: $ (0.30) $ (0.32) $ (0.69) $ (0.82)

Weighted average shares used in loss per share calculation:

Basic 15,422 12,315 14,746 11,840

Diluted 15,422 12,315 14,746 11,840

XML 28 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6

Loss Per Share
9 Months Ended

Sep. 30, 2012

Loss Per Share [Abstract]

Loss Per Share
NOTE 4 — Loss Per Share

Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed using the average share price for the period and applying the treasury stock method to potentially dilutive outstanding options. In all applicable periods, all potential common stock equivalents were anti-dilutive and, accordingly, were not included in the computation of diluted loss per share.

The following table presents information necessary to calculate loss per share for the three and nine month periods ended September 30, 2012 and 2011 (in thousands, except per share amounts):

Three Months Ended Sept. 30, Nine Months Ended Sept. 30,
2012 2011 2012 2011

Net Loss $ (4,583 ) $ (3,960 ) $ (10,123 ) $ (9,759 )
Average common shares outstanding 15,422 12,315 14,746 11,840
Basic and diluted loss per share $ (0.30 ) $ (0.32 ) $ (0.69 ) $ (0.82 )

Potential common stock of 5,264,207 and 5,260,795 common shares underlying stock options and warrants for the periods ended September 30, 2012 and 2011, respectively, were excluded from the above calculation of diluted loss per share because they were anti-dilutive. Potential common stock for the periods ended September 30, 2012 and 2011, includes Series A Warrants to purchase 1,749,270 shares of our common stock at an exercise price of $0.01. Also included in potential common stock for the periods ended September 30, 2012 and 2011, are Series B Warrants to purchase 1,569,421 and 1,690,500 shares, respectively, of our common stock at an exercise price of $2.49 issued in our February 8, 2011 public offering.

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=16381557&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6

Accrued Expenses
9 Months Ended

Sep. 30, 2012

Accrued Expenses [Abstract]

Accrued Expenses
NOTE 3 — Accrued Expenses

Accrued expenses consist of the following (in thousands):

September 30, 2012 December 31, 2011

Patent costs $ 123 $ 51
Research and development costs 44 87
Personnel related costs 28 70
Other 134 45
Total $ 329 $ 253

X

- Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 24

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6

Loss Per Share - Additional Information (Detail) (USD $)
9 Months Ended

Sep. 30, 2012

Sep. 30, 2011

Earnings Per Share Disclosure [Line Items]

Anti-dilutive shares of common stock excluded from computation of earning per share 5,264,207 5,260,795

Series A Warrants [Member]

Earnings Per Share Disclosure [Line Items]

Anti-dilutive shares of common stock excluded from computation of earning per share 1,749,270 1,749,270

Warrants, exercise price per share 0.01 0.01

Series B Warrants [Member]

Earnings Per Share Disclosure [Line Items]

Anti-dilutive shares of common stock excluded from computation of earning per share 1,569,421 1,690,500

Warrants, exercise price per share 2.49 2.49

X

- Definition

Antidilutive Securities Excluded from Computation of Earnings Per Share, Weighted Average Exercise Price

+ References

No definition available.

+ Details

Name: rprx_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareWeightedAverageExercisePrice

Namespace Prefix: rprx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: rprx_EarningsPerShareDisclosureLineItems

Namespace Prefix: rprx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 31 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6

Organization, Operations and Liquidity - Additional Information (Detail) (USD $)
9 Months Ended

Sep. 30, 2012

Dec. 31, 2011

Sep. 30, 2011

Dec. 31, 2010

Product Information [Line Items]

Number of subjects in open label safety study 500

Proceeds from Issuance of Private Placement $ 23,000,000

Deficit accumulated during development stage 201,858,000 191,735,000

Cash and cash equivalents 29,583,000 4,565,000 7,070,000 2,957,000

Accounts payable and accrued expenses 1,800,000

Private Placement [Member]

Product Information [Line Items]

Issuance of common stock, share 2,145,636

Common stock, price per share $ 11.00

One year [Member]

Product Information [Line Items]

Number of subjects required for registration 100

Six months [Member]

Product Information [Line Items]

Number of subjects required for registration 800

Issuance During Period 2nd [Member]

Product Information [Line Items]

Issuance of common stock, share 2,463,537

Common stock, price per share $ 4.50

Issuance of stock net of offering costs $ 10,300,000

X

- Definition

Number of Subjects in Study

+ References

No definition available.

+ Details

Name: rprx_NumberOfSubjectsInStudy

Namespace Prefix: rprx_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of Subjects Required for Registration

+ References

No definition available.

+ Details

Name: rprx_NumberOfSubjectsRequiredForRegistration

Namespace Prefix: rprx_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition

Public offering, net proceeds

+ References

No definition available.

+ Details

Name: rprx_PublicOfferingNetProceeds

Namespace Prefix: rprx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Cumulative net losses reported during the development stage.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 210

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472335&loc=d3e37729-110921

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 7

-Paragraph 11

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount per share assigned to the consideration received for shares issued.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 215

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6472370&loc=d3e38297-110927

+ Details

Name: us-gaap_EquityIssuancePerShareAmount

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_ProductInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 32 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6

Organization, Operations and Liquidity (Tables)
9 Months Ended

Sep. 30, 2012

Organization, Operations and Liquidity [Abstract]

Product Development Pipeline
Our product development pipeline is summarized in the table below:

Product Candidate (Indication)

Androxal®
Status Next Expected Milestone(s)

Secondary Hypogonadism Phase 3
Complete first Phase 3 pivotal study (Q2 2013)

Complete open label safety study (Q4 2013)

Complete DEXA study (Q1 2014)

Proellex®

Uterine Fibroids Phase 2
Complete Phase 2 study (vaginal delivery) (Q4 2012)

Endometriosis
Phase 2
Initiate Phase 2 study (oral delivery) (Q4 2012)

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of product information that are included in the discussion of the nature of an entity's operations.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfProductInformationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6

Commitments and Contingencies
9 Months Ended

Sep. 30, 2012

Commitments and Contingencies [Abstract]

Commitments and Contingencies
NOTE 5 — Commitmentsand Contingencies

Therapeutic uses of our Androxal^® product candidate are covered in the United States by five issued U.S. patents and seven pending patent applications. Foreign coverage of therapeutic uses of our Androxal^® product candidate includes 55 issued foreign patents and 53 foreign pending patent applications. The issued patents and pending applications relate to methods for treating certain conditions including the treatment of testosterone deficiency in men, the treatment of diabetes mellitus Type 2, the treatment of metabolic syndrome and conditions associated therewith, and the treatment of infertility in hypogonadal men. Androxal^® (the trans-isomer of clomiphene) is purified from clomiphene citrate. A third party individual holds two issued patents related to the use of an anti-estrogen such as clomiphene citrate and others for use in the treatment of androgen deficiency and disorders related thereto. We requested re-examination of one of these patents by the U.S. Patent and Trademark Office (“PTO”) based on prior art. The patent holder amended the claims in the re-examination proceedings, which led the PTO to determine that the amended claims were patentable in view of those publications under consideration and a re-examination certificate was issued. We subsequently filed a second request for re-examination by the PTO in light of a number of additional publications. The request was granted and all of the claims were finally rejected by the PTO in the re-examination. The patent holder appealed the rejections to the PTO Board of Patent Appeals and Interferences (the “PTO Board”) which ultimately reversed the rejections of several dependent claims in view of those publications under consideration. The patent holder filed a Notice of Appeal to the Federal Circuit on September 28, 2010 contesting the rejections maintained by the PTO Board. A decision was rendered by the Federal Circuit on December 12, 2011, affirming the rejection of the appealed claims. We expect that a re-examination certificate will be issued confirming the patentability of the remaining claims; however, if such a re-examination certificate were to issue, we believe that our development of Androxal® would not infringe any of the remaining claims and that all of the remaining claims are invalid on various grounds including additional prior art publications. We also believe that the second of these two patents is invalid in view of published prior art not considered by the PTO. If necessary, we intend to vigorously defend any and all claims against the holder of such patents in a court of competent jurisdiction in order to develop Androxal^® further. Adverse determinations in litigation proceedings could require us to seek licenses which may not be available on commercially reasonable terms, or at all, or subject us to significant liabilities, in which case we may not be able to successfully commercialize or out-license Androxal® until such patents expire or are otherwise no longer in force.

On March 1, 2010, we were served with a lawsuit where we were named as a co-defendant along with one of our clinical regulatory service providers (“CRO”) relating to the Proellex^® clinical trial study. The lawsuit was filed in the State of Tennessee, 30th Judicial District Chancery Court at Memphis by an investigator and claims that the CRO did not pay it amounts owing to it relating to the Proellex® study. We did not engage the investigator and under our agreement with the CRO, we believe the CRO is responsible for any such costs or damages regarding such lawsuit. Pursuant to a Settlement Agreement and Mutual Release entered into in October 2009, such CRO, on behalf of itself and its agents, released us from all claims which could be asserted by them against us. We believe such release covers the claims set forth in this lawsuit. The CRO failed to respond to the lawsuit, and a default judgment was entered against it in the amount of $172,901.29. We intend to vigorously defend any and all claims asserted by the investigator. An estimate of the possible costs or expenses to defend ourselves in this matter or risk of exposure under the litigation cannot be made at this time.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6

Subsequent Events
9 Months Ended

Sep. 30, 2012

Subsequent Events [Abstract]

Subsequent Events
NOTE 6 — Subsequent Events

On October 31, 2012, Dr. Jean Fourcroy, MD, PhD, MPH, a member of Repros Therapeutics Inc.’s (the “Company”) board of directors (the “Board”) resigned her position as a member of the Board. Such resignation was not a result of any disagreements relating to the Company’s operations, policies or practices.

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6

Accrued Expenses (Tables)
9 Months Ended

Sep. 30, 2012

Accrued Expenses [Abstract]

Accrued Expenses
Accrued expenses consist of the following (in thousands):

September 30, 2012 December 31, 2011

Patent costs $ 123 $ 51
Research and development costs 44 87
Personnel related costs 28 70
Other 134 45
Total $ 329 $ 253

X

- Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the components of accrued liabilities.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6

Accrued Expenses (Detail) (USD $)
In Thousands, unless otherwise specified

Sep. 30, 2012

Dec. 31, 2011

Schedule of Accrued Liabilities [Line Items]

Patent costs $ 123 $ 51

Research and development costs 44 87

Personnel related costs 28 70

Other 134 45

Total $ 329 $ 253

X

- Definition

Accrued Patent Expense, Current

+ References

No definition available.

+ Details

Name: rprx_AccruedPatentExpenseCurrent

Namespace Prefix: rprx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accrued Personnel Expense Current

+ References

No definition available.

+ Details

Name: rprx_AccruedPersonnelExpenseCurrent

Namespace Prefix: rprx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accrued Research and Development Expense, Current

+ References

No definition available.

+ Details

Name: rprx_AccruedResearchAndDevelopmentExpenseCurrent

Namespace Prefix: rprx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: rprx_ScheduleOfAccruedLiabilitiesLineItems

Namespace Prefix: rprx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 7

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6911-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e7018-107765

+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 37 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)
In Thousands, except Share data

Total

USD ($)

Issuance During Period 1st [Member]

Issuance During Period 2nd [Member]

USD ($)

Issuance During Period 3rd [Member]

Issuance During Period 4th [Member]

USD ($)

Common Stock [Member]

USD ($)

Common Stock [Member]

Issuance During Period 1st [Member]

Common Stock [Member]

Issuance During Period 2nd [Member]

USD ($)

Common Stock [Member]

Issuance During Period 3rd [Member]

Common Stock [Member]

Issuance During Period 4th [Member]

USD ($)

Additional Paid-in Capital [Member]

USD ($)

Additional Paid-in Capital [Member]

Issuance During Period 2nd [Member]

USD ($)

Additional Paid-in Capital [Member]

Issuance During Period 4th [Member]

USD ($)

Treasury Stock [Member]

USD ($)

Deficit Accumulated During the Development Stage [Member]

USD ($)

Beginning Balance at Dec. 31, 2011 $ 4,666 $ 12 $ 197,769 $ (1,380) $ (191,735)

Beginning Balance (in shares) at Dec. 31, 2011 12,470,694 112,350

Stock based option compensation 1,902 1,902

Issuance of common stock (in shares) 100 2,463,537 11,173 2,145,636 100 2,463,537 11,173 2,145,636

Issuance of common stock 10,310 23,018 3 2 10,307 23,061

Exercise of stock options to purchase common stock for cash ($1.33 to $10.88 per share)(in shares) 16,488

Exercise of stock options to purchase common stock for cash ($1.33 to $10.88 per share) 121 121

Exercise of 121,079 Series B Warrants to purchase common stock for cash @ $2.49 per share (in shares) 121,079

Exercise of 3,675 Series B Warrants to purchase common stock for cash @ $2.49 per share 301 301

Net loss (10,123) (10,123)

Ending Balance at Sep. 30, 2012 $ 30,195 $ 17 $ 233,416 $ (1,380) $ (201,858)

Ending Balance (in shares) at Sep. 30, 2012 17,228,707 112,350

X

- Definition

Number of shares issued during the period as a result of the exercise of warrants.

+ References

No definition available.

+ Details

Name: rprx_StockIssuedDuringPeriodSharesStockWarrantsExercised

Namespace Prefix: rprx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Value stock issued during the period as a result of the exercise of warrants.

+ References

No definition available.

+ Details

Name: rprx_StockIssuedDuringPeriodValueStockWarrantsExercised

Namespace Prefix: rprx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11178-113907

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415241&loc=d3e4534-113899

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A91

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11149-113907

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 39

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_SharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of stock issued as a result of the exercise of stock options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 38 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6

Patents and Patent Applications
9 Months Ended

Sep. 30, 2012

Patents and Patent Applications [Abstract]

Patents and Patent Applications
NOTE 2 — Patents and Patent Applications

As of September 30, 2012, we had approximately $1,939,000 in capitalized patent and patent application costs reflected on its balance sheet. Of this amount, $1,594,000 relates to patent and patent application costs for Androxal® and $345,000 relates to patent and patent application costs for Proellex®.

Should we not continue development of either drug candidate or should we not continue as a going concern, the remaining capitalized patent and patent application costs may not be recoverable, which would result in charges to operating results in future periods.

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all or part of the information related to intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 44, 45, 46

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16373-109275

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16265-109275

+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 50 127 1 false 24 0 false 4 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.zonagen.com/role/DocumentDocumentandEntityInformation Document and Entity Information true false R2.htm 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.zonagen.com/role/StatementOfFinancialPositionClassified CONDENSED CONSOLIDATED BALANCE SHEETS false false R3.htm 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.zonagen.com/role/StatementOfFinancialPositionClassifiedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.zonagen.com/role/StatementOfIncomeAlternative CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.zonagen.com/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY false false R6.htm 006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://www.zonagen.com/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) false false R7.htm 007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.zonagen.com/role/StatementOfCashFlowsIndirect CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS false false R8.htm 008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Sheet http://www.zonagen.com/role/StatementOfCashFlowsIndirectParenthetical CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) false false R9.htm 009 - Disclosure - Organization, Operations and Liquidity Sheet http://www.zonagen.com/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Organization, Operations and Liquidity false false R10.htm 010 - Disclosure - Patents and Patent Applications Sheet http://www.zonagen.com/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock Patents and Patent Applications false false R11.htm 011 - Disclosure - Accrued Expenses Sheet http://www.zonagen.com/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Accrued Expenses false false R12.htm 012 - Disclosure - Loss Per Share Sheet http://www.zonagen.com/role/NotesToFinancialStatementsEarningsPerShareTextBlock Loss Per Share false false R13.htm 013 - Disclosure - Commitments and Contingencies Sheet http://www.zonagen.com/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies false false R14.htm 014 - Disclosure - Subsequent Events Sheet http://www.zonagen.com/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Events false false R15.htm 015 - Disclosure - Organization, Operations and Liquidity (Tables) Sheet http://www.zonagen.com/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockTables Organization, Operations and Liquidity (Tables) false false R16.htm 016 - Disclosure - Accrued Expenses (Tables) Sheet http://www.zonagen.com/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables Accrued Expenses (Tables) false false R17.htm 017 - Disclosure - Loss Per Share (Tables) Sheet http://www.zonagen.com/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Loss Per Share (Tables) false false R18.htm 018 - Disclosure - Product Development Pipeline (Detail) Sheet http://www.zonagen.com/role/DisclosureProductDevelopmentPipeline Product Development Pipeline (Detail) false false R19.htm 019 - Disclosure - Organization, Operations and Liquidity - Additional Information (Detail) Sheet http://www.zonagen.com/role/DisclosureOrganizationOperationsAndLiquidityAdditionalInformation Organization, Operations and Liquidity - Additional Information (Detail) false false R20.htm 020 - Disclosure - Patents and Patent Applications - Additional Information (Detail) Sheet http://www.zonagen.com/role/DisclosurePatentsAndPatentApplicationsAdditionalInformation Patents and Patent Applications - Additional Information (Detail) false false R21.htm 021 - Disclosure - Accrued Expenses (Detail) Sheet http://www.zonagen.com/role/DisclosureAccruedExpenses Accrued Expenses (Detail) false false R22.htm 022 - Disclosure - Calculation of Loss Per Share (Detail) Sheet http://www.zonagen.com/role/DisclosureCalculationOfLossPerShare Calculation of Loss Per Share (Detail) false false R23.htm 023 - Disclosure - Loss Per Share - Additional Information (Detail) Sheet http://www.zonagen.com/role/DisclosureLossPerShareAdditionalInformation Loss Per Share - Additional Information (Detail) false false R24.htm 024 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.zonagen.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) false false All Reports Book All Reports 'Monetary' elements on report '019 - Disclosure - Organization, Operations and Liquidity - Additional Information (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Sep. 30, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Process Flow-Through: 007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Process Flow-Through: 008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) rprx-20120930.xml rprx-20120930.xsd rprx-20120930_cal.xml rprx-20120930_def.xml rprx-20120930_lab.xml rprx-20120930_pre.xml true true XML 40 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6

Patents and Patent Applications - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified

Sep. 30, 2012

Dec. 31, 2011

Finite-Lived Intangible Assets [Line Items]

Capitalized patent and patent application costs $ 1,939 $ 1,385

Androxal [Member]

Finite-Lived Intangible Assets [Line Items]

Capitalized patent and patent application costs 1,594

Proellex [Member]

Finite-Lived Intangible Assets [Line Items]

Capitalized patent and patent application costs $ 345

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 42, 45

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

Accrued Expenses (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Schedule of Accrued Liabilities [Line Items]
Patent costs	$ 123	$ 51
Research and development costs	44	87
Personnel related costs	28	70
Other	134	45
Total	$ 329	$ 253

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $) In Thousands, except Share data	Total USD ($)	Issuance During Period 1st [Member]	Issuance During Period 2nd [Member] USD ($)	Issuance During Period 3rd [Member]	Issuance During Period 4th [Member] USD ($)	Common Stock [Member] USD ($)	Common Stock [Member] Issuance During Period 1st [Member]	Common Stock [Member] Issuance During Period 2nd [Member] USD ($)	Common Stock [Member] Issuance During Period 3rd [Member]	Common Stock [Member] Issuance During Period 4th [Member] USD ($)	Additional Paid-in Capital [Member] USD ($)	Additional Paid-in Capital [Member] Issuance During Period 2nd [Member] USD ($)	Additional Paid-in Capital [Member] Issuance During Period 4th [Member] USD ($)	Treasury Stock [Member] USD ($)	Deficit Accumulated During the Development Stage [Member] USD ($)
Beginning Balance at Dec. 31, 2011	$ 4,666					$ 12					$ 197,769			$ (1,380)	$ (191,735)
Beginning Balance (in shares) at Dec. 31, 2011						12,470,694								112,350
Stock based option compensation	1,902										1,902
Issuance of common stock (in shares)		100	2,463,537	11,173	2,145,636		100	2,463,537	11,173	2,145,636
Issuance of common stock			10,310		23,018			3		2		10,307	23,061
Exercise of stock options to purchase common stock for cash ($1.33 to $10.88 per share)(in shares)						16,488
Exercise of stock options to purchase common stock for cash ($1.33 to $10.88 per share)	121										121
Exercise of 121,079 Series B Warrants to purchase common stock for cash @ $2.49 per share (in shares)						121,079
Exercise of 3,675 Series B Warrants to purchase common stock for cash @ $2.49 per share	301										301
Net loss	(10,123)														(10,123)
Ending Balance at Sep. 30, 2012	$ 30,195					$ 17					$ 233,416			$ (1,380)	$ (201,858)
Ending Balance (in shares) at Sep. 30, 2012						17,228,707								112,350

Patents and Patent Applications - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Finite-Lived Intangible Assets [Line Items]
Capitalized patent and patent application costs	$ 1,939	$ 1,385
Androxal [Member]
Finite-Lived Intangible Assets [Line Items]
Capitalized patent and patent application costs	1,594
Proellex [Member]
Finite-Lived Intangible Assets [Line Items]
Capitalized patent and patent application costs	$ 345